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1. Introduction 
1.1 Cardiovascular disease - mortality and risk factors 
Cardiovascular disease (CVD) is the main cause of death in western societies. 
According to the World Health Organization (WHO) CVD is the number one cause of 
death globally: more people die annually from CVD than from any other cause and 
the number of people dying from CVD, mainly heart disease and stroke, will increase 
to reach 23.3 million by 20301,2. CVD is projected to remain the single leading cause 
of death2. The term CVD covers a wide array of disorders, including diseases of the 
vascular system supplying blood to the heart, brain and other vital organs, damages 
to the heart muscle and heart valves, malformations of the heart structure and 
diseases such as deep vein thrombosis3.  
Risk factors for CVD are unhealthy diet, physical inactivity, tobacco use and 
harmful use of alcohol. The effects of unhealthy diet and physical inactivity may show 
up in individuals as a raise in blood pressure, blood glucose and blood lipids, in 
addition to overweight and obesity. These “intermediate risks factors” can be 
measured in primary care facilities and indicate an increased risk of developing a 
heart attack, stroke, heart failure and other complications such as deep vein 
thrombosis or pulmonary embolism4. However, there is an urgent need for new 
medications treating acute CVDs like myocardial infarction and ischemic stroke. 
Therefore, it is very important for the future to investigate the underlying mechanisms 
of these pathologies and to devise new therapeutical treatments to prevent and cure 
CVD. 
Heart attacks and strokes are usually acute events and are mainly caused by a 
blockage that prevents blood from flowing to the heart or brain. The most common 
reason for this is a build-up of fatty deposits on the inner walls of the blood vessels, 
which supply the heart or brain. Strokes can also be caused by bleeding from a blood 
vessel in the brain or from blood clots5.  
The underlying pathophysiology leading to these cardio- and cerebrovascular 
incidents is called atherosclerosis. It is defined as an inflammatory fibro-proliferative 
response to various forms of endothelial injury, which develops mainly at sites of 
disturbed blood flow such as at bifurcations6. 
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1.2 Atherosclerosis 
1.2.1 Pathogenesis of atherosclerosis 
Blood vessels are constructed in three main layers, so-called tunics (Figure 1). The 
innermost layer (tunica interna, tunica intima or shortly intima) is comprised of 
endothelial cells on the luminal side, extracellular connective tissue matrix 
(proteoglycans and collagen) and the inner elastic lamina (IEL) at the medial end. 
Below the IEL follows the middle layer, the so-called tunica media (or shortly media). 
It consists of vascular smooth muscle cells (VSMCs) embedded in interstitial 
extracellular matrix. Last the vessel is enclosed by the tunica adventitia or tunica 
externa (shortly adventitia), which is composed mainly of collagen with interspersed 
fibroblasts and SMCs and is supported by the external elastica lamina (EEL)7,8. 
 
 
Figure 1: Structure of an artery. A blood vessel is composed of three different layers. The intima, 
also called the tunica interna, carries endothelial cells on the luminal side and the internal elastic 
lamina on the peripheral side. The second layer (media or tunica media) consists of SMCs and the 
outer layer (adventitia, tunica externa) is built up of connective tissue with interspersed fibroblasts and 
SMCs. (Figure from Lusis A.J.8) 
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Atherosclerosis is thought to be initiated by damage of the endothelium, 
resulting in dysfunction and activation of endothelial cells9. Cardiovascular risk 
factors such as hyperlipidemia, smoking, hypertension and oxidative stress cause 
endothelial dysfunction10. Also, endogenous cytokines or disturbed flow in areas 
predisposed to atherosclerosis, as e.g. at bifurcations, lead to endothelial cell 
activation11,12. Nitric oxide (NO) is an important mediator in endothelial cells and 
fulfills multiple functions in the context of vascular reactivity and atherosclerosis. It 
mediates endothelium-dependent vasodilation by opposing the effects of 
endothelium-derived vasoconstrictors such as angiotensin II and endothelin. 
Furthermore, it inhibits platelet aggregation and adherence on the endothelium and 
with leukocyte infiltration. Also, NO interferes with SMC proliferation and prevents the 
oxidation of low-density lipoprotein (LDL)9,13. The loss of nitric oxide (NO) is not only 
defined as a hallmark for endothelial dysfunction but it leads as well to increased 
endothelial activation. Once endothelial cells are activated, they express adhesion 
molecules such as E-selectin, P-selectin, vascular cell adhesion molecule-1 (VCAM-
1) and the chemokine monocyte chemoattractant protein-1 (MCP-1)10. 
Endothelial dysfunction and activation trigger atherogenesis as they permit the 
subendothelial accumulation of LDL and inflammatory cells (T-cells, monocytes)10,14. 
Once the LDL particles have entered the intima they are susceptible to oxidation by 
reactive oxygen species or enzymes as e.g. myeloperoxidase released from 
inflammatory cells. Oxidized lipids and LDL (oxLDL) trigger the further activation of 
endothelial cells, leading to enhanced expression of adhesion molecules and 
increased secretion of chemokines attracting more immune cells to infiltrate the 
vessel wall. Leukocyte invasion occurs through rolling over the endothelium, 
adhesion and transmigration through the endothelium into the intima (Figure 2b). The 
first cells to adhere and enter are monocytes, which then subsequently differentiate 
into macrophages. Macrophages are crucial players in atherosclerotic lesions, 
contributing to atherogenesis14. They take up oxLDL accumulating in the lesions and 
produce crucial pro-inflammatory markers sustaining plaque progression. Early lesion 
formations mainly contain monocyte-derived-macrophage-like-foam cells in addition 
to T-cells, and are therefore called “fatty streaks” (Figure 2b)14,15.  
The progression into more complex lesions is stimulated by the continuous 
accumulation of immune cells and the development of a necrotic core. Lipid 
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overloading eventually triggers macrophage death and the formation of necrotic 
cores, a hallmark of progressed lesions. The release of foam cell content leads to 
further accumulation of extracellular lipids and pro-inflammatory cytokines, which 
sustain inflammation. VSMCs migrate from the adventitia and media to the intima, 
where they proliferate and together with collagen fibers form a fibrous cap covering 
the atherosclerotic lesion. Although the fibrous cap stabilizes the plaque, it causes as 
well augmentation of the atherosclerotic bulk, which now protrudes into the lumen of 
the artery7,16 (Figure 2c). Progressed plaques can be classified into different 
categories according to their lesion content. While a plaque with a large necrotic 
core, high levels of inflammatory cells and a thin fibrous cap is called an unstable 
plaque, a plaque with a thicker fibrous cap, less inflammatory cells and a smaller 
necrotic core is classified as a stable plaque. Unstable plaques are more prone to 
rupture. This will trigger thrombus formation (Figure 2d), which can occlude the 
lumen and cause myocardial infarction or stroke17.  
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Figure 2: Initiation and progression of atherosclerosis. (a) Under normal conditions the artery 
consists of three layers: the intima with an endothelial cell cover on the luminal side, the media and 
the surrounding adventitia. (b) Under pro-inflammatory conditions endothelial cell dysfunction and 
activation lead to increased permeability and expression of adhesion molecules. These adhesion 
molecules help leukocytes such as T-cells and monocytes to adhere to the activated endothelium, 
which is followed by their transmigration into the intima. Once in the intima, monocytes differentiate 
into macrophages, which accumulate lipids and transform into foam cells, which make up fatty streaks. 
(c) Continued leukocyte influx and deposition of cholesterol crystals further stimulate 
atheroprogression. Cytokines produced in the plaque, as e.g. PDGF-beta, trigger the migration of 
SMCs into the plaque giving rise to a fibroproliferative progression of the lesion. Together with 
collagen fibres, these SMCs form a protective fibrous cap covering the plaque. (d) Apoptosis of 
macrophage foam cells and other plaque cells result in the formation of a necrotic core composed of 
dead cell material and accumulated lipids. The thickness of the protective fibrous cap can with time 
decrease due to matrix degradation by proteases, making the plaque unstable and prone to plaque 
rupture. Once a plaque has ruptured, the lesion content is released, the coagulation system gets 
activated and a thrombus is formed, which can occlude the artery and lead to heart attack or stroke. 
(Figure from Libby P. et al.18)  
 
Many immune cells, both from the innate as well as the adaptive immune 
system, are involved in the development and progression of atherosclerosis14,15,19. As 
mentioned before, monocytes are the first cells to adhere to the endothelium and 
transmigrate into the intima, where they differentiate into macrophages. 
Macrophages are highly versatile cells, taking on many different phenotypes. M1 
(classically activated macrophages) and M2 macrophages (non-classically activated 
macrophages) are suggested to play opposite roles during inflammation, but both are 
present in atherosclerotic lesions. M1 macrophages can be found in plaque 
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shoulders, which are predilection sites for rupture20, and can release elevated levels 
of tumor necrosis factor-α (TNFα), IL-1β and IL-6 cytokines, which have been 
attributed to further activate endothelial and smooth muscle cells, thus driving 
atherosclerotic progression21. On the contrary, M2 cells were shown to induce 
differentiation of atheroprotective regulatory T-cells22 and are rather found far from 
the lipid core, in more stable zones of the lesion, suggesting atheroprotective 
functions23. Furthermore, M2 macrophages produce anti-inflammatory cytokines IL-4, 
IL-13, and IL-10, which through their immunosuppressive effects on T-cell and 
macrophage activation, may lead to decreased endothelial cell and smooth muscle 
cell activation21. Additionally, M2 macrophages have been involved in promoting 
angiogenesis, tissue remodeling and repair24. 
Neutrophils are involved in the initiation and progression of atherosclerosis14. 
Hyperlipidemia increases the number of circulating neutrophils and with help of 
specific chemokine receptors, such as CCR1, CCR2, CCR5 and CXCR2, they 
infiltrate the lesion25. Early neutrophil inflammatory signals attract and recruit 
monocytes into the plaque and apoptotic neutrophils sustain monocyte recruitment26. 
Neutrophil activation triggers the formation of NETs, which are neutrophil 
extracellular traps. Such NETs have been shown to promote atheroprogression and 
thrombus growth27,28. All together neutrophils have been suggested to drive the 
initiation and progression of atherosclerosis by providing chronic inflammatory 
triggers29.  
Together with macrophages, T-cells can be found already in early lesions.  
They can be subdivided into different subtypes, which are all involved in 
atherosclerosis. CD4+ T-cells can be divided into at least four types of T helper (Th) 
cells: Th1, Th2, Th17 and regulatory T-cells (Treg). Th1 cells produce high levels of 
IFN-γ and mediate cellular immune responses that are atherogenic. For example, 
IFN-γ activates monocytes/macrophages and dendritic cells. Furthermore, IFN-γ 
inhibits  SMC proliferation and collagen production, which subsequently leads to the 
formation of unstable plaques prone to rupture30. Also Th17 cells have been 
demonstrated to be critical in atherosclerotic plaque progression, as they release the 
pro-inflammatory cytokine IL-17, which has been shown to exacerbate 
atherosclerotic lesion development31. Th2 cells are hardly found in atherosclerotic 
lesions and their role in atherogenesis has been debated. One study observed a 
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decrease in atherosclerotic lesion formation upon deficiency of IL-4, the prototypic 
Th2-related cytokine, suggesting a potentially proatherogenic role of IL-4 and Th2 
cells32. In contrast, another study showed that Th2 cells antagonize the 
proatherogenic effect of Th1 cells by downregulating IFN-γ production by Th1 cells 
through IL433. Thus, the role of Th2 cells in atherogenesis remains controversial and 
might be dependent on the stage of the atherosclerotic process and/or anatomic 
location of the lesion. Finally, Tregs exert important immunoregulatory functions in 
atherosclerosis by controlling Th1 and Th2 immune responses and have been 
attributed an atheroprotective function34. 
Dendritic cells (DCs) are specialized antigen-presenting cells that are required 
for the activation of naive T-cells and the development of antigen-specific T-cell-
mediated immune responses. DCs are already present in the intima before 
atherosclerotic lesion development35 and play a crucial pathogenic role in all stages 
of the atherosclerotic process. At early stages of lesion development, DCs 
accumulate in large numbers within the intima of atherosclerosis-susceptible regions. 
Their continued accumulation during lesion development is correlated with lesion 
progression and inflammation36. Plasmacytoid dendritic cells (pDCs), which are a 
distinct set of DCs producing large amounts of IFN- type 1, were found at plaque 
shoulder regions. An atheroprogressive role of pDCs was revealed through its 
effector cytokine IFNγ, which increased macrophage accumulation in atherosclerotic 
lesions37. Also, pDCs induce an up-regulation of the molecule TRAIL on T-cells. 
TRAIL-expressing T-cells effectively kill plaque-resident cells, weakening the lesion 
content and rendering the plaque vulnerable38. On the other hand, pDCs were also 
shown to have atheroprotective properties39. 
B-cells are involved as well in all stages of atherosclerosis40 and can be divided 
into 3 subtypes: B1 and B2 B-cells and regulatory B-cells (Bregs). B1 B-cells have 
been demonstrated to protect from atherosclerosis, while B2 B-cells have an 
atherogenic effect and aggravate atherosclerosis. Bregs produce IL-10, and therefore 
it has been suggested that they might have a protective role similarly to Tregs, 
although the direct role of Bregs still remains to be studied41.  
In summary atherosclerosis is a complex disease modulated by various risk 
factors and involving different immune cell types42,43. Although many processes have 
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been identified to trigger the initiation and progression of atherosclerosis, many 
questions on detailed mechanisms are still un-answered. Being the leading pathology 
to heart attack and stroke, a greater understanding of this disease is vital for the 
development of new therapies. 
 
1.2.2 Haemodynamic forces in atherosclerosis 
As mentioned in the previous chapter, haemodynamic forces are one of the 
mechanisms triggering endothelial activation and changes of the endothelial 
phenotype, subsequently leading to the initiation of atherosclerosis12,44,45. 
Atherosclerotic lesions mainly develop at predilections sites along the arterial tree, 
which are exposed to disturbed flow6. These regions are e.g. the inner curvature of 
the aortic arch and branching points along the aorta as well as bifurcations e.g. in the 
brachiocephalic artery, as shown in Figure 3. In contrast, in straight parts of the 
arterial tree, blood flow is laminar and wall shear stress is high. Laminar flow and 
high shear stress both are considered to be atheroprotective, whereas low shear 
stress associated with disturbed flow pre-activates the endothelium and is described 
as pro-atherogenic46.  
 
 
  
 
 
 
 
Figure 3: Atherosclerosis mainly develops 
at regions with disturbed blood flow. 
Schematic drawing of the arterial tree, 
indicated in blue the areas, where 
atherosclerotic plaques are prone to develop. 
1) aortic sinus 2) ascending aorta 3) inner 
curvature of aortic arch 4) outer curvature of 
aortic arch 5) innominate or brachiocephalic 
artery 6) right common carotid artery 7) left 
common carotid artery 8) left subclavian artery 
9) thoracic aorta 10) renal artery 11) abdominal 
aorta 12) iliac artery (Figure from Chiu J.J. et 
al.6)  
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Vascular endothelial cells serve as important homeostatic regulators in 
response to chemical and mechanical forces47. Endothelial cells sense the wall shear 
stress and transmit this information as intracellular signals. Several theories have 
been postulated on how endothelial cells sense shear stress, which include ion 
channel activation, aveolae-mediated regulation of Ca2+, activation of G-protein-
coupled receptors and tyrosine kinase receptors, adhesive protein activation, 
glycocalyx elongation and bending of primary cilia48. These mechanosensors 
generate, in response to shear stress, biochemical signals that initiate complex and 
multiple signalling cascades49. The type of shear, laminar or disturbed, impacts which 
signal transduction pathways are initiated as well as which subsequent genes are 
transcribed, thereby influencing endothelial phenotype and function48. The pro-
atherogenic effects attributed to low endothelial shear stress can be explained by the 
activation of pro-inflammatory transcription factors such as AP1 and NF-κB, whereas 
the anti-atherogenic effects of high shear stress are mediated by anti-inflammatory 
transcription factors like KLF2 and NRF250. Furthermore, haemodynamic forces 
regulate as well the induction of various microRNAs (miRs), which can mediate either 
athero-protective or –progressive functions51. An insight on miRs is given in the 
following chapter. More details concerning the transcription factor NF-κB and its 
activation and involvement in atherosclerosis are given in chapter 1.3. 
 
1.2.3 MicroRNAs in atherosclerosis 
MicroRNAs (miRs) are short, highly conserved, non-coding RNAs, which play a key 
regulatory role in the complex network of posttranscriptional gene expression. More 
than 10.000 miRs have been identified to date and 940 of them in the human 
organism. In mammals miRs control the expression of 50% of all protein coding 
genes52. 
MiRs originate either from protein-independent genes being transcribed by RNA 
polymerase II and III or from introns of protein-coding genes. The primary transcript, 
so called pri-miRs, remains in the nucleus and undergoes cleavage, mediated by 
Drosha, an RNase III enzyme, and DGCR8 as a cofactor, to form a ~60-70 
nucleotide long hairpin structure, known as pre-miR. Pre-miRs are exported through 
the nuclear pore complexes into the cytoplasm by binding to Exportin-5–Ran-GTP. 
Once in the cytoplasm, the pre-miR is further processed into mature miR by another 
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RNase III enzyme known as Dicer, which forms a multi-protein complex together with 
TRBP, PACT and an Argonaute (Ago) protein. The Dicer produces a miR duplex, 
consisting of a passenger and a guide strand. While the passenger strand is cleaved 
off and mostly degraded, the guide strand assembles with proteins of the Ago family, 
a process that shapes the effector RNA-induced silencing complex (RISC)52,53. This 
RISC complex then induces translational repression or mRNA degradation of the 
target mRNA through binding of the miR to this target (Figure 4). 
 
 
 
Figure 4: Biogenesis of microRNA (miR). Primary miRNA (pri-miRNA) is transcribed by RNA 
polymerase II and then cleaved by the Drosha/DGCR8 complex into a hairpin forming pre-miRNA. 
Pre-miRNA is transported out of the nucleus into the cytoplasm with the help of RanGTP and Exportin-
5, where it is processed into a miRNA duplex form by Dicer. One of the duplex strands is incorporated 
into RISC (guide strand), while the other strand (passenger strand) is mostly degraded. MiRNA binds 
to the 3´UTR region of the target mRNA, leading to translational repression or mRNA degradation. 
(Figure from Yamakuchi M.54) 
 
An individual miR is capable of targeting hundreds of mRNAs and a single 
mRNA can be regulated by multiple miRs. MiRs target mRNAs by complementary 
sequence in the 3´UTR regions using basic base-pairing. The gene regulation takes 
place by the down-regulation of the respective mRNA, either by mRNA translational 
repression or mRNA cleavage54.  
Altered miR expression patterns have been implicated in various disease 
states, including cancer and cardiovascular disease55,56. As mentioned shortly in the 
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previous chapter, miRs were found in atherosclerotic lesions and changes in 
haemodynamic forces result in altered expression of miRs in endothelial cells57. In 
areas with high shear stress the expression of atheroprotective miRs is upregulated, 
whereas pro-inflammatory miRs are downregulated58. For example, the down-
regulation of miR-92a by high shear stress increases the expression of the 
endothelial NO synthase (eNOS), whereas the up-regulation of miR-19a contributes 
to the shear stress-induced inhibition of cell proliferation59. Similarly, the expression 
of miR-10 is enhanced in atheroprotected regions, which reduces the inflammatory 
response of endothelial cells50. But miRs do not only play a key role in endothelial 
cell activation and phenotype60, miRs are as well involved in the communication 
between cells e.g. endothelial cells and monocytes or between endothelial cells and 
smooth muscle cells, which is of crucial importance in atherosclerosis61. For 
example, miRs regulate the phenotype, the proliferation and migration of SMCs and 
control the inflammatory response in macrophages62,63. 
To summarize, miRs are important fine tuners of various biological processes in 
order to maintain homeostasis, but also play an important role in the context of 
inflammation, such as in atherosclerosis. 
 
1.3 The transcription factor NF-κB 
1.3.1 NF-κB activation pathway 
As described in the previous chapter 1.2.1, atherosclerosis is an inflammatory fibro-
proliferative disease, in which inflammation plays a central role in the initiation as well 
as the progression of atherosclerosis. Thereby, not only vascular cells undergo an 
inflammatory activation, but as well the circulating, adhering and infiltrating 
leukocytes. The transcription factor nuclear factor kappa B (NF-κB), first identified in 
198664, has been implicated with pro-inflammatory reactions as well as with 
atherosclerosis65. The NF-κB family has five members: RelA (p65), RelB and c-Rel 
and the precursor proteins NF-κB1 (p105) and NF-κB2 (p100). Both of these 
precursor proteins need to be processed into an active NF-κB form, being p50 and 
p52, respectively, whereas the other family members are already present in a mature 
state in the cytoplasm. The NF-κB transcription factors form dimers and bind to κB 
sites in promoters and enhancers of a variety of genes to induce as well as repress 
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gene transcription66. All family members share a conserved central region known as 
the Rel homology domain, which is involved in dimerization of the NF-κB proteins, 
DNA binding and interaction with the inhibitory molecules IκB. The vertebrate NF-κB 
transcription factor is induced by over 150 different stimuli, and in turn, active NF-κB 
controls transcription of over 150 target genes. The range of NF-κB-inducing stimuli, 
include physical, physiological and oxidative stress, bacterial and viral infections, 
inflammatory cytokines and engagement of antigen receptors, all able to elicit NF-κB 
activation. NF-κB regulates the expression of inflammatory cytokines, chemokines, 
immunoreceptors and cell adhesion molecules. In addition, NF-κB regulates cell 
differentiation, proliferation and survival. Because of this large variety in functions, 
NF-κB has often been called a “central mediator of human immune response”66,67. 
In resting conditions NF-κB is present in the cytoplasm bound to an inhibitory 
protein, named inhibitor of κB (IκB), which prevents NF-κB to translocate to the 
nucleus. NF-κB signalling can be activated via two main pathways, the classical 
(canonical) or the alternative (non-canonical pathway)68, as shown in Figure 5. While 
the canonical NF-κB pathway is mainly triggered by physiological pro-inflammatory 
stimuli such as TNF (in Figure 5 represented by TNFR1 signalling), the non-
canonical pathway is activated by TNF family members such as CD40L, BAFF and 
lymphotoxin-β (LT-β). In the canonical pathway, receptor stimulation triggers 
intracellular signalling leading to activation of the IκB kinase (IKK) complex69. The 
IKK complex consists of two catalytically active kinases, IKKα and IKKβ, and one 
regulatory component, IKKγ (NEMO). Once the IKK complex is activated, IKKβ 
mediates the phosphorylation of IκB proteins on two N-terminal serine residues in an 
NEMO-dependent manner. This then leads to the ubiquitination and proteasomal 
degradation of IκB70. Once the NF-κB dimer, mainly p65-containing heterodimers, is 
released from IκB, it is already in an active state and can translocate to the nucleus 
and start gene transcription66,71. The transcriptional activity of NF-κB is regulated by 
post-translational modifications, including acetylation, phosphorylation and 
ubiquitination. These post-translational modifications are necessary to ensure a tight 
regulation of NF-κB activity, given the wide range of biological processes that are 
affected by NF-κB72. 
Whereas the canonical NF-κB pathway mainly plays a central role in 
inflammatory responses, the non-canonical pathway has been implicated in B-cell 
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maturation and lymphoid development73. Non-canonical NF-κB signalling is triggered 
by TNF family members such as LT-β and depends only on the IKKα kinase and not 
IKKβ or IKKγ, in contrast to the canonical NF-κB pathway74. In resting conditions the 
inhibitory protein TRAF3 is associated with the kinase NIK and mediates its 
ubiquitination and proteasomal degradation75. Upon stimulation TRAF3 gets 
degraded (mediated by TRAF2 and cIAP), resulting in the stabilization of NIK76. 
Stabilized NIK activates IKKα homodimers by phosphorylation and in turn active IKKα 
mediates the phosphorylation and proteasomal processing of the NF-κB precursor 
p100. This processing leads to transcriptional active p52/RelB NF-κB 
heterodimers77,78 (Figure 5). To prevent exuberant NF-κB activation in response to 
non-canonical NF-κB stimuli, the deubiquitinase OTUD7B provides a negative 
feedback keeping non-canonical NF-κB activation in check by binding to TRAF3 and 
protecting it from degradation79. 
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Figure 5: Signalling pathways to NF-κB activation. The transcription factor NF-κB plays a central 
role in inflammatory reactions. It is activated via two main pathways. Inflammatory signals such as 
TNF induce canonical NF-κB activation through the IKKβ/NEMO kinase complex (left side). Once the 
IKK complex is activated, IKKβ phosphorylates in an NEMO-dependent manner the inhibitory protein 
IκB, causing its ubiquitination and proteasomal degradation. Once IκB is removed, the NF-κB dimer 
can translocate to the nucleus and start gene transcription. The transcriptional activity of NF-κB is 
regulated by post-translational modifications. Non-canonical NF-κB activation on the other hand is 
dependent on the IKKα kinase. NIK activates IKKα homodimers, which in turn phosphorylate the NF-
κB precursor p100 triggering its processing into a transcriptional active form. (Figure from 
Oeckinghaus, A. et al.66) 
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1.3.2 NF-κB activation in atherosclerosis 
NF-κB has been involved in different stages of atherosclerosis, from its initiation to 
plaque destabilization and rupture65,80,81. NF-κB expression has been found both in 
human atherosclerotic lesions82, e.g. in aortas of patients suffering from coronary 
atherosclerosis83, as well as in plaques from Ldl receptor (Ldlr)-deficient mice84. 
During initiation of atherosclerosis, endothelial cells become activated in response to 
various stimuli as described in the previous chapter. Once activated, endothelial cells 
express adhesion molecules (e.g. ICAM-1, VCAM-1, E-selectins), chemokines (e.g. 
MCP-1), cytokines (e.g. TNFα, IL-1, IL-6 and IL-8) and other pro-inflammatory 
proteins, which recruit leukocytes, help them to adhere to the endothelium and to 
infiltrate into the vessel wall. As many of these proteins are targets genes of NF-κB, 
this process involves the activation of NF-κB in endothelial cells in response to pro-
inflammatory molecules such as lipopolysaccharides (LPS), TNFα, oxLDL or 
cytokines65,85. Furthermore, endothelial dysfunction activates NF-κB through impaired 
NO production, which has been shown to inhibit NF-κB activation by increasing the 
expression of IκBα86,87. Also, haemodynamic forces influence vascular inflammation 
by regulating NF-κB activation in endothelial cells88. For example, the up-regulation 
of VCAM-1 and ICAM-1, both target genes of NF-κB, have been shown to be most 
prominent at lesion-prone sites with altered blood flow89. Human aortic ECs (HAECs) 
exposed to low shear stress or disturbed flow conditions, showed a significant 
increase in NF-κB (p50 and p65) activation compared with HAECs exposed to high 
shear stress (laminar flow conditions)90. And as already described in the previous 
chapter, NF-κB activity is elevated at regions of the arterial tree that are exposed to 
disturbed blood flow, while atheroprotected regions exposed to steady flow show 
increased expression of the protective transcription factor KLF2 (Figure 6)91-93. 
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Figure 6: NF-κB and haemodynamic forces. Schematic of flow conditions in a human carotid 
bifurcation. The straight segment displays uniform and laminar flow and here endothelial cells are 
exposed to high shear stress. These areas show an athero-protected, anti-inflammatory and anti-
thrombotic phenotype, which is induced by the increased expression of the transcription factor KLF2, 
which mainly targets atheroprotective and anti-inflammatory genes. In contrast, at the bifurcation, 
disturbed blood flow with flow reversal and secondary flows is typical. These areas are predisposed to 
atherosclerosis and the shear stress is relatively low. NF-κB activity is high in these regions leading to 
enhanced expression of pro-atherogenic NF-κB dependent genes (Figure adapted from Collins, T. et 
al.93) 
 
Furthermore NF-κB has been detected in advanced lesions in SMCs, 
macrophages and T-cells82,94. Canonical NF-κB activation results in the up-regulation 
of pro-inflammatory proteins as cytokines (e.g. TNFα, IL-6 and IL-8) and matrix 
metalloproteases (MMPs), but also of pro-thrombotic tissue factor (TF), most of these 
contributing to plaque progression and instability.   Through this regulation of gene 
expression, NF-κB signalling sustains pro-atherogenic recruitment and activation of 
inflammatory cells, and induces SMC proliferation80. Additionally, NF-κB has been 
associated with plaque rupture. Patients with unstable angina and high risk of plaque 
rupture showed increased NF-κB activity in their leukocytes95 and unstable plaques 
show higher NF-κB expression than stable plaques96. MMPs contribute to the 
destruction of extracellular matrix at shoulder regions of plaques and high MMP 
activity in macrophages has been associated with plaque rupture. MMP-1,-3 and -9, 
shown to be linked with plaque destabilization, are regulated by NF-κB97,98. 
The functions of NF-κB in atherosclerosis seem to be complex and NF-κB has 
been suggested as a potential therapeutic target for the treatment of 
atherosclerosis85,99. Reduced lesion formation in Apolipoprotein E (Apoe)-deficient 
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mice was observed when treated with the NF-κB inhibitor DHMEQ, which prevented 
the TNF-α-induced nuclear translocation of p65100. Recent studies showed anti-
inflammatory effects after selective inhibition of cRel, such as reduced neointima 
formation after vascular injury upon NF-κB inhibition in SMCs101 or decreased 
atherosclerotic lesion  size102. Furthermore, myeloid deficiency of IκBα, the inhibitor 
of NF-κB, promoted atherosclerosis by the recruitment of leukocytes into the 
lesion103. Also, the genetic deletion of NF-κB1 in macrophages of Ldlr-/- mice resulted 
in a decrease in atherosclerosis104. 
This demonstrates the potential of using NF-κB as a potential therapeutic target, 
but so far no drug has yet made it through clinical trials. One reason might be the 
complexity of NF-κB and its multiple functions in different cell types. Of note, in 
addition to its pro-inflammatory function, NF-κB activity in leukocytes has an 
important role in the resolution of inflammation through transcription of anti-
inflammatory cytokines such as IL-10105 and the suppression of pro-inflammatory IL1-
β secretion106. Therefore, although NF-κB-suppressing strategies to interfere with its 
pro-inflammatory functions seem to be a valid direction in pharmaceutical 
treatment81, caution has to be raised because of the important anti-inflammatory 
functions of NF-κB. Furthermore, as NF-κB is critical for many immune and 
inflammatory responses and additionally plays a central role in homeostasis, chronic 
inhibition and non-tissue specific inhibition would cause serious side effects. 
Therefore, the interest in developing selective and specific inhibitors targeting 
specific NF-κB signalling pathways over e.g. IKKα or IKKβ is high and could result in 
promising therapeutic instruments107,108.  
 
1.4 The IKK family 
1.4.1 Introducing IKK family members 
The IKK kinase complex is the core element of the NF-κB cascade. It essentially 
consists of two kinases (IKKα and IKKβ) and a regulatory subunit, IKKγ (also known 
as NEMO). The complex activated by external, inflammatory stimuli, is in charge of 
the phosphorylation of either the inhibitory protein IκB or the NF-κB precursor p100. 
These two separate NF-κB activation pathways require different subunits of the IKK 
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complex: while the canonical pathway depends on IKKβ and NEMO to trigger 
phosphorylation of IκB, the noncanonical pathway requires only IKKα for 
phosphorylation of p100. Several years ago, two protein kinases with structural 
similarities to IKKα and IKKβ were found. One was called IKK-ε or IKK-I and the other 
was named Tank-binding Kinase (TBK)-1, and both play a key role in the activation 
of IRF3 and IRF7, important for the induction of type 1 interferon (IFN-I)109. 
IKKα and IKKβ were first identified by Chen et al. (1996) and Didonato et al. 
(1997) with help of biochemical purification. Investigating the kinases responsible for 
phosphorylation of IκB proteins, they observed a complex migrating around 700-900 
kDa, containing two related catalytic subunits, later called IKKα (or IKK1) and IKKβ 
(or IKK2)110,111. NEMO was identified later and although this subunit does not have a 
catalytic function, cell lines deficient for NEMO cannot activate NF-κB, thereby 
proving the important regulatory function of NEMO in activating  NF-κB112,113. 
The two kinase subunits of the IKK complex, IKKα and IKKβ, have a high 
sequence homology (approximately 50% identity)114. Both are serine/threonine 
kinases, contain an N-terminal kinase domain (KD), α‐helical scaffold/dimerization 
domain (SDD) and a C-terminal NEMO-binding domain (NBD)115. Additionally, IKKα 
has a nuclear localization sequence, which is possibly linked with nuclear activity116. 
Furthermore, IKKβ contains a central, conserved ubiquitin‐like domain (ULD), which 
has been suggested to be required for kinase activity and, together with the SDD, to 
be involved in the exact positioning of the kinase substrate IκBα115 (Figure 7). A 
similar domain was not found in IKKα. Activation of IKKα and IKKβ is based on 
phosphorylation of two serine residues, S176/180 for IKKα and S177/181 for IKKβ, 
located in the so-called activation loop117. These phosphorylations probably lead to a 
conformational change and subsequently to kinase activity. A mutation of these 
serine residues to alanine renders the kinases inactive70. Nevertheless, how signal 
transmission from a stimulated receptor results in phosphorylation of the IKK 
activation loop is still discussed. The first scenario proposed is that the IKKs 
phosphorylate each other by autophosphorylation facilitated by either conformational 
changes within the IKK complex or induced proximity through the oligomerization of 
multiple core IKK complexes118. The second theory is the existence of separate IKK 
complexes that target these residues. Both theories seem plausible and of course it 
could be feasible that both mechanisms take place independently or together119,120. 
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Figure 7: Domain structures of IKK complex family members. IKKα and IKKβ both have an N-
terminal kinase domain (KD), α‐helical scaffold/dimerization domain (SDD) and a C-terminal NEMO-
binding domain (NBD). IKKβ has additionally an ubiquitin‐like domain (ULD), required for kinase 
activity. NEMO consists of two coiled‐coil domains (CC), a leucine zipper (LZ), a C‐terminal zinc‐finger 
(ZF) region and an IKKα/IKKβ binding zone located in amino acid 44‐111. (Figure adapted from Hinz, 
M. et al.115) 
 
A detailed inspection of IKKβ´s crystal structure revealed that when the kinase 
is inactive, the activation loop adopts conformations that are incompatible with 
protein substrate binding, which supports the theory that phosphorylation of the 
serine residues of IKKβ leads to conformational change121. Furthermore, it has been 
proposed that multiple combinations of IKK subunits exist, including homodimers of 
IKKα or IKKβ either associated or distinct from NEMO, but most biochemical 
evidence indicates that the majority of cellular IKK complexes contains a core of 
IKKα-IKKβ-NEMO in the ratio of 1:1:2 122. 
NEMO is a regulatory non-enzymatic scaffold protein and has been suggested 
to be a mainly α‐helical protein containing two coiled‐coil domains (CC), a leucine 
zipper (LZ) and a C‐terminal zinc‐finger (ZF) region123,124. In addition, NEMO has a 
minimal oligomerization domain (MOD) and an IKKα/IKKβ binding zone located in 
amino acid 44‐111 of NEMO (Figure 7). The MOD is an N‐terminal dimerization 
domain that enables the formation of higher order oligomers. The ZF has been 
implicated in efficient IκBα binding and might direct IκBα to the ULD/SDD of IKKβ125. 
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Of note, it was shown that IKK activation depends on NEMO. Exactly how NEMO 
regulates IKK activity is still unknown, but there is no doubt that it is a key regulator of 
the IKK complex, both positively and negatively122. It is possible that NEMO may 
function as a chaperone protein that brings the IKK complex to upstream 
polyubiquitinated kinases such as RIP-1, leading to IKK activation. However, 
phosphorylation of NEMO on S68, which is located in the region responsible for IKK 
interaction, has been shown to downregulate NF-κB activation in the presence of 
stimuli, providing the possibility that phosphorylation of NEMO can serve as a 
negative regulatory event. 
 
1.4.2 IKKβ and NEMO in atherosclerosis 
In recent years studies have focused on NF-κB and the IKK complex as potential 
therapeutic targets. As already mentioned in chapter 1.3.2 several studies 
successfully showed that blocking NF-κB could have atheroprotective, antithrombotic 
and anti-inflammatory effects. In terms of the IKK complex most studies chose IKKβ 
as their research target, due to its strong involvement in canonical NF-κB activation 
126
.  
Kanters et al. inhibited NF-κB activity specifically in macrophages and 
neutrophils using bone marrow transfer from LysM-Cre+ Ikkβ-floxed mice into Ldlr-/- 
recipient mice. In contrast to what was expected from inhibiting NF-κB activation, 
they observed increased atherosclerotic plaque development, which was linked with 
an important anti-inflammatory role of IKKβ/ NF-κB in regulating expression of the 
anti-inflammatory cytokine IL-10127.In the same direction, an anti-inflammatory role 
was described for IKKβ by suppression of the classically activated (or M1) 
macrophage phenotype128. However, a recent study observed, that deficiency of Ikkβ 
decreased adhesion, migration and lipid uptake in macrophages and reduced 
atherosclerosis in Ldlr-/- mice129. These inconsistent observations regarding the pro- 
vs anti-atherogenic function of IKKβ suggest that further research is needed to define 
the role of macrophage IKKβ/NF-κB signalling in atherosclerosis.   
Other studies showed a more pro-inflammatory and pro-thrombotic function for 
IKKβ. Low shear stress, which is seen as pro-atherogenic, induced both IKKα and 
IKKβ in HAECs, but IKKβ contributed to the majority of the IKK kinase activity130. 
Furthermore, IKKβ inhibition induced expression of endothelial thrombomodulin 
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,critically involved in anticoagulation, in a KLF2 manner131. Also, Ashida et al recently 
observed that upon IKKβ inhibition vascular endothelial cell permeability was 
increased and cell migration was decreased132. In relation to SMCs, IKKβ functions 
as a regulator of vascular inflammatory responses and atherosclerosis. Ikkβ 
deficiency specifically in SMCs rendered Ldlr-/- mice resistant to vascular 
inflammation and atherosclerosis induced by high-fat feeding, again suggesting a 
pro-atherogenic role of IKKβ133. 
Although it has been shown how essential NEMO is in case of cell survival and 
as a regulator of IKK activity, so far only one study used NEMO as potential NF-kB 
inhibition target. Gareus and colleagues generated a mouse model with an EC‐
specific ablation of NEMO to interfere with IKK activation, which resulted in greatly 
reduced atherosclerotic lesions134. This again links the IKK complex and canonical 
NF-κB activation with pro-atherogenic functions. 
Thus, NEMO/IKKβ/NF-κB signalling plays a complex role in inflammation and 
atherogenesis by driving pro-, but also anti-inflammatory processes and the outcome 
seems dependent on which cells are studied. 
 
1.4.3 Versatile functions of IKKα 
In contrast to IKKβ and NEMO the role of IKKα (IKK1/ CHUK) activity in 
atherosclerosis has not yet been investigated. However, IKKα exerts multiple 
versatile functions involved in inflammatory reactions and immune responses115, 
which could influence atherogenesis. 
In case of canonical NF-κB pathway, IKKβ and not IKKα is responsible for IκBα 
phosphorylation, but some studies have shown that IKKα has a compensatory 
function upon IKKβ inhibition and is able to directly phosphorylate IκBα itself135, 136. In 
addition to its compensatory function, IKKα has also been involved in resolving 
canonical NF-κB activation in macrophages and thus resolving inflammation, by 
triggering phosphorylation-induced degradation of the NF-κB isoform p65137. This 
observation could imply an atheroprotective function for IKKα as macrophages are 
atheroprogression-driving cells or rather imply atheroprotection based on the 
previously revealed anti-atherogenic role of IKKβ/ NF-κB signalling in 
macrophages127. Apart from its function in regulating canonical NF-κB signalling 
through p65 destabilization, IKKα homodimers are critical for alternative NF-κB 
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activation66. As mentioned in the previous chapter on NF-κB, IKKα mediates 
alternative pathway signalling through phosphorylation of NF-κB p100, triggering 
p100 processing and the release and nuclear localization of RelB-p52 dimers74. This 
pathway plays a crucial role in B-cell maturation and could thereby implicate IKKα in 
atherogenesis through the role of B-cells in atherosclerosis41.  
Furthermore, IKKα has multiple other roles, e.g. IKKα exerts different nuclear 
functions. Multiple studies have shown that IKKα can be detected in both the 
cytoplasm and the nucleus, whereas IKKβ is detected predominantly in the 
cytoplasm138. The observation of nuclear/cytoplasm shuttling of IKKα led to the 
discovery of the first nuclear role of IKKα in phosphorylating histone H3, involved in 
both NF-κB-dependent as -independent gene expression139,140. IKKα has also been 
involved in negative regulation and termination of gene transcription. For example, 
diverse pro-inflammatory stimuli trigger IKKα-mediated phosphorylation of the 
transcriptional repressor PIAS1, which then negatively regulates the expression of a 
predominantly pro-inflammatory subset of p65- and STAT1-dependent genes141. 
Also, the IKKα-mediated phosphorylation of TAX1BP1 triggers the assembly of the 
A20 ubiquitin-editing complex, which is an important negative regulator of canonical 
NF-κB activation142. 
Aside from nuclear regulation of gene transcription, nuclear IKKα has also been 
associated with functions independent of its kinase activity. For example, in 
keratinocytes, nuclear IKKα is a critical co-regulator of a Smad4-independent TGFb-
Smad2/3 signalling pathway, which induces cell cycle arrest and terminal 
differentiation138,143. 
In conclusion, the IKKα kinase is involved in diverse functions which could be 
classified as both pro- as well as anti-inflammatory. Being such a versatile regulator 
of cell signalling and pro- and anti-inflammatory gene expression, IKKα could play a 
distinctive role in atherosclerosis. 
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2. Aim of the study 
One of the pressing goals within atherosclerosis research is to find therapeutic 
strategies to treat plaque development, progression and rupture in order to prevent 
cardio- and cerebrovascular complications. 
Given the versatile functions of IKKα such as e.g. in alternative NF-κB 
activation66, termination of the canonical NF-κB activation in macrophages137 or 
modulation of gene expression by e.g. phosphorylating histone H3139, IKKα could 
potentially be a new therapeutic target for treating atherosclerosis. However, its 
function in atherogenesis first needs to be studied in detail. Hence, the overall aim of 
this study was to determine the role of haematopoietic IKKα activation versus the 
global function of IKKα activation in atherosclerosis. For both approaches an 
activation-resistant Ikkα (IkkαAA/AA) mouse model, in which the Ikkα kinase activity 
cannot be activated, was used144, with a hyperlipidemic Apolipoprotein E-deficient 
(Apoe-/-) background. 
(1) In the first part of the study, the role of Ikkα kinase activity in haematopoietic 
cells was determined, as inflammatory cells are crucial players driving 
atherosclerosis. Haematopoiesis and atherogenesis were studied after lethal 
radiation and transplantation of atherosclerosis-prone Apoe−/− mice with bone marrow 
carrying an activation-resistant IkkαAA/AA mutant. The mice received a high-fat diet for 
either 8 or 13 weeks and the haematopoietic profile was investigated with help of flow 
cytometric analysis to determine the importance of Ikkα in the development and 
homeostasis of leukocyte populations. The extent of atherosclerotic progression, 
lesion composition and intracellular lipid accumulation were examined to reveal 
potential roles of haematopoietic Ikkα kinase activity in atherogenesis and in 
macrophage lipid uptake, the latter being an important task of macrophages to clean 
up lipid deposits in the vascular wall. Due to the reported function of Ikkα on 
canonical NF-κB activation137, the effect of haematopoietic activation-resistant Ikkα 
mutation on the activation of the canonical NF-kB isoform p65 was examined in 
macrophages, as modulation of canonical NF-kB activation could interfere with 
macrophage function or survival and thus with atherogenesis. In context of the latter, 
I examined macrophage apoptosis in atherosclerotic lesions from IkkαAA/AAApoe-/- 
mutant vs control mice. Furthermore, the effect of Ikkα mutation on inflammatory 
  Aim of the study 
24 
 
gene expression in macrophages was studied, to reveal potential mechanisms how 
Ikkα could affect inflammatory processes and thus atherogenesis in macrophages.  
(2) The second part of the study focussed on the global role of Ikkα kinase 
activation in atherosclerosis, which was studied by comparing atherosclerosis in 
IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- mice after 13 weeks of high-fat diet. Similarly as for 
the first study, the contribution of Ikkα in atherogenesis was studied on the level of 
plaque size and atherosclerotic lesion composition. Additionally, potential site-
specific functions of Ikkα kinase activity were analysed by comparing the effect of 
Ikkα mutation on atherogenesis in the aortic root, aortic arch and aorta. This is 
important because previous studies have shown such site-specific effects of other 
proteins on atherogenesis145,146. Furthermore, because of the known role of Ikkα in 
both NF-κB-dependent as -independent gene expression139,140, the effect of IkkαAA 
mutation on downstream signalling, such as NF-κB p65 activity and histone H3 
phosphorylation, was studied at different vascular regions, to reveal potential 
mechanisms on how Ikkα kinase activity could affect atherogenic processes. Also, 
gene expression studies were performed in IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- mice at 
different vascular regions, to asses the involvement of Ikkα on site-specific gene 
regulation. Site-specific expression and activation profiles of Ikkα itself were studied 
at different vascular regions in Apoe-deficient mice to estimate whether flow 
conditions or different vascular regions would differentially influence Ikkα activity or 
expression and thereby influence the atherosclerotic outcome. On the same note, a 
potential role for miRs in controlling and regulating Ikkα expression was investigated, 
as miRs have been shown to be highly involved in flow-dependent vascular 
remodeling58.  
The IkkαAA mouse model and all techniques and methods are explained in detail in 
the following chapter 3. 
Materials and Methods 
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3. Materials and Methods 
3.1 Materials 
3.1.1 General equipment 
Table 1: List of general equipment 
Equipment Manufacturer 
Autoclave Systec 2540EL (Systec, Germany) 
Balance Sartorius, Germany 
Centrifuges Eppendorf 5417C (Eppendorf, 
Germany) 
Eppendorf 5425 (Eppendorf, 
Germany) 
Flow cytometer FACSCanto-II (BD Biosciences, USA) 
Fluorescence plate reader Infinite M200 (Tecan, Germany) 
Incubator Hera Cell 240 (Fisher Scientific 
GmbH, Germany) 
Laminar flow hood Herasafe (Heraeus, Germany) 
Microscopes Leica DM2500 (Leica, Germany) 
CCD camera 
 
Microtome Leica RM2245 (Leica, Germany) 
Cryotome Leica CM3050S (Leica, Germany) 
pH-meter InoLab level 1 (WTW, Germany) 
PCR thermocyclers MyCycler (Bio-Rad, Hercules, CA) 
DNA Engine Opticon (MJResearch, 
Hercules, CA, USA) 
Spectrometer NanoDrop (Peqlab, Erlangen, 
Germany) 
Homogenizer TissueLyser LT (Qiagen, Hilden, 
Germany) 
Real-Time PCR Thermocycler ViiA7 (Applied Biosystems, Life 
Technologies, Germany) 
 
3.1.2 Mice 
Wild-type C57BL/6, Apolipoprotein E-deficient (Apoe-/-) were obtained from the local 
animal breeding facility. Apoe-/- mice are established mouse models to study the 
development and disease progression of atherosclerosis147. To study the effect of 
Ikkα activation in atherosclerosis, a knock-in mouse model was used expressing an 
activation-resistant IkkαAA/AA mutant, with two serine phospho-acceptor sites in the 
activation loop replaced by alanines144. The IkkαAA/AA mutants were then crossed with 
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atherosclerosis-prone C57BL/6 Apoe-/- mice to generate IkkαAA/AAApoe-/- mice. The 
genotyping protocol is described in chapter 3.2.3.2. 
 
3.1.3 General consumables 
 
Table 2: List of consumables 
Consumable Manufacturer 
6-well plates (flat bottom) uncoated Greiner Bio-one, Germany 
12-well plates (flat bottom) uncoated Greiner Bio-one, Germany 
24-well plates (flat bottom) uncoated Greiner Bio-one, Germany 
96-well plates (flat bottom) Becton Dickinson, USA 
96-well plates (round bottom) Nunc, Denmark 
Cell strainer (70/100 µm) BD Biosciences, USA 
Culture dishes (15 cm) Greiner Bio-one, Germany 
Culture flasks (T25, T75, T175) Greiner Bio-one, Germany 
FACS-tubes BD Biosciences, USA 
EDTA-coated tubes Sarstedt, Germany 
FACS-tubes BD Biosciences, USA 
Glass microscope slides Thermo Scientific, Germany 
Needles 23/27 G BD Microlance, USA 
PD 10 column GE Healthcare, Germany 
Pipettes (0.1-2 µl; 2-20µl; 10-100µl, 
20-200µl, 100-100µl) and 
Multichannel-Pipette 
VWR, USA 
Serological pipettes (5 ml, 10 ml, 25 
ml) 
Corning, USA 
Sutures Seraflex, USP 7/0 Naila, Germany 
Syringes (1 ml) Braun, Germany 
Syringes (2 ml, 5 ml, 10 ml, 20 ml) Terumo, Belgium 
 
3.1.4 Miscellaneous reagents, media and buffers 
Table 3: List of miscellaneous reagents and suppliers 
Reagent Supplier 
Accutase  PAA, Austria 
Bovine serum albumin (BSA) Serva, Germany 
Complete mini EDTA-free Protease 
Inhibitor Cocktail 
Roche, Germany 
DAPI Vector Burlingame, USA 
 1,10-dioctadecyl-3,3,3030-
tetramethylindocyanide perchlorate 
(DiI) 
Life Technologies, USA 
Eosin G-Solution 0,5%  Roth, Germany 
EDTA Bohringer Mannheim, USA 
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Fetal calf serum (FCS) PAA, Austria 
Gentamycin Gibco, Germany 
Hank´s Buffered Saline Solution 
(HBSS) 
Gibco, Germany 
Hematoxylin Applichem, Germany 
Hepes Gibco, Germany 
Human serum Innovative Research, USA 
Isoflurane Abbott, Germany 
Ketamine CEVA, Germany 
LDL Calbiochem, USA 
L-Glutamine PAA, Austria 
Lysis Buffer 10 x Cell Signaling, USA 
Mounting Medium with DAPI Laboratories Inc., USA 
Mouse serum Sigma-Aldrich, USA 
Nile Red Sigma-Aldrich, USA 
Oil-Red-O Sigma-Aldrich, USA 
Paraformaldehyde Sigma-Aldrich, USA 
PBS PAA, Austria 
Penicillin PAA, Austria 
Picric acid Sigma-Aldrich, USA 
Picrofuchsin solution Merck Milipore, Germany 
Rabbit serum Sigma-Aldrich, USA 
Resorcin-Fuchsin solution Carl Roth, Germany 
RNAlater Ambion Life Technologies, Germany 
RPMI 1640 Sigma-Aldrich, USA 
Sirius Red Polysciences, Inc., USA 
Tissue Tek® O.C.T compound Sakura Finetek Europe B.V., 
Netherland 
Vectashield mounting medium w/wo 
DAPI (4',6-diamidino-2-phenylindol) 
Vector Laboratories, Inc., USA 
Vitro-Clud Augenbrinck, Germany 
Xylazine Medistar, Germany 
 
Table 4: Preparation of buffers, solutions and media 
Buffer/ Solutions/ Medium Composition 
ASDCL solution 50 ml PBS with 0.4 ml 
hexazoniumsolution, adjust pH to 6.58 
and add 1 ml Naphtol-AS-D 
Chloroacetate solution 
Antibody diluting solution PBS containing 
10% blocking solution 
Anesthesia 0.05 ml Xylazine (final dose: 10 
mg/kg), 0.1 ml 
Ketamine (final dose: 100 mg/kg) and 
0.85 ml 
0.9% sodium chloride 
Blocking solution PBS containing 1% bovine serum 
albumin (BSA) and 2.5% horse serum 
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Buffer A 10 mM Hepes pH 7.8, 1.5 mM MgCl2, 
0.5 mM DTT and freshly added 1× 
Complete EDTA-free protease 
inhibitor cocktail 
Buffer B 20 mM Hepes pH 7.8, 420 mM NaCl; 
1.2 mM MgCl2, 0.2 mM EDTA, 25% 
glycerol, 0.5 mM DTT and freshly 
added 1× Complete EDTA-free 
protease inhibitor cocktail 
FACS staining buffer 2% mouse serum, 2% human serum, 
2% rabbit serum, 2% BSA in PBS 
Hank’s complete solution 1 x HBSS containing 0.3 mM 
EDTA, 0.1% BSA in Millipore water 
L929 Culturing Medium RPMI 1640 with L-Glutamine and 
10% FCS, 5 mM Hepes, 1% Penicillin  
Macrophage Culturing Medium RPMI 1640 with L-Glutamine and 
10% FCS, 10 mM Hepes, 100 U/mL 
Gentamycin and 15% LCM (L929-
conditioned-medium) 
Nile Red Working Solution Dilute Nile Red stock solution with 
75% glycerin to an end concentration 
of 2.5 µg/ml. Both stock and working 
solutions should be kept dark and at 
4°C. (Concentration Nile Red stock 
solution 500 µg/ml, dissolved in 
aceton)  
Paraformaldehyde (PFA) 
fixation solution 
4% PFA, 5% sucrose and 0.02 M 
EDTA in PBS  
(pH 7.4) 
Red blood cell lysis buffer 0.8% NH4Cl, 10 mM KHCO3 and 0.1 
mM EDTA 
in Millipore water (pH 7.4) 
Sirius Red solution 0.1% Sirius Red in picric acid 
Sodium citrate cooking buffer 
 
12.6 ml of 0.1 M citric acid, 57.4 ml of 
0.1 M sodium-citrate dehydrate and 
0.35 ml Tween20 dissolved in 630 ml 
distilled water 
Vitro-Clud mounting medium Vitro-Clud in xylene 
Weigert’s A solution 10 g hematoxylin, 1000 ml 96% 
ethanol 
Weigert’s B solution 40 ml 29% ferric-chloride-solution, 
950ml distilled water, 7.5 ml 37% HCl 
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3.1.5 Antibodies, cytokines, endotoxins and inhibitors 
Table 5: List of cytokines, endotoxins and inhibitors 
Cytokine Manufacturer 
Murine Tnf-α Peprotech, USA 
LPS Sigma Aldrich, USA 
Cytochalasin D (CytD) Abcam, UK 
 
Table 6: List of antibodies 
Antibody 
Target 
Specificity Conjugate Application Manufacturer 
Cd115 Monocytes, 
Macrophages 
PE FC eBioscience, USA 
Cd11b Monocytes, 
Neutrophils, 
Macrophages 
FITC FC BD Biosciences, 
USA 
Cd4 T helper cells FITC FC eBioscience, USA 
Cd3 T-cells APC FC BD Biosciences, 
USA 
Cd45 Leukocytes APC-Cy7 FC BD Biosciences, 
USA 
Cd8a Cytotoxic  T-
cells 
PE-Cy7 FC eBioscience, USA 
Gr1 Monocytes, 
Neutrophils 
PerCP FC eBioscience, USA 
Cd11c Dendritic cells Pe-Cy7 FC eBioscience, USA 
Cd19 B-cells PerCP FC BD Biosciences, 
USA 
MHCII Dendritic 
cells, 
plasmacytoid 
dendritic cells, 
recheck 
datasheet, as 
also on other 
cell types (eg 
macrophages) 
FITC FC BD Biosciences, 
USA 
Cd62L Naive T-cells, 
central 
memory T-
cells 
FITC FC BD Biosciences, 
USA 
Cd44 Effector 
memory T-
cells, central 
memory T-
cells 
PerCP FC eBioscience, USA 
Cd25 Regulatory T- PE FC BD Biosciences, 
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cells, B-cells USA 
440c Plasmacytoid 
dendritic cells 
AF647 
(APC) 
FC eBioscience, USA 
F4/80 Macrophages APC FC eBioscience, USA 
FoxP3 Regulatory T-
cells 
APC FC eBioscience, USA 
Mac2 Macrophages Purified IFS Cedarlane, 
Canada 
Sma Smooth 
muscle cells 
Purified IFS Dako, Denmark 
Cd3 T-cells Purified IFS AbD Serotec, 
USA 
Goat IgG Goat IgG Cy3 IFS Jackson 
ImmunoResearch, 
USA 
Rat IgG Rat IgG FITC IFS Jackson 
ImmunoResearch, 
USA 
Mouse IgG Mouse IgG Cy3 IFS Jackson 
ImmunoResearch, 
USA 
 
3.1.6 Assay kits 
Table 7: List of assay kits 
Assay Supplier 
Bradford Quick Start Protein Assay BioRad, Germany 
cDNA SuperScript Synthesis Vilo kit Life Technologies, USA 
Cobas Enzymatic Assay cholesterol + 
triglyceride kit 
Roche, Germany 
Cytokine Bead Array (CBA) Mouse 
Inflammation Kit 
BD Biosciences, 
USA 
DNase, RNase-free Qiagen, Germany 
In situ Death Detection kit Roche, Germany 
Mcp1 ELISA R&D Systems, USA 
mirVana RNA Isolation kit Ambion Life Technologies, USA 
PathScan Phospho-Histone H3 
Sandwich ELISA kit 
Cell signaling, USA 
PhosphoTracer IKKα (pS176/180) + 
total IKKα ELISA kit 
Abcam, UK 
TaqMan MicroRNA Assay Ambion Life Technologies, USA 
TransAM NF-κB p65 ELISA Active Motif, the Netherlands 
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3.1.7 Primers 
Table 8: List of primers 
Primer 
name 
Sequence Use Supplier 
Ikkα 
Wildtype 
Primer 1: 5´-
GGTTTGTAAAAACATTGGTACCTT
TT and Primer 2: 5´-
CAATGTTCCCACAAAAGATGTACA
GAGACT 
Genotyping 
PCR 
Primers 
Sigma 
Aldrich, 
USA 
IkkαAA/AA 
Mutant 
Primer 1: 5´-
CCTCTCAGTGGCTCACCTTT and 
Primer 2: 5´-
CAATGTTCCCACAAACGCTGTACA
GAGCGC 
Genotyping 
PCR 
Primers 
Sigma 
Aldrich, 
USA 
β-actin 5′-CAACGAGCGGTTCCGATG and 
5′-GCCACAGGATTCCATACCCAA 
SYBR 
Green 
qPCR 
Sigma 
Aldrich, 
USA 
Ikkα 5′-CCTCTCAGTGGCTCACCTTT and 
5′-
CAATGTTCCCACAAAAGATGTACA
GAGACT 
SYBR 
Green 
qPCR 
Sigma 
Aldrich, 
USA 
IkkαAA/AA  5′-CCTCTCAGTGGCTCACCTTT and 
5′-
CAATGTTCCCACAAACGCTGTACA
GAGCGC 
SYBR 
Green 
qPCR 
Sigma 
Aldrich, 
USA 
Il-6 5′-ATGGATGCTACCAAACTGGAT 
and 5´-
TGAAGGACTCTGGCTTTGTCT 
SYBR 
Green 
qPCR 
Sigma 
Aldrich, 
USA 
Vcam-1 5′-TGCCGAGCTAAATTACACATTG 
and 5´-
CCTTGTGGAGGGATGTACAGA 
SYBR 
Green 
qPCR 
Sigma 
Aldrich, 
USA 
18S-Rna 5′-CGGACAGGATTGACAGATTG 
and 5´-
CAAATCGCTCCACCAACTAA 
SYBR 
Green 
qPCR 
Sigma 
Aldrich, 
USA 
 
Gapdh 
 
5´-ATTGTCAGCAATGCATCCTG 
and 5´-
ATGGACTGTGGTCATGAGCC 
 
SYBR 
Green 
qPCR 
 
Sigma 
Aldrich, 
USA 
 
The following targets (chuk/ikkα, gapdh, hprt-1, 18S-rna, ccl-19, ccr7, mmp-3-9-13, 
mir-23a, mir-425, mir-301a/b, let7b, mir-16, mir-152, sno-135 and mir-429) were 
analysed using Taqman real-time PCR (Life Technologies, USA). 
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3.1.8 Software 
Table 9: List of software 
Software Supplier 
Diskus Hilgers, Germany 
FACSDiva BD Biosciences, USA 
FlowJo Treestar, USA 
GraphPad Prism 5 GraphPad Software, USA 
Image J National Institutes of Health, USA 
 
3.2 Methods 
3.2.1 Mouse experiments 
3.2.1.1 Organ isolation 
Eight-weeks old female IkkαAA/AAApoe-/- and littermate Apoe-/- mice were fed a high-
fat diet containing 21% fat and 0.15% cholesterol (Atromin) for 8 or 13 weeks, 
respectively, depending on the experimental setup. In some experiments a normal 
chow diet control group was included. On time of organ isolation, the mice received 
Ketamin/Xylazin anesthesia and the blood was withdrawn by cardiac puncture, after 
which the mouse was perfused with 10 ml PBS. 
Tissue needed for protein isolation was harvested and stored in ice-cold PBS 
on ice until further processed (chapter 3.2.4.1). Protein extraction was performed 
from aortic root, thoracic aorta and aortic arch. If the tissue was needed for RNA 
isolation, the mouse was perfused with 5 ml RNAlater. Afterwards the tissue was 
harvested and stored in RNAlater until further processed (chapter 3.2.3.2). RNA was 
isolated from aortic root, thoracic aorta, aortic arch and carotid arteries. 
Tissue needed for cell isolation and subsequent flow cytometric analysis was 
only perfused with PBS and stored in Hank´s complete (3.2.4.1). 
If the tissue was used for atherosclerotic lesion analysis, the mouse was 
additionally perfused with 10 ml 4% PFA. The extent of atherosclerosis was 
assessed in aortic root and thoraco-abdominal aorta by staining for lipid deposition 
with Oil-red-O (3.2.5.2) and in the brachiocephalic artery (BCA) by Elastica-Van-
Gieson staining. The relative content of macrophages, neutrophils, Cd3+ T-cells, 
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SMCs and apoptotic cells was determined by histochemical and immunofluorescent 
staining (all described in chapter 3.2.5).  
The BCA was fixed overnight in 4% PFA at 4°C, dehydrated and then 
embedded in paraffin. Within a standardized distance (0 to 500 µm) from the 
bifurcation, serial 5 µm transversal sections from the paraffin-embedded carotid 
arteries were collected on glass microscopy slides by cutting with a microtome. 
The aortic root was fixed overnight in 4% PFA at 4°C, embedded in TissueTek 
and serial 5 µm transversal sections were made and collected on SuperFrost glass 
microscopy slides by cutting with a cryotome. 
The aorta was fixed overnight in 4% PFA at room temperature. The next day 
the aorta was opened longitudinally and fixed on a rubber-coated microscopy slide 
with the endothelium facing upwards. 
3.2.1.2  Bone marrow transplantation model 
Bone marrow (BM) cells from IkkαAA/AAApoe−/− mice and control Ikkα+/+Apoe−/− 
littermates were isolated from femur and tibia under sterile conditions. The cells were 
subsequently administered to female C57BL/6 Apoe−/− recipient mice (3×106 
cells/mouse) by lateral tail vein injection one day after a lethal dose of whole-body 
irradiation (2×6.5 Gy). After four weeks of recovery, the success of the 
transplantation was analysed with help of real-time quantitative PCR analysis. 
In order to determine the degree of chimerism in the bone marrow-transplanted 
mice, the mutated IkkαAA allele was quantified relatively to the wild-type Ikkα allele in 
genomic DNA isolated from blood cells. Real-time PCR was performed using the 
Maxima SYBR Green qPCR Mastermix (Fermentas) using specific primer pairs for 
Ikkα, IkkαAA/AA and β-actin as a reference gene. The method was validated by 
analyzing a standard curve using genomic DNA from IkkαAA/AAApoe−/− and 
Ikkα+/+Apoe−/− blood cells, mixed at different ratios.  
Once the chimerism was confirmed, the mice received a high-fat diet for either 8 
or 13 weeks.  
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3.2.1.3  Partial ligation model 
The partial ligation model is a model to create turbulent flow conditions in the carotid 
artery. Female mice were subjected to partial ligation of the left carotid artery as 
described earlier148. Mice were anesthetized by intraperitoneal injection of 
ketamine/xylazine (100 mg/kg ketamine and 10 mg/kg xylazine) anesthesia solution. 
The shaved area of the frontal neck was disinfected and a ventral midline incision 
was made in the left lateral side of the neck. The left carotid artery was exposed by 
blunt dissection using a stereo-microscope (Olympus SZX7). The external (ECA), 
internal (ICA) and the occipital arteries (OA) were completely ligated using sutures 
allowing blood outflow only via the superior thyroid artery (STA) (Figure 8). The 
incision was closed with wound clips. The right (RCA) and left carotid artery (LCA) 
were harvested for RNA isolation after 1, 7 days and 6 weeks respectively, following 
perfusion with PBS and RNAlater. 
 
Figure 8: Schematic representation of the partial ligation model. Three branches of the left carotid 
artery (LCA) get ligated: the external carotid artery (ECA), internal carotid artery (ICA), and occipital 
artery (OA). The small superior thyroid artery (STA) is left open, so all blood flow from the LCA now 
runs through the STA under turbulent flow conditions (Figure adapted from Nam, D. et al.148) 
 
3.2.2 Cell culture 
3.2.2.1 Isolation, culturing and stimulation of bone marrow-derived 
macrophages 
The femurs and tibiae from IkkαAA/AAApoe-/- and Apoe-/- mice were isolated and stored 
in PBS on ice. Bone marrow was flushed with ice-cold PBS using a 27-G needle 
under sterile conditions and the bone marrow was resuspended in PBS by repeated 
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vigorous pipetting. Then the homogenous solution was filtered using a 70 µM cell 
strainer. The filtered solution was centrifuged, the resulting pellet resuspended in 
macrophage culture medium and the cells plated on 15 cm untreated culture dishes. 
Bone marrow-derived macrophages from cryopreserved bone marrow cells were 
generated as described149. Both culturing and stimulation of the macrophages were 
performed in macrophage cultivation medium, at which the 15% LCM was always 
added freshly. After 7 days of culturing, differentiated macrophages were used for 
stimulation experiments and transferred onto untreated 6-well dishes. The cells were 
left for 24 hours to adhere und were then stimulated with 100 ng/ml LPS, 10 ng/ml 
mouse Tnf-α or 50 µg/ml mildly oxidized LDL. In all experiments an unstimulated 
control was included.  
3.2.2.2  Generation of L929-conditioned medium (LCM) 
Cryopreserved L929 cells were defrosted at 37°C and the cells plated in pre-warmed 
L929 culture medium in a T-75 flask. Cell were split twice every week with trypsin 
and subsequently seeded on new T-75 flasks. The cells were expanded for 
approximately 1 week until enough cells were available to fill 4 T-175. The flasks 
were filled up with culture medium and the cells left for 11 days at 37°C to incubate. 
After 11 days the medium was poured off and filtered while the cells were discarded. 
The filtered L929 conditioned medium (LCM) was aliquoted, flash-frozen and stored 
at -80°C.  
3.2.2.3  Preparation of oxLDL  
OxLDL was prepared by oxidation of LDL with a 50 nM copper sulphate solution for 4 
hours at 37°C to receive mildly oxidized LDL and overnight for heavily oxidized LDL. 
The oxidation was stopped by addition of EDTA and afterwards the oxLDL solution 
was purified over a PD 10 column. The oxLDL solution was kept dark at 4°C and was 
used for a maximum of 2 weeks. 
For lipid uptake experiments heavily oxidized LDL was labelled with Dil. Dil is an 
orange-red fluorescent lipophilic membrane stain that diffuses laterally to stain the 
entire cell. The amount of Dil-labeled oxLDL taken up by the macrophages can be 
measured by flow cytometry. After incubation of 0.5 mg/ml oxLDL with 20 µL of Dil 
(stock 3 mg/ml in DMSO) overnight at 37°C, the Dil-labelled oxLDL was purified over 
a PD 10 column and stored at 4°C for a maximum of 2 weeks. 
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3.2.2.4  Foam cell formation 
Foam cells develop from macrophages that take up oxidized lipids such as oxLDL. In 
order to quantify the uptake of DiI-labelled heavily oxidized LDL by BM-derived 
macrophages, macrophages were plated on 24-well plates and left to adhere 
overnight at 37°C. The next day, non-adherent cells were rinsed off with PBS and 
medium containing 1 µg/ml or 10 µg/ml Dil-oxLDL was added. The actin inhibitor 
cytochalasin D was used to analyse whether the lipid uptake occurred in an actin-
dependent manner. For this set-up, controls were pre-incubated for 1 h with 10 mM 
cytochalasin D, followed by a stimulation with 10 µg/ml Dil-oxLDL and 10 mM 
cytochalasin D. The cells were stimulated for 3 or 24 hours, washed with PBS and 
stained for the macrophage marker F4/80. As control, cells without diI-oxLDL 
incubation were used to assess background staining resulting from cell 
autofluorescence of the macrophages. Flow cytometric analysis was performed using 
a FACSCanto II and the data were analysed using FlowJo software. Data were 
calculated by subtracting the autofluorescence of the controls from the fluorescence 
of the diI-oxLDL-treated samples and were expressed as geometric mean 
fluorescence intensity (gMFI). 
To measure the possible cytokine and chemokine secretion from BM-derived 
macrophages, cells were plated in 6-well plates, left for 24 h to adhere. The next day 
the macrophages were stimulated with 10 ng/ml murine Tnf-α or 50 µg/ml heavily 
oxidized LDL. As control, unstimulated cells were included. After 24 h the medium 
was harvested from the cells, and cytokine and chemokine levels were measured by 
flow cytometry using a Cytometric Bead Array. In addition, Mcp1 levels were 
measured using a mouse Mcp1 ELISA. 
 
3.2.3 Molecular methods 
3.2.3.1  DNA isolation  
Genomic DNA (gDNA) for mouse genotyping was isolated from mouse tail cuts with 
the Bio Sprinter 96 from Qiagen (Hilden, Germany) according to the manufacturer’s 
protocol. 
Materials and Methods 
 
37 
 
3.2.3.2  Genotyping for the IkkαAA/AA mutation 
DNA was isolated either from blood or mouse tails as described in the previous 
chapter. Once the DNA concentration was measured and adjusted to 100 ng/µl, a 
mastermix according to the following composition was made. 
Table 10: PCR mastermix for genotyping Ikkα mutant (IkkαAA/AA) and wildtype allele 
Component Volume Final Concentration 
5x Green Gotaq Flexi 
buffer 
5 µl 1 x 
MgCl2 3 µl 3 mM 
dNTPs 0.5 µl 0.2 mM 
Primer 1 2.5 µl 0.2 µM 
Primer 2 2.5 µl 0.2 µM 
GoTaq DNA Polymerase 0.13 µl - 
Water Fill up to 25 µl - 
gDNA 2 µl - 
Total Volume 25 µl  
 
The primer combinations for detecting the Ikkα mutant (IkkαAA/AA) and wildtype 
allele are given in table 8. Samples as well as controls for Ikkα mutant, wildtype and 
heterozygote mice were included for testing. The PCR run was designed according 
to the following conditions described in table 11. 
Table 11: PCR run for Ikkα genotyping 
Step Temperature Time 
Initial Denaturation 95 °C 10 min 
Step 1. Denaturation 95 °C 30 s 
Step 2. Annealing 58 °C 30 s 
Step 3. Elongation 72 °C 45 s 
Final Elongation 72 °C 3 min 
Storing 4°C - 
Repeat Step 1-3 in 35 cycles 
 
The PCR were finally tested on 2% agarose gel at 130 V with 100 bp DNA 
ladder. 
3.2.3.3  RNA Isolation and cDNA synthesis  
RNA was isolated from aortic root, arch and thoracic aorta from IkkαAA/AAApoe-/- and 
control mice after 6 weeks of high-fat diet or normal diet. After partial ligation of  
Apoe-/- mice, RNA was isolated from left and right carotid artery. For miR studies 
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RNA was isolated from aortic root, arch and thoracic aorta from Apoe-/- mice after diet 
conditions, as well as carotid arteries after partial ligation. In all cases the mirVana 
RNA Isolation kit was used as described by the manufacturer. RNA isolation was 
followed by digestion of genomic DNA using the RNase-free DNase set according to 
the manufacturer’s protocol. 
cDNA for quantitative real-time PCR was reversed transcribed from RNA using 
the SuperScript cDNA Synthesis Vilo kit. In case of the miR studies the isolated miRs 
were reverse transcribed into cDNA using the TaqMan miR Reverse Transcription kit. 
Quantitative real-time PCR for miRs was performed with help of TaqMan miR Assays 
as described in the manufacturer´s protocol.  
3.2.3.4  Quantification of RNA/ DNA 
DNA and RNA concentrations and purity were determined by measuring the 
absorbance at 260 nm (A260) and 280nm (A280) in a spectrophotometer 
(Nanodrop). Pure DNA or RNA has an A260/A280 ratio of 1.8-2.0 at pH 7.0. 
3.2.3.5  Quantitative real-time PCR 
Quantitative real-time polymerase chain reaction (qPCR) is a laboratory technique 
used to amplify, detect and quantify a target DNA molecule. The principle is based on 
a regular PCR, with the addition that the amplified DNA is detected with help of 
fluorescent reporters in “real time”150. There are basically two main methods for 
quantitative detection of PCR products. One method is the usage of double-strand 
binding fluorescent dye as reporter, and the other method is performed with help of 
fluorescent probe as reporter. In the first method the DNA-binding dye, such as 
SYBR Green, is unspecific and thereby binds to all double-stranded DNA, causing 
fluorescence. An increase in DNA product by amplification leads to an increase in 
fluorescence intensity. 
The fluorescent reporter probe only binds to the DNA containing a sequence 
complementary to the probe sequence. The probe is an oligonucleotide with a 
fluorescent reporter at one end and a fluorescence quencher at the opposite end of 
the probe (e.g. Taqman probe). As long as the probe is intact the reporter and 
quencher stay close to each other, which prevents the emission of any fluorescence. 
After hybridization of the probe to the complementary DNA sequence the DNA Taq 
polymerase starts the extension. The 5´endonuclease activity of the DNA Taq 
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polymerase cleaves the probe during extension, which separates reporter and 
quencher, thereby releasing the fluorescent reporter and fluorescence can be 
detected.  
An increase of fluorescence over reaction time can be associated with the initial 
mRNA concentration in both methods. Both methods can be used for relative 
quantification of gene expression, i.e. relative to the expression of “constantly 
expressed” housekeeping genes. The quantification is expressed as change in 
expression compared to a control sample151. 
Quantification and data analysis are done with help of the Ct value. This Ct 
value is defined as the fractional PCR cycle number at which the reporter 
fluorescence reaches a threshold fluorescence level, which is (manually) chosen in 
the exponential region of amplification. With help of a mathematic equation the 
relative expression level of a target gene can be calculated relative to a sample 
control. The amount of target gene in the sample is first normalized to a 
housekeeping gene (Cttarget-Ctreference=∆ct). The next step is to normalize the ∆Ct of 
the sample to the ∆Ct of a control sample such as an untreated sample       
(∆Ctsample- ∆Ctcontrol = ∆∆Ct). Finally the relative expression of a target gene is 
calculated as (2- ∆∆Ct)152.  
For this study both the Sybr Green as well as Taqman method were used for 
quantitative real-time PCR (Primers and Probes listed in chapter 3.1.7.) 
At last miR studies were performed for miR-23a, miR-425, miR-301a,b, let7b, 
miR-16 and miR-152. As reference miRs sno-135 and miR-429 were selected151. The 
miR expression levels were quantified using Taqman miRNA and Taqman universal 
PCR master mix.  
 
3.2.4 Protein extraction and protein assays 
3.2.4.1 Preparation of nuclear extracts and total protein isolation 
Nuclear extracts were isolated as previously described127. In summary, BM-derived 
macrophages were washed once with PBS and scraped from the culture dish using 
PBS with 5 mM EDTA. The cells were centrifuged and the cell pellet was 
resuspended in 100 µl buffer A and freshly added 1× Complete EDTA-free protease 
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inhibitor cocktail. After 2 min incubation on ice, 100 µl of buffer A supplemented with 
1.28% NP40 was added to the cell suspension and incubated on ice for 10 min. The 
cells were vortexed for 10 sec and centrifuged for 10 min at 2000 rpm. The 
supernatant was discarded and the pellet was dissolved in 50 µl buffer B with freshly 
added Complete EDTA-free protease inhibitor cocktail. The samples were incubated 
on ice for 30 min with vigorous vortexing every 5 min. Afterwards the samples were 
centrifuged for 15 min at 4000 rpm. The supernatant, being the nuclear extract, was 
flash-frozen with liquid nitrogen and the samples were stored at -80°C. The protein 
concentration was measured using the Quick Start Bradford Protein Assay and then 
the samples were used for NF-κB p65 DNA-binding ELISA. 
Proteins from tissues were isolated at the same day of isolation. After sacrificing 
the mice and blood withdrawal, the circulatory system was perfused with PBS and 
the desired tissue was stored in PBS on ice. Then the tissue was added into 1x cell 
lysis buffer and incubated on ice for 10 min. Afterwards the tissue was homogenized 
using stainless steel beads in a TissueLyser LT. The tissue was homogenized at 50 
Hz for 5 min until all cell clumps were removed. Subsequently the suspension was 
centrifuged for 10 min at 14,000 x g in a cold microcentrifuge, the supernatant snap-
frozen and stored -80°C. Similarly as for the nuclear extracts the protein 
concentration was determined using the Quick Start Bradford Protein Assay before 
using the samples for NF-κB p65 ELISA, phospho-histone H3 ELISA, phospho-IKKα 
and total IKKα ELISA. 
3.2.4.2  Flow cytometry 
Flow cytometry is used to analyse cells based on their size, granularity and protein 
expression (by e.g. fluorescence-conjugated detection antibodies). In a buffer 
stream, one cell at a time passes an argon laser, which excites fluorescently labeled 
cells. Measurements of the size (forward scatter) and granularity (sideward scatter) 
are independent from the fluorescence signal. Measurement of fluorescence intensity 
using fluorescence-labelled antibodies was performed to examine and distinguish 
different cell populations in blood, lymph nodes, spleen, bone marrow and thymus.  
In order to examine leukocyte populations in blood samples, the samples first 
had to undergo red blood cell lysis before staining with specific fluorescence-
conjugated antibodies. 
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Lymph nodes and thymus were grinded and filtered through a 100 µm filter in 
order to get a homogenous single-cell solution. 
Bone marrow from one femur bone was flushed out and the erythrocytes were 
lysed with erythrocyte lysis buffer in order to prepare the sample for fluorescent 
staining. 
The spleen had to be homogenized similarly as the lymph node and thymus, 
and subsequently the red blood cells were lysed. 
Once a sample was prepared into a homogenous cell solution, the samples 
were resuspended in FACS staining buffer with specific fluorescence-conjugated 
antibodies (1:100) and incubated for 30 min on ice, protected from light. Afterwards 
the cells were washed with Hanks Complete buffer and analysed immediately in a 
FACS CantoII (BD Biosciences) and evaluated with FlowJo Software (Treestar, Inc, 
Ashland, OR, USA). As control the fluorescence minus one (FMO) method was used 
or isotype controls were included. All flow cytometry results were displayed as dot 
plots showing the logarithmic distribution of the fluorescence intensity or as diagrams 
demonstrating the change in mean fluorescence intensity (MFI). Cell populations 
were quantified as percentage of leukocytes or as percentage of the parental 
subpopulation (e.g. Cd4+ T-cells as percentage of Cd3+ T-cells). 
3.2.4.3  Enzyme-linked immunosorbent assay (ELISA) 
ELISA (enzyme-linked immunosorbent assay) is an immunological method to detect 
and quantify the amount of a specific antigen in biological fluids. All ELISAs 
performed for this study are based on the principle of a sandwich immunoassay. 
Briefly, a purified capture antibody specific for the antigen of interest is pre-coated 
onto a microplate. Once samples and standards are added, the antigen of interest, if 
present, will bind to the capture antibody. After washing to remove unbound proteins, 
a detection antibody is added, which binds to the captured antigen. So the antigen is 
bound between the capture and the detection antibody. The detection antibody, or a 
secondary antibody binding the detection antibody, is either fluorescently labeled or 
linked to an enzyme that triggers a color change by cleaving a specific substrate.  
The intensity of the color or fluorescence measured is in proportion to the amount of 
antigen bound in the initial step. Quantification of the sample values is then 
performed based on a standard curve. 
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Nuclear extracts, tissue extracts, mouse sera and cell culture supernatants 
were analysed for one or more of the following targets: nuclear extracts and tissue 
protein extracts were analysed for active NF-κB p65 levels with a TransAM NF-κB 
p65 ELISA. To measure the active NF-κB p65 concentration in the tissue extracts a 
standard curve was measured using recombinant NF-κB p65 protein. Cell culture 
supernatants were tested for Mcp-1 with a Mcp-1 ELISA and lastly, tissue protein 
extracts were analysed for histone 3 phosphorylation levels using a total PathScan 
Phospho-Histone H3 Sandwich ELISA kit and for total Ikkα and phosphorylated Ikkα 
levels with the PhosphoTracer IKKα (pS176/180) + total IKKα ELISA kit. For all 
ELISAs the sample values were corrected for background by incubation with lysis 
buffer only. 
3.2.4.4  Cytokine bead array 
Cell culture supernatants and mouse sera were analysed for various cytokines using 
the BD cytometric bead array “mouse inflammation kit”. It simultaneously quantifies 5 
different cytokines (Il-6, Il-10, Il-12p, IFN-γ and Tnf) and the chemokine Mcp1 in a 
single sample. Sample preparation and analysis were performed according to the 
manufacturer´s protocol.  
Briefly, the principle: The bead-based assay contains capture beads which have 
been conjugated with specific antibodies against the cytokines and chemokine, and 
which have a specific size for each protein to be quantified. A provided detection 
reagent, which is a mixture of PE-conjugated antibodies, will bind to bead bound 
analyte, forming a sandwich complex of capture bead plus analyte plus detection 
reagent. The intensity of the fluorescent signal of each sandwich complex reveals the 
concentration of bound analyte. The samples are measured using flow cytometry and 
the results analysed with help of specific FCAP Array software.  The kit provides 
standards for quantifying cytokine and chemokine concentrations. 
The samples were diluted if necessary and both standards and samples were 
incubated with capture beads and PE detection reagent for 2 h, at room temperature 
protected from light. The samples and standards were washed, centrifuged and 
supernatant discarded. The bead pellets were resuspended in wash buffer and the 
samples and standard were acquired on the flow cytometer. The FCAP Array 
software helps to create standard curves based on the MFI of the standards for each 
cytokine/ chemokine in order to quantify sample cytokine/chemokine concentration. 
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3.2.5 Histochemistry, immunohistochemistry and 
immunofluorescence 
While histochemistry is a branch of histology studying the chemistry of tissues and 
cells with help of stains, immunohistochemistry (IHC) and immunofluorescence (IF) 
are techniques used for the detection of antigens on tissues or cells. These antigens 
can range from amino acids and proteins to infectious agents and specific cellular 
populations. Instead of using stains for detection, like in histochemistry, IHC and IF 
use antibodies. IHC/IF are important tools for scientific research and are 
complementary techniques for the elucidation of differential diagnoses which are not 
determinable by conventional histochemistry153. 
Within this study the histochemical stainings of Oil-Red O were used for staining 
lipid depositions in the aortic root and aorta. Chloroesterase staining was used on 
aortic roots to detect neutrophil content within the atherosclerotic plaques and Sirius 
red staining to analyse the collagen content. Nile red, as well a histochemical 
staining, was performed together with fluorescent staining for Mac2, an IF staining for 
macrophages, to visualize lipid droplets within macrophage foam cells. Last, the 
histochemical Elastica-van-Gieson staining was performed on BCA to analyse 
atherosclerotic lesion sizes. Both aortic root and BCA were stained for Mac2 and 
SMA (staining of SMCs) using IF. Additionally, IF stainings for Cd3+ T-cells and for 
apoptotic cells (Tunel) were made on aortic root. 
In case of the aorta, the whole aorta was stained for Oil-red-O to analyse lipid 
depositions along the thoraco-abdominal aorta. In case of aortic root 2-3 transversal 
sections were chosen for staining, in order to establish mean values. Similarly, 10 
sections were chosen from BCA (each 40 µm separated) to get mean values of the 
lesion size and cellular content. 
3.2.5.1  Deparaffinization, dehydration and antigen retrieval step 
Formalin-fixed, paraffin-embedded tissue sections must be treated to remove the 
paraffin and unmask the antigen epitopes in preparation for immunohistochemical 
staining. If these steps are not performed, the antibodies will not have complete 
access to the tissue and will be unable to bind to the correct epitopes. In case of 
histochemical stainings the unmasking step is not essential, but still sections need to 
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be removed from paraffin. Below is a table with the essential steps for paraffin 
removal. 
Table 12: Steps for deparaffinization 
Procedure Time 
Xylol 2 x 15 min 
100% Isopropanol 2 x 5 min 
96% Isopropanol 5 min 
70% Isopropanol 5 min 
PBS 5 min 
 
In case of paraffin sections which receive histochemical stainings, a subsequent 
dehydration step is necessary. The table below describes the essential steps. 
Table 13: Steps for dehydratation 
Procedure Time 
70% Isopropanol Dip 
96% Isopropanol Dip 
100% Isopropanol Dip 
100% Isopropanol Dip 
Xylol 5 min 
 
There are a couple of different antigen retrieval techniques. We used the heat-
induced epitope retrieval method by cooking sections in citrate buffer for 20-30 min. 
After (immune) histochemical stainings the sections were mounted with 
Vitroclud mounting medium and sealed with nailpolish, whereas after IF stainings the 
sections were mounted with Vectashield containing 4',6-diamidino-2-phenylindol 
(DAPI), which counterstains cell nuclei. 
3.2.5.2  Oil-Red-O staining 
The extent of atherosclerosis was assessed in aortic roots and on thoraco-abdominal 
aortas by staining for lipid depositions with 0.5% Oil-red-O. For roots 5 µm 
transversal sections were used. Aortas were opened longitudinally along the ventral 
midline, and lesion areas in en face preparation were stained. The percentage of lipid 
deposition was calculated by dividing the stained area by the total surface. The 
images were made with help of a Leica DM2500 fluorescence microscope and CCD 
camera and the lesions were quantified with Diskus image analysis. 
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Table 14: Protocol for Oil-Red-O staining of aortic root and aorta 
Procedure Time 
PBS (for roots) 
Flowing water (for aorta) 
5 min 
dip shortly 
60% Isopropanol 10 x dip 
0.5% Oil-Red O 15 min 
60% Isopropanol 10 x dip 
Flowing water 5 min (for root) 
Shortly (for aorta) 
Hemalum 30s (only root) 
Flowing water 5 min (only root) 
Coverslip with Vectashield mounting 
medium 
For root 
Coverslip with glycerin gelantine 
mounting 
For aorta 
 
3.2.5.3  SMA and Mac2 staining 
The atherosclerotic plaque in the aortic root and the BCA was analysed for 
macrophages and SMCs by immunofluorescent co-staining for Mac2 and Sma, 
respectively, followed by a FITC- or Cy3-conjugated secondary antibody staining.  
Appropriate IgG antibodies were used as isotype controls. Nuclei were 
counterstained with DAPI. Images were recorded with a Leica DM2500 fluorescence 
microscope and CCD camera. The lesion composition was analysed using Diskus 
Software without prior knowledge of the genotype. A general protocol for 
iimmunofluorescent staining is given in table 15. In case of Mac2 the primary 
antibody was rat anti-mouse and the secondary antibody was anti-rat FITC. For SMC 
staining Sma goat anti-mouse and anti-goat Cy3 was used. Before staining, the BCA 
was removed from paraffin, and both aortic root and BCA received an antigen 
retrieval step by cooking the sections in citrate buffer. Both BCA and aortic root were 
mounted with Vectashield and counter-stained with DAPI after the staining. 
Quantification of positive cells was made as percentage of all plaque cells and 
relative to the plaque area.  
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Table 15: Protocol of immunostaining 
Procedure Time 
Cooking in citrate buffer 20 min 
PBS (after sections cooled off) 5 min 
Blocking solution 30 min 
Primary Antibody Overnight at 4°C 
PBS 2 x 5 min 
Hemalum 30 s (only root) 
Secondary Antibody 1 h, kept cool and dark 
PBS 5 min 
Vectashield mounting medium with 
DAPI 
- 
 
3.2.5.4  T-cell Cd3+ staining 
To analyse the lesion for presence of T-cell lymphocytes, aortic root sections were 
stained with the primary goat anti-mouse Cd3+ antibody and secondary antibody anti-
goat Cy3. The sections were mounted with Vectashield mounting medium with DAPI. 
Quantification of positive cells was made as percentage of all plaque cells and 
relative to the plaque area. 
3.2.5.5  Tunel/Mac2 Staining 
Tunel staining was performed with the in situ death detection kit (TMR red) to 
visualize apoptotic cells and the double-staining with Mac2 to indicate apoptotic 
macrophages. The Tunel staining was performed according to manufacturer´s 
protocol, briefly described in table 16. If a co-staining for Mac2 was made, the 
sections were first stained for Mac2, followed by Tunel staining. 
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Table 16: Protocol for In Situ Tunel staining 
Procedure Time 
Permeabilize sections in 0.1% Triton 
X-100 and 0.1% Sodium citrate 
(2v:1v) on ice 
2 min 
PBS 5 min 
Mix label solution with enzyme 
solution (take out 100 µl for neg. 
control from label solution, then mix 
50 µl enzyme solution with 450 µl 
label solution) 
- 
Label/enzyme solution 15-20 min at room temperature 
10 min at 37°C 
PBS 2 x 5 min 
Vectashield mounting medium with 
DAPI 
- 
 
After the staining the sections were stored protected from light at 4°C. The 
images were taken at the same day of labeling to prevent loss of staining intensity 
due to the fluorescence instability. Quantification of apoptotic cells and apoptotic 
macrophages was made as percentage of plaque cells. 
3.2.5.6  Chloroesterase staining 
The chloroesterase staining is a histochemical staining to visualize neutrophils. 
Thereby the naphthol AS-D chloroacetate within the ASDCL solution is enzymatically 
hydrolyzed by "specific esterase", specific for cells of granulocytic lineage, liberating 
a free naphthol compound. This then couples with a diazonium compound, forming 
highly colored deposits at sites of enzyme activity. Aortic roots were stained to 
analyse the neutrophil content in the atherosclerotic lesions.  
Table 17: Protocol for chloroesterase staining 
Procedure  Time 
PBS 5 min 
ASDCL Solution 80 min 
Flowing water - 
Hemalum dip 8 x times  
Flowing water - 
Distilled water 5 min 
Mounting with Vitroclud - 
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3.2.5.7  Elastica-van-Gieson staining 
To analyse the atherosclerotic plaque size in the BCA 10 sections per mouse (each 
40 µm apart) were stained using the Elastica-van-Gieson (EVG) stain at room 
temperature. Images were recorded with a Leica DM2500 fluorescence microscope 
and CCD camera. The lesion area, which is the area between lumen and interna 
elastica lamina were measured and quantified using Diskus Software.  
 
Table 18: Protocol of EVG staining 
Procedure (after deparaffinization) Time 
Distilled water 5 min 
Resorcin-Fuchsin solution 15 min (60°C) 
Distilled water Dip 
80% ethanol Dip 
Distilled water - 
Weigert’s A + B solution 5 min 
Distilled water Dip 
0.5% HCl-alcohol Dip 
Distilled water - 
Picrofuchsin 3 min 
Distilled water Dip 
Dehydration step, mounting with 
Vitroclud 
 
 
3.2.5.8  Sirius Red staining 
To distinguish the collagen content in the aortic root a Sirius Red staining was used. 
Sirius Red has been shown to be able to detect all types and species of collagen, 
such as type I to V collagen. Images were recorded with a Leica DM2500 
fluorescence microscope and CCD camera. The collagen content was analysed by 
Image J software. 
 
Table 19: Protocol of Sirius Red staining 
Staining Procedure Time 
0.1% Sirius Red staining solution 1h 
1% HCl 2 min 
Flowing water Shortly 
Coverslip with Vitroclud mounting 
medium 
- 
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3.2.5.9  Nile Red/ Mac2 staining 
Nile Red primarily stains hydrophobic structures and is similar as the Oil-Red- O 
staining used in lipid staining, with that difference that it is a fluorescent stain154. In 
order to detect foam cells a fluorescent co-staining of Nile Red and Mac2 was 
performed, and additionally the sections were mounted with DAPI to stain the nuclei. 
The images were taken with a Leica DM2500 fluorescence microscope and CCD 
camera, and analysed with Image J. 
In order to perform the double-staining the sections first need to be stained for 
Mac2 (see chapter 3.2.5.3). After the Mac2 staining is complete, 100 µL of Nile 
Red/Glycerin working solution was added on top of the tissue. After 5 min of 
incubation in the dark, the sections were washed in PBS and mounted with mounting 
medium containing DAPI. The images were taken at the day of staining, due to the 
instability of the Nile Red fluorescence. 
3.2.5.10  Lesion classification 
After HE staining, atherosclerotic lesions were classified according to their severity. 
Three categories were distinguished according to their phenotype: (1) early lesions, 
containing only foam cells, (2) intermediate-type lesions, presenting foam cells, some 
necrosis and a fibrotic cap formation, (3) advanced lesions, showing extended 
fibrosis and necrosis and infiltration of the plaque into the media. 
 
3.2.6 Quantification of plasma lipids 
Plasma cholesterol and triglyceride levels were quantified using enzymatic assays 
according to the manufacturer’s protocol (Cobas enzymatic assay, Roche). The 
plasma and standards were diluted with 0.9% NaCl and after adding a chromogenic 
reagent for 30 minutes at room temperature, the absorbance in plasma was 
measured at a wavelength of 505 nm by a 96-well plate reader. 
 
3.2.7 Data illustration and statistical analysis 
Data are represented as mean ± SEM and analysed by students t-test, 1-way Anova 
with Newman-Keuls post-test, Tukey´s post-test or Kruskal-Wallis test with Dunn´s 
post-test. Also the 2-way ANOVA with Bonferroni post-test was used. Differences of 
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ρ<0.05 were considered to be statistically significant. All data was processed and 
displayed with GraphPad Prism 5 software. 
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4. Results 
The first part will describe experiments performed for the investigation of the 
haematopoietic role of IKKα in atherosclerosis. For this a bone marrow (BM)-
transplantation model was used, in which atherosclerosis-prone Apoe-/- mice were 
lethally irradiated to demolish their own bone marrow and transplanted with bone 
marrow from IkkαAA/AAApoe-/-  (Ikkα mutant) and Ikkα+/+Apoe-/- (Ikkα wildtype) mice. 
This model ensured me to only investigate the function of IKKα in haematopoietic or 
BM-derived cells, in atherosclerosis.  After transplantation the mice were fed a high-
fat diet for 8 or 13 weeks, and the atherosclerotic lesion size was analysed in aortic 
root, the BCA and the thoraco-abdominal aorta. Lesion composition and classification 
were studied in aortic roots. Additionally the haematopoietic profile was examined in 
blood, bone marrow, spleen, lymph nodes and thymus. A general blood count was 
made and serum was used for lipid profiling and cytokine measurements. 
Furthermore, I analysed the function of Ikkα in macrophage activation and foam cell 
formation in in vitro studies. 
The second part of this chapter describes experiments carried out to study the 
global contribution of IKKα in atherosclerosis. Here, IkkαAA/AAApoe-/- and Ikkα+/+Apoe-/- 
mice were set on a high-fat diet for 13 weeks. Similarly as for the first study, the 
atherosclerotic lesion size was analysed in aortic root, BCA and thoraco-abdominal 
aorta. Lesion composition was examined both in the aortic root as well as in the BCA. 
Lipid levels and cytokine levels in serum were quantified and whole blood count was 
performed. Quantitative real-time PCR studies were done to investigate Ikkα 
expression profiles: 
• under turbulent flow conditions 
• in a comparative study of aortic root, arch and thoracic aorta after normal 
and high-fat diet conditions 
Furthermore, expression profiling of inflammatory genes was performed in 
IkkαAA/AAApoe-/- and Ikkα+/+Apoe-/- mice after normal and high-fat diet, comparing 
aortic root vs arch and thoracic aorta. To examine downstream signalling effects of 
the IkkαAA mutation, histone H3 phosphorylation levels and NF-κB p65 activity were 
measured in aortic root vs arch and thoracic aorta from IkkαAA/AAApoe-/- and 
Ikkα+/+Apoe-/- mice, both after normal as well as high-fat diet. Additionally, distinct miR 
  Results  
52 
 
expression profiles were studied in order to distinguish whether Ikkα expression 
could be controlled by miRs. Finally total and active (phosphorylated) Ikkα levels 
were examined in aortic root vs arch and thoracic aorta of Apoe-/- mice after normal 
and high-fat diet. 
 
4.1  Role of haematopoietic Ikkα in atherosclerotic lesion 
formation and its effects on leukocyte populations and functions 
related to atherosclerosis 
Blood cells are derived from haematopoietic stem cells (HSCs), which reside in the 
bone marrow. HSCs are self-renewing, which means that when they proliferate some 
of their daughter cells remain as HSCs, so the pool of stem cells does not become 
depleted. The other daughter cells of HSCs differentiate into common myeloid (CMP) 
and common lymphoid progenitor (CLP) cells. While CMPs are progenitor cells for 
erythrocytes, thrombocytes, monocytes, neutrophils and dendritic cells, CLPs are 
precursor cells for T- and B-cells (Figure 9). As mentioned in the introduction, 
leukocytes play a key role in the development and progression of atherosclerosis and 
therefore I aimed to investigate whether the loss of Ikkα function in haematopoietic 
cells would influence leukocytosis and atherogenesis. 
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Figure 9: Haematopoiesis. A schematic illustration showing the development of different blood cells 
from haematopoietic stem cells (HSCs). CMP=common myeloid progenitor cell, CLP=common 
lymphoid progenitor cell, NK=natural killer cell. 
 
4.1.1 Analysis of transplantation efficiency 
To investigate whether engraftment of transplanted IkkαAA/AAApoe-/- bone marrow 
cells was successful, a quantitative real-time PCR was performed to quantify the 
mutant IkkαAA allele vs the wildtype Ikkα allele in isolated genomic DNA from blood 
withdrawn from the bone marrow (BM)-transplanted mice, 4 weeks after 
transplantation. Relative quantification was performed using a standard curve 
generated from genomic DNA from IkkαAA/AAApoe−/− and Ikkα+/+Apoe−/− blood cells, 
mixed at different ratios. 
In a first transplantation study real-time PCR showed that on average 96.1% 
(±1.2) of leukocytes carried the mutant IkkαAA/AA allele, confirming a successful 
transplantation. In a second transplantation study, engraftment was equally efficient, 
showing the mutant IkkαAA allele to be present in 94.3% (± 2.7) of blood leukocytes. 
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4.1.2 Bone marrow-specific loss of Ikkα activity influences 
leukocyte populations 
Apoe-/- mice transplanted with IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- BM received a high-
fat diet for 13 weeks. After sacrificing the mouse, blood and organs were isolated. 
Haematopoietic profiling was performed by flow cytometric analysis and different 
leukocyte subsets were examined with help of fluorescent antibody stainings. B-cells 
were identified as Cd45+Cd19+; T-cells as Cd45+Cd3+; naive T-cells as 
Cd44lowCd62Lhigh T-cells; effector memory T-cells as Cd44highCd62Llow T-cells; 
central memory T-cells as Cd44highCd62Lhigh T-cells; regulatory T-cells (Treg cells) as 
Cd4+Cd25+Foxp3+ T-cells; neutrophils as Cd45+Cd115−Gr1high; monocytes as 
Cd45+Cd115+; conventional DCs (cDCs) as Cd45+Cd11c+MhcII+; and pDCs as 
Cd45+Cd11c+Cd11b−440c+.  
As Kaisho et al. reported an essential function of Ikkα in B-cell development155, 
B-cell levels were analysed in blood, bone marrow and lymphoid organs. 
Interestingly, IkkαAA/AAApoe−/− bone marrow chimeras showed indeed a significantly 
reduced Cd19+ B-cell population in peripheral blood. A similar decrease in B-cell 
number was seen in BM and lymph nodes, whereas no difference was observed in 
the splenic B-cell population. 
Meanwhile, blood and lymph nodes of IkkαAA/AAApoe−/− transplanted mice 
displayed more Cd3+ T-cells among the leukocyte population, whereas Cd3+ T-cell 
levels in spleen were unaltered. No changes in the relative proportions of cytotoxic 
Cd8+ T-cells and Cd4+T-helper cells were observed in blood or lymphoid organs 
(Figure 10). 
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Figure 10: Reduced B-cell and increased T-cell population in IkkαAA/AAApoe-/- transplanted mice. 
FACS analysis of Cd45+ Cd19+ B-cell population in bone marrow (A) and of Cd3+ T-cells with Cd8+ 
and Cd4+ T-cell subsets in blood (B), lymph nodes (C) and spleen (D) of bone marrow chimeras after 
13 weeks of high-fat diet. All graphs represent the mean ± SEM (n=18-19); 2-tailed t-test, ***p<0.001. 
 
Also other T-subsets were analysed, such as Tregs, naive T-cells, effector 
memory T-cells and central memory T-cells. Treg levels were found to be significantly 
reduced among the Cd3+ T-cell population in peripheral blood, thymus and 
secondary lymphoid organs of IkkαAA/AAApoe−/− BM-transplanted mice. The Treg 
frequency was also considerably decreased among Cd45+ leukocytes in blood and 
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spleen of the IkkαAA/AAApoe−/− BM chimeras. However, this was not observed in the 
lymph nodes (Figure 11). 
 
Figure 11: Decrease of Tregs in IkkαAA/AAApoe−/− BM chimeras. FACS analysis of Tregs relatively to 
Cd45+ leukocytes (B) and Cd3+ T-cells (A) in blood, thymus and secondary lymphoid organs of Apoe-/- 
mice transplanted with IkkαAA/AAApoe-/- and Ikkα+/+Apoe-/- BM after 13 weeks of high-fat diet. All graphs 
represent the mean ± SEM (n=18-19); 2-tailed t-test, **p<0.01, ***p<0.001. 
 
Additionally, the effector memory T-cell population was significantly diminished 
in spleen and lymph nodes of IkkαAA/AAApoe−/−-transplanted mice, whereas the naive 
T-cell population displayed a significant increase. Also, the central memory T-cell 
population was significantly decreased among T-lymphocytes and total leukocytes in 
spleen. In lymph nodes, central memory T-cells were unaltered among Cd3+ T-cells, 
but displayed increased levels among Cd45+ leukocytes (Figure 12). 
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Figure 12: IkkαAA/AAApoe-/- BM chimeras have less effector memory T-cells, but more naive T-
cells in spleen and lymph nodes. Splenic central memory T-cells are decreased, whereas lymph 
nodes display an opposite effect. Shown is flow cytometric analysis of naive, effector memory (A,B) 
and central memory T-cell (C,D) subsets in spleen and lymph nodes from Apoe−/− mice transplanted 
with IkkαAA/AAApoe−/− or Ikkα+/+Apoe−/− BM after 13 weeks of high-fat diet. Data are represented as 
percentage of Cd3+ T-cells (A,C) and as percentage of Cd45+ leukocytes (B,D). Graphs represent the 
mean ± SEM (n = 18–19), 2-tailed t-test, *p<0.05, **p<0.01, ***p<0.001. 
 
Flow cytometric analysis of dendritic cells showed comparable frequencies of 
Cd11c+MhcII+ cDCs and Cd11c+Cd11b−440c+ pDCs in spleen. Nonetheless, 
expression of the activation marker MhcII was significantly reduced on splenic pDCs 
of IkkαAA/AAApoe−/− BM chimeras (Figure 13). Furthermore, levels of Cd115−Gr1+ 
neutrophils, Cd115+ monocytes and both Gr1high and Gr1low monocyte subsets in 
peripheral blood were not altered (Table 20).  
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Figure 13: Levels of cDCs and pDCs are unaltered in IkkαAA/AAApoe-/- BM chimeras. Shown is 
flow cytometric analysis of splenic cDCs and pDCs and surface expression of MhcII (B). Data are 
represented as percentage of Cd45+ leukocytes (A). Graphs represent the mean ± SEM (n = 18–19), 
2-tailed t-test, *p<0.05. 
 
Table 20: Monocyte, monocyte subsets and neutrophil population in peripheral blood. 
 
Ikkα+/+Apoe-/- BM 
chimeras 
IkkαAA/AAApoe-/- BM 
chimeras 
Monocytes (% of leukocytes) 7.9 ± 0.5 8.7 ± 0.6 
Gr1high monocytes (% monocytes 66.0 ± 2.0 68.1 ± 2.7 
Gr1low monocytes (% monocytes) 5.2 ± 0.3 5.7 ± 0.3 
Gr1high monocytes (% leukocytes) 29.8 ± 2.1 26.9 ± 2.4 
Gr1low monocytes (% leukocytes) 2.4 ± 0.3 2.5 ± 0.3 
Neutrophils (% of leukocytes) 19.0 ± 1.3 20.4 ± 1.2 
 
These data indicate an important role for Ikkα kinase activity in haematopoiesis, 
with reduced B-cells and Tregs lymphocytes upon haematopoietic expression of an 
Ikkα mutant that cannot be activated. 
 
4.1.3 Haematopoietic Ikkα mutation does not alter atherogenesis 
Following identification of the importance of Ikkα for lymphocyte populations, the 
effect of the IkkαAA mutation on atherosclerotic lesion formation was studied. After 13 
weeks of high-fat diet, lipid levels were measured in serum of IkkαAA/AAApoe−/− and 
Ikkα+/+Apoe−/− BM chimeras, and the extent of atherosclerosis was analysed in the 
aorta, the BCA and aortic root. Whereas body weight and serum triglyceride values 
were similar, cholesterol levels were significantly increased in IkkαAA/AAApoe−/− vs 
Ikkα+/+Apoe−/− BM-transplanted Apoe−/− mice. This could be attributed to an increase 
in very low-density lipoprotein (VLDL) and LDL lipoprotein fractions, as shown by a 
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cholesterol analysis after HPLC-based lipoprotein size separation of pooled serum 
samples (Figure 14). 
 
 
Figure 14: IkkαAA/AAApoe−/− bone marrow chimeras have the same weight as Ikkα+/+Apoe−/−, but 
exhibit increased VLDL values and thereby increased cholesterol levels. After 13 weeks of HFD, 
body weight (A) was recorded and lipid levels (B) measured in serum of Apoe-/- mice transplanted with 
IkkαAA/AAApoe−/− or Ikkα+/+Apoe−/− BM. (C) HPLC fractionation of serum showed elevated VLDL levels 
in IkkαAA/AAApoe-/- bone marrow-transplanted mice. (n = 18–27) Graphs represent the mean ± SEM; 2-
tailed t-test, ***p<0.001. 
 
Despite these differences in cholesterol and specifically VLDL levels, 
atherosclerotic lesion sizes in the aorta, brachiocephalic artery and aortic root were 
comparable in IkkαAA/AAApoe−/− and Ikkα+/+Apoe−/− BM chimeras (Figure 15). 
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Figure 15: Atherosclerotic lesion analysis in aorta, aortic root and BCA are unaltered in 
IkkαAA/AAApoe−/− BM chimeras. After 13 weeks of high-fat diet, atherosclerotic plaque sizes were 
analysed in aorta (A), aortic root (B) and BCA (C). Representative pictures of Oil-Red O-stained lipid 
depositions in aorta and aortic root and of EVG stainings of BCAs are shown. Scale bar aortic root= 
500 µm, scale bar BCA= 200 µm. (n = 18–27) Graphs represent the mean ± SEM.   
 
To explore potential qualitative effects on atherosclerosis, atherosclerotic 
lesions in the aortic root and BCA were classified according to their severity and 
progression. Lesions were classified into early, intermediate-type and advanced 
lesions, as previously described127. Classification showed that plaques in aortic root 
were already far progressed, however no differences were found between both 
groups (Figure 16). 
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Figure 16: Atherosclerotic plaque classification show same plaque severity between 
IkkαAA/AAApoe−/− and Ikkα+/+Apoe−/−  BM-transplanted mice in BCA and aortic root. Lesions in BCA 
(A) and aortic root (B) were classified according to their phenotype. Data shown is plaque distribution 
as percentage of total number of lesions analysed. Aortic root (n=22-26), BCA (n=9-5). Graphs 
represent the mean ± SEM. 
 
In order to assess whether Ikkα would contribute to a different atherosclerotic 
lesion phenotype, different parameters were analysed in regard to cellular lesion 
composition, apoptosis (Tunel staining) and lipid uptake by plaque macrophages 
(lipid depositions with Nile Red staining) in aortic root lesions. Immunofluorescent 
staining presented equal content of macrophages (Mac2+), SMCs (Sma+) and Cd3+ 
T-lymphocytes in atherosclerotic plaques (Figure 17).  
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Figure 17: IkkαAA/AA knock-in in haematopoietic cells does not influence atherosclerotic lesion 
composition. Immunofluorescent stainings of aortic roots from IkkαAA/AAApoe-/- and from Ikkα+/+Apoe-/- 
BM-transplanted mice after high-fat diet for 13 weeks. (A-C) Quantification of Mac2+ macrophages (A, 
n = 17-18), Sma+ SMCs (B, n = 16-17) and Cd3+ T-cells (C, n = 7-8) as percentage of all plaque cells 
(left) and relative to plaque area (right). Graphs represent mean ± SEM. Representative pictures are 
shown. Scale bar = 100 µm. 
 
To assess whether IkkαAA/AA BM transplantation would influence neutrophil 
infiltration and content in atherosclerotic lesions, neutrophils in aortic roots of BM-
transplanted mice were stained using histochemical chloroesterase staining. 
However, despite the present of neutrophils outside the plaque region, no neutrophils 
could be detected in atherosclerotic lesions of IkkαAA/AAApoe−/− or Ikkα+/+Apoe−/− BM 
chimeras (Figure 18). 
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Figure 18: Inactivatable Ikkα kinase knock-in in BM cells does not alter neutrophil infiltration in 
atherosclerotic lesions. Chloroesterase staining of aortic roots from Apoe-/- mice, transplanted with 
Ikkα+/+ApoE-/- and IkkαAA/AAApoe-/- BM, after high-fat diet for 13 weeks. Representative pictures show that 
neither in wildtype nor mutant mice neutrophils could be detected within the atherosclerotic lesions. 
Graphs represent the mean ± SEM. Scale bar = 500 µm (upper pictures); Scale bar = 200 µm (lower 
pictures). 
 
Next, necrosis and apoptosis were quantified in aortic root lesions of 
IkkαAA/AAApoe-/- and Ikkα+/+Apoe-/- BM chimeras after 13 weeks of high-fat diet. 
Necrotic core was measured after immunofluorescent staining of lesions with DAPI, 
measuring cell-free areas within the atherosclerotic plaque. In case of apoptosis 
(visualized with help of a Tunel in situ apoptosis detection kit), I analysed not only 
apoptotic cells but as well apoptotic macrophages, as it has been reported that Ikkα 
decreases apoptosis of macrophages in inflammatory conditions137. As shown in 
Figure 19, necrotic core sizes were comparable, and no significant differences were 
found in the content of Tunel+ apoptotic cells and apoptotic macrophages in aortic 
root lesions of IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- BM chimeras. 
 
 
Figure 19: Knock-in of IkkαAA/AA in haematopoietic cells does not influence apoptosis or 
necrosis in atherosclerotic lesions. Analysis of aortic root lesions of Apoe-/- mice transplanted with 
IkkαAA/AAApoe-/- and Ikkα+/+ Apoe-/- BM after 13 weeks of high-fat diet. (A) Quantification of necrotic 
cores as percentage of plaque area. (B,C) Quantification of apoptotic cells (Tunel+, B) and apoptotic 
macrophages (Tunel+Mac2+, C) as percentage of all plaque cells. Graphs represent the mean ± SEM 
(n = 10–12). 
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Next, I quantified lipid deposits in aortic root lesions of IkkαAA/AAApoe-/- and 
Ikkα+/+Apoe-/- BM chimeras after 13 weeks of high-fat diet using Nile Red staining. 
Also, Nile Red-positive macrophages after co-staining for Mac2 were quantified. Both 
the level of lesional lipid deposits as well as the percentage of lipid-laden 
macrophages were unaltered between IkkαAA/AAApoe-/- and Ikkα+/+Apoe-/- BM-
transplanted mice (Figure 20). 
 
 
Figure 20: Intracellular lipid depositions and lipid-laden macrophages were not influenced by 
the activation-resistant Ikkα mutation in haematopoietic cells. Aortic root lesions were stained 
with Nile Red and co-stained with Mac2 in order to quantify lipid-laden macrophages. (A) Nile Red 
staining was quantified relatively to the plaque area (left graph), and Nile Red+ cells were quantified 
as percentage of total plaque cells (right graph). (B) Lipid uptake by macrophages was quantified as 
Nile Red+Mac2+ area as % of Mac2+ area (left graph), and as Nile Red+Mac2+ cells as % of Mac2+-
cells. Shown are representative pictures from Nile Red stainings (red fluorescence; left image). The 
middle and right image demonstrate Image J analyses. Displayed are the plaque area (thin red line), 
macrophage area (green), plaque cell nuclei (blue), Nile Red+ area (yellow) and Mac2+ Nile Red+ 
area (white, lipid deposits in macrophages). Graphs represent the mean ± SEM (n = 5–6).  
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Due to highly progressed atherosclerotic lesions within the aortic root (Figure 
16), the bone marrow transplantation was repeated and the mice received a high-fat 
diet for only 8 weeks, in order to investigate whether Ikkα mutation would reveal 
effects at earlier stages of atherosclerosis. 
Similarly as for the previous experiment, the weight was measured before 
sacrificing the mice. Lipids were assessed in serum and cholesterol fractionation was 
performed with HPLC. 
 
 
Figure 21: IkkαAA/AAApoe-/- bone marrow transplantation into Apoe-/- mice does not influence 
weight or cholesterol levels after 8 weeks of high-fat diet. (A) Body weight and (B) lipid analysis in 
blood serum (n = 7–9) were not changed in Ikkα mutant mice. (C) Cholesterol levels after HPLC-based 
size fractionation of pooled blood serum samples showed comparable levels of VLDL, LDL and HDL in 
both mice groups. Graphs represent the mean ± SEM.  
 
After this shorter period of high-fat diet, no differences were obtained in body 
weight or lipid levels in the serum, and also HPLC-based lipoprotein fractionation of 
pooled serum samples showed similar HDL-, LDL- and VLDL-associated cholesterol 
peaks (Figure 21). Atherosclerotic lesions were analysed in aorta, aortic root and 
BCA and lesions classified in aortic root and BCA. Corresponding to the 13 week-
high-fat diet study, IkkαAA/AAApoe-/- and Ikkα+/+Apoe-/- BM chimeras presented 
comparable atherosclerotic lesion sizes in the aorta, aortic root and BCA (Figure 22).  
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Figure 22: Transplantation of BM carrying an activation-resistant Ikkα mutant does not affect 
early stage atherosclerosis. Apoe-/- mice were transplanted with IkkαAA/AAApoe-/- or Ikkα+/+Apoe-/- BM 
and received a high-fat diet for 8 weeks. Atherosclerotic lesion sizes were analysed in the aorta (A), 
aortic root (B) and BCA (C). Representative pictures of Oil-Red-O+ lipid depositions in aorta and aortic 
root and EVG stainings of BCA are shown. Scale bar = 500 µm (aortic root), scale bar = 200 µm 
(BCA). Graphs represent the mean ± SEM. 
 
Also, classification of the plaques into early, intermediate or advanced stages 
revealed comparable lesion stages in IkkαAA/AAApoe-/- and Ikkα+/+Apoe-/-  BM-
transplanted Apoe-/-  mice, although the lesions were less advanced compared to the 
13 week-diet study (Figure 23). 
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Figure 23: IkkαAA/AA knock-in in BM cells does not influence lesion classification at early stages 
of atherogenesis. Classification of atherosclerotic lesions from IkkαAA/AAApoe-/- and Ikkα+/+Apoe-/- BM 
chimeras after 8 weeks of high-fat diet. Classification of lesions in aortic root and BCA was performed 
according to their severity. Shown is the plaque distribution as percentage of the total number of 
lesions examined. (B) Aortic root (n = 22–26), (A) BCA (n=9-5); Graphs represent the mean ± SEM; 2-
tailed t-test, ***p<0.001.  
 
In summary, these data indicated that transplantation of IkkαAA/AAApoe-/- -mutant 
BM does not affect the size, phenotype or cellular content of atherosclerotic lesions 
in atherosclerosis-prone Apoe-/- mice. 
 
4.1.4 BM-specific expression of an activation-resistant Ikkα mutant 
has no effect on inflammatory gene expression or macrophage 
activation 
As described in the introduction, the canonical NF-kB pathway has been shown to 
play an important role in controlling atheroprogression65. In macrophages Ikkα was 
shown to be able to stop LPS-induced macrophage activation by terminating NF-kB 
activity through phosphorylation and degradation of the NF-kB isoform p65137. 
Thus, I studied the effect of IkkαAA/AA knock-in on canonical NF-kB activity in 
macrophages in the context of atherosclerosis. Specifically, the DNA binding capacity 
of the NF-κB isoform p65 was analysed in nuclear extracts of IkkαAA/AAApoe-/- vs 
Ikkα+/+Apoe-/- BM-derived macrophages in vitro. Macrophages were stimulated with 
LPS, Tnf-α or mildly oxidized LDL, mimicking inflammatory or pro-atherogenic 
surroundings. Unexpectedly, IkkαAA/AA knock-in did not enhance or prolong p65 
activity in Apoe-deficient macrophages upon stimulation. In case of Tnf-α stimulation 
p65 activation was slowed down in IkkαAA/AAApoe-/- macrophages. No differences 
were observed in p65 activity upon LPS or oxLDL stimulation of IkkαAA/AAApoe-/- vs 
Ikkα+/+Apoe-/- BM-derived macrophages (Figure 24). 
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Figure 24: IkkαAA/AA knock-in does not enhance or prolong NF-kB p65 activity in vitro. Nuclear 
extracts were isolated from BM-derived macrophages from IkkαAA/AAApoe-/- and Ikkα+/+Apoe-/- mice, 
which were stimulated in vitro with (A) 10 ng/ml Tnf-α, (B) 50 mg/ml of mildly oxidized LDL or (C) 100 
ng/ml LPS for the indicated time. Activation of p65 was quantified using a TransAm p65 assay. Graphs 
represent the mean ± range/2 of 2 independent experiments; 2-way Anova with Bonferroni post-test, 
***p<0.001.  
 
To determine the potential effect of IkkαAA/AA knock-in on inflammatory protein 
expression, BM-derived macrophages were stimulated in vitro with either Tnfα or 
heavily oxidized oxLDL for 24 hours and the cytokine and chemokine content in the 
supernatants were measured with help of a cytometric bead assay (CBA). The 
concentration of Tnf-α, Il-6 and Mcp1 in supernatants of Tnf-α- or oxLDL-stimulated 
IkkαAA/AAApoe-/- and Ikkα+/+Apoe-/- BM-derived macrophages were not significantly 
different, although IkkαAA/AA knock-in significantly enhanced the basal secretion of 
Mcp1, in contrast to Tnf-α or Il-6. Neither Tnf-α nor oxLDL were able to induce 
secretion of Il-10 or Il-12p70 in vitro, although Il-12p70 secretion was found to be 
significantly higher in oxLDL-stimulated macrophages upon IkkαAA/AA knock-in (Figure 
25). 
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Figure 25: Effect of IkkαAA/AA knock-in on cytokine secretion from BM-derived macrophages. 
Shown are cytokine concentrations of Tnf-α (A), Il-6 (B), Mcp-1 (C), Il-10 (D) and Il-12p70 (E) in the 
supernatants of IkkαAA/AAApoe-/- or Ikkα+/+Apoe-/- BM-derived macrophages, unstimulated (control) or 
after stimulation for 24 h with 10 ng/ml Tnf-α or 50 µg/ml oxLDL, as indicated. Graphs represent mean 
± SEM (n=9 from 3 independent experiments); 2-way Anova with Bonferroni post-test, *p<0.05, 
**p<0.01. 
 
In addition, cytokines and chemokines were quantified in serum of 
IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- BM-transplanted mice after 8 weeks of high-fat diet 
using the CBA assay The concentration of Tnf-α, Il-6 and Mcp1 in serum of 
IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- BM chimeras did not reveal significant differences, 
whereas the cytokines Ifn-γ, Il-12 and Il-10 remained below the detection limit in both 
groups (Figure 26).  
 
 
Figure 26: Activation-resistant IkkαAA/AA mutation in haematopoietic cells does not alter 
cytokine or chemokine concentration in vivo. Concentrations of (A) Tnf-a, (B) Il-6 and (C) Mcp1 
and in serum of Apoe-/- mice transplanted with IkkαAA/AAApoe-/- or Ikkα+/+Apoe-/- BM and receiving a 
high-fat diet for 8 weeks. Graphs represent the mean ± SEM (n = 7–9). 
 
Given the importance of lipid uptake by macrophages in atherosclerotic lesions, 
I examined a possible effect of IkkαAA/AA knock-in on macrophage foam cell formation 
in vitro. With 2 different incubation times and oxLDL doses, no significant difference 
  Results  
70 
 
in oxLDL uptake by IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- BM-derived macrophages was 
observed. Cytochalasin D severely reduced the oxLDL-associated fluorescence 
signal, indicating that oxLDL was actively taken up by the cells in an actin-dependent 
way and not merely binding the cell surface (Figure 27). 
 
 
 
Figure 27: BM-derived macrophages from IkkαAA/AAApoe-/- mice does not reveal altered lipid 
uptake. Flow cytometric analysis of Dil-oxLDL uptake by BM-derived macrophages. Cells were 
incubated without or with Dil-oxLDL (1 mg/ml or 10 mg/ml) for 3 h or 24 h, as indicated. To exclude 
only cell surface binding of Dil-oxLDL, additional controls were simultaneously treated with 
cytochalasin D (cytD). Representative flow cytometric histograms are shown. Graphs represent the 
mean ± SEM (n = 3); 2-way Anova with Bonferroni post-test.  
 
Recapitulating the obtained results, these data show, that knock-in of an 
activation-resistant IkkαAA mutant in an Apoe-/- background does not enhance NF-kB 
p65 activation or influences the secretion of important inflammatory proteins from 
Tnf-α- or oxLDL-stimulated macrophages, nor does it significantly affect macrophage 
foam cell formation. 
 
Taking together the results from this study of haematopoietic Ikkα function, an 
important and unrecognized role for haematopoietic Ikkα kinase activity in B- and T-
cell homeostasis was observed. However, no effect of BM-specific IkkαAA/AA knock-in 
was revealed on the size or phenotype of atherosclerotic lesions in Apoe-/- mice on 
high-fat diet. 
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4.2  The global role of Ikkα in the development of atherosclerosis 
The dysfunction of resident vascular cells and recruitment of infiltrating leukocyte 
cells orchestrate a complex interplay of inflammatory processes in the initiation and 
development of atherosclerosis. In order to determine the global contribution of Ikkα 
kinase activity to these atherogenic processes, IkkαAA/AA knock-in mice were put on 
high-fat diet for 13 weeks and atherosclerosis was inspected. 
 
4.2.1 Global inactive Ikkα does not alter lipid levels, body weight or 
serum cytokine levels 
Similar to the haematopoietic study, atherosclerosis-prone mice carrying an 
activation-resistant Ikkα mutant (IkkαAA/AAApoe-/-) were put for 6 or 13 weeks on high-
fat diet from the age of 8 weeks. Body weights were recorded before sacrifice, lipid 
levels were measured in serum and serum cytokine/chemokine concentrations were 
analysed with help of a CBA bead assay. A whole blood cell count was analysed in 
an automated hematology analyser. 
After 13 weeks of high-fat diet, mice had comparable serum total cholesterol, 
HDL and LDL levels. Also, serum triglyceride values were unaltered. Body weights 
after 6 weeks and 13 weeks of high-fat diet did not differ between the groups (Figure 
28). In addition, quantification of Il-10 and Mcp1 in serum of IkkαAA/AAApoe-/- vs 
Ikkα+/+Apoe-/- after 13 weeks of high-fat diet using the cytokine bead assay did not 
reveal significant differences, whereas the cytokine levels of Ifn-γ, Il-6, Il-12 and Tnf-α 
were below the detection limit in both groups (Figure 28). 
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Figure 28: Global knock-in of IkkαAA/AA does not influence body weight, serum lipid levels or 
cytokine concentrations. IkkαAA/AAApoe-/- or Ikkα+/+Apoe-/- mice received a high-fat diet for 13 weeks 
before analysis. (A,B) Lipid analysis was performed in serum after 13 weeks of high-fat diet (n=17-18) 
(C,D) The body weight was measured after 6 weeks (n = 6) and 13 weeks of high-fat diet (n = 17-18).  
(E,F) Concentrations of Il-10 and Mcp1 in serum of IkkαAA/AAApoe-/- or Ikkα+/+Apoe-/- mice after 13 
weeks of high-fat diet (n=13-14). Graphs represent the mean ± SEM.  
 
Whole blood cell count of leukocytes, thrombocytes as well as erythrocytes was 
not significantly influenced by IkkαAA/AA knock-in. 
 
Table 21: Whole blood cell count from IkkαAA/AAApoe-/- or Ikkα+/+Apoe-/- mice after 6 weeks of 
high-fat diet. 
 Ikkα+/+Apoe-/- IkkαAA/AAApoe-/-  
Leukocytes (x103/µl blood) 6.8 ± 1.1 9.8 ± 1.6 (P=0.15 ns) 
Erythrocytes (x106/µl blood) 8.9 ± 0.3 9.1 ± 0.2 
Thrombocytes (x103/µl blood) 781.5 ± 158.3 694.3 ± 99.29 
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4.2.2 Activation-defective Ikkα influences atherosclerotic lesion 
development site-specifically 
Whereas haematopoietic Ikkα did not influence atherosclerosis, the global IkkαAA/AA 
knock-in revealed interesting effects. After a high-fat diet for 13 weeks, quantification 
of atherosclerotic lesions in aorta by en face staining with Oil-red O revealed 
increased plaque development in IkkαAA/AAApoe-/- mice compared to Apoe-/- controls. 
In order to distinguish potential site-specific effects, lesions in the abdominal and 
thoracic part of the aorta and the aortic arch were analysed separately. Whereas the 
lesion area in the abdominal part was unaltered between the groups, the thoracic 
aorta showed a trend for elevated plaque formation, though not statistically 
significant.  However, the aortic arch exhibited a significant 70% increase in plaque 
development in the Ikkα-inactive mice compared to the control group (Figure 29). 
 
Figure 29: Atherosclerotic plaque sizes are increased in aorta of IkkαAA/AAApoe-/- compared to 
Ikkα+/+Apoe-/- mice after 13 weeks of high-fat diet. Atherosclerotic lesions were stained in aorta by 
en face Oil-Red O staining. Lesions were quantified in the total aorta (A) and separately in aortic arch 
(B), thoracic aorta (C) and abdominal aorta (D). Graphs represent the mean ± SEM; n=17-19, 2-tailed 
t-test, *p<0.05. 
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Similarly, the BCA tended to form bigger lesions in IkkαAA/AAApoe-/- mice, 
however without reaching statistical significance (Figure 30). 
 
 
Figure 30: Atherosclerotic plaque sizes show an increased trend in BCA of IkkαAA/AAApoe-/- 
compared to Ikkα+/+Apoe-/- mice after 13 weeks of high-fat diet. Atherosclerotic lesions were 
stained in BCAs by EVG staining. Graphs represent the mean ± SEM; Scale bar = 200 µm, n=12-13, 
2-tailed t-test. 
 
However, IkkαAA/AA knock-in had an adverse effect on atherogenesis in aortic 
root (Figure 31). The more advanced lesions in aortic root compared to aorta or BCA 
were significantly decreased in IkkαAA/AAApoe-/- mice. 
 
 
Figure 31: Loss of Ikkα activity decreases atherosclerotic lesion development in aortic roots. 
Atherosclerotic lesions were stained in aortic root by Oil-Red O staining. Graphs represent the mean ± 
SEM; Scale bar = 500 µm, n=18-19, 2-tailed t-test, **p<0.01. 
 
These opposite atherosclerotic results in aorta, BCA and aortic root reflect a 
site-dependent or disease stage-dependent role for Ikkα in atherogenesis. 
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4.2.3 Defective Ikkα activation does not affect lesion phenotypes 
Because the cellular composition of atherosclerotic plaques, along with lesion size, is 
critically important in atherogenesis, atherosclerotic lesions were characterized in 
regard to cell composition, apoptosis and matrix components. 
The cellular composition of aortic root lesions was comparable, presenting an 
equal content of macrophages (Mac2+) and SMCs (Sma+) after immunofluorescent 
stainings. Also for Cd3+ T-lymphocytes, no significant differences were observed, 
whereas no neutrophils could be detected in the aortic root lesions (Figure 32). 
 
 
Figure 32: Global IkkαAA/AA knock-in does not influence atherosclerotic lesion composition. 
Immunofluorescent stainings of aortic roots from IkkαAA/AAApoe-/- and from Ikkα+/+Apoe-/- mice after 
high-fat diet for 13 weeks. (A–C) Quantification of Mac2+ macrophages (A, n = 10–11), Sma+ SMCs 
(B, n = 15–18) and Cd3+ T-cells (C, n = 12–15) as percentage of all plaque cells (left) and relative to 
the plaque area (right). Graphs represent the mean ± SEM. Representative pictures are shown. Scale 
bar = 100 µm. 
 
Furthermore, no significant differences were found in the content of total Tunel+ 
apoptotic cells or apoptotic macrophages in aortic root lesions of IkkαAA/AAApoe-/- and 
Ikkα+/+Apoe-/- mice. Also, the collagen deposition within aortic root lesions was similar 
between the two groups of mice (Figure 33). 
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Figure 33: IkkαAA/AA knock-in does not alter apoptosis or the collagen content in atherosclerotic 
lesions of aortic roots. Analysis of (A,B) apoptosis, apoptotic macrophages and (C) collagen content 
in atherosclerotic plaques of IkkαAA/AAApoe-/- and Ikkα+/+Apoe-/- mice in aortic root by Tunel and Sirius 
Red staining after 13 weeks of high-fat diet. Graphs represent means ± SEM. (n=6-10). 
 
Similarly, content of macrophages (Mac2+) and SMCs (Sma+) in BCA lesions 
were comparable (Figure 34).  
 
 
Figure 34: Global IkkαAA/AA knock-in does not influence atherosclerotic lesion composition in 
BCA. Immunofluorescent stainings of BCAs from IkkαAA/AAApoe-/- and from Ikkα+/+Apoe-/- mice after 
high-fat diet for 13 weeks. (A) Quantification of Mac2+ macrophages, Sma+ SMCs (B) as percentage 
of all plaque area (left) and cells relative to the plaque area (right). Graphs represent the mean ± SEM. 
Representative pictures are shown. (n=6-8), Scale bar = 50 µm.  
 
These findings indicate that IkkαAA mutation does not have an effect on lesion 
composition. Thus, the observed site-specific effects on atherosclerotic lesion size 
might be induced by differential effects on intracellular signalling and inflammatory 
gene expression instead, potentially caused by site-specific expression or activation 
patterns of Ikkα. Hence, I proceeded to analyse potential regional differences of 
IkkαAA/AA knock-in on NF-κB p65 activity and histone H3 phosphorylation, as Ikkα was 
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previously shown to affect gene expression by negatively regulating canonical NF-κB 
activation and by controlling phosphorylation of histone H3 (see chapter 4.2.4).   
 
4.2.4 Loss of Ikkα activity does not influence NF-κB activation and 
reduces histone H3 phosphorylation to an only minor extent 
specifically in aortic arch 
Proteins were extracted from aortic root, arch and thoracic aorta from IkkαAA/AAApoe-/- 
vs Ikkα+/+Apoe-/- mice after 6 weeks of high-fat diet and the DNA binding capacity of 
p65 and the levels of phosphorylated histone H3 were studied by ELISA. 
Unexpectedly, IkkαAA/AA knock-in did not result in enhanced NF-κB p65 activity 
in Apoe-deficient mice and NF-κB activity levels did not significantly vary between 
aortic root, arch or thoracic aorta neither in control mice nor in IkkαAA/AA knock-in mice 
(Figure 35). Comparing histone H3 phosphorylation signals in aortic root, arch and 
thoracic aorta in IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- mice, wildtype mice showed a 
significantly increased level of histone H3 phosphorylation within the aortic arch in 
comparison to the aorta and a trend for increase compared to root. In contrast, only a 
trend for increased expression in aortic arch vs root and aorta was observed in 
IkkαAA/AA knock-in mice, without reaching statistical significance (Figure 35). These 
data indicate that histone H3 phosphorylation is site-specifically controlled between 
aortic arch vs thoracic aorta and root, with a minor role for Ikkα kinase activity in 
regulating H3 phosphorylation in aortic arch. This might underlie at least to a small 
extent the observation that IkkαAA/AA knock-in differentially affects atherogenesis in 
aortic arch (showing significantly increased plaque formation) compared to thoracal 
aorta (non-significant increase in plaque formation) and aortic root (significant 
decrease in plaque size).   
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Figure 35: Activation-resistant Ikkα mutation does not alter NF-κB p65 activity, but reduces 
enhanced histone H3 phosphorylation in aortic arch compared to aorta and aortic root. Proteins 
were extracted from IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- mice after 6 weeks of high-fat diet from aortic 
root, arch and thoracic aorta. DNA binding capacity of active NF-κB p65 was measured in extracts 
using a TransAM NF-kB ELISA and binding capacity, revealing p65 activity and concentration, was 
determined with help of a standard curve (A). Histone H3 phosphorylation was measured by ELISA 
and signal was normalized to protein extract concentration used for measurement (B). (n=5-6 each). 
au = arbitrary units. Data are expressed as mean ± SEM, 2-way Anova with Bonferroni post-test for 
comparison of IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/-; 1-way Anova test with Dunnette’s post test for 
comparing organs in between 1 genotype, *p<0.05. 
 
4.2.5 Ikkα is differentially expressed and activated at different 
vascular regions in Apoe-deficient mice 
To examine whether the regional atherosclerotic differences in the aortic root vs arch 
and aorta would be caused by differential Ikkα expression, Apoe-/- mice were put for 5 
and 10 weeks on high-fat diet, or received normal diet as control. Total protein 
extracts were made from aortic root, arch and thoracic aorta and a specifically 
designed ELISA was used to detect endogenous levels of total Ikkα and Ikkα when 
phosphorylated at Ser176/180 (activated form) at the different vascular regions. 
Interestingly, protein levels of Ikkα were different between aortic root vs arch 
and aorta. Compared to arch and aorta, the total Ikkα levels were increased in the 
aortic root both under control conditions as well as after 5 and 10 weeks of high-fat 
diet. In contrast, the levels of phosphorylated, active Ikkα were significantly reduced 
in the aortic root compared to the arch/ thoracic aorta. Especially when analyzing the 
ratio of activated Ikkα to total Ikkα levels, it became obvious that relative 
phosphorylation of Ikkα was greatly enhanced in arch and thoracic aorta compared to 
root (Figure 36). As Ikkα phosphorylation at Ser176/S180 is important to activate Ikkα 
kinase function, these data suggest that regional differences of Ikkα phosphorylation 
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extent could result in regional-dependent effects of Ikkα kinase functions on 
atherogenesis. 
 
 
Figure 36: Ikkα is differentially expressed and activated in aortic root compared to 
arch/thoracic aorta in Apoe-/- mice. Total protein extracts were prepared from aortic root, arch and 
thoracic aorta from Apoe-/- mice after normal diet or 5 and 10 weeks of high-fat diet. ELISA quantifying 
both endogenous total Ikkα protein levels, as well as active, phosphorylated Ikkα (P-Ikkα) was 
performed, showing higher total Ikkα levels (A) in aortic root, whereas arch/thoracic aorta revealed 
increased levels of P-Ikkα (B,C). 1-way Anova with Tukey´s post-test, all graphs represent the mean ± 
SEM (n=3, each from pooling 4 mice); *p<0.05; **p<0.01, ***p<0.001. 
 
To investigate whether regional differences in Ikkα protein expression were a 
direct result from differential gene expression, a qPCR was performed to analyse 
Ikkα expression in aortic root vs arch/thoracic aorta in Apoe-/- mice after 7 weeks of 
high-fat diet or normal diet conditions. Surprisingly, qPCR data showed opposite 
results than protein analysis. Under normal dietary conditions the expression of Ikkα 
was significantly higher in thoracic aorta compared to aortic root. Similarly after 7 
weeks of high-fat diet aorta revealed increased mRNA levels of Ikkα (Figure 37A). 
To exclude that results were influenced due to instable expression of the 
housekeeping gene gapdh in between organs or upon diet conditions (which would 
make it an inappropriate housekeeping gene), I quantified gapdh expression levels 
relative to input mRNA, and did not observe expression differences, indicating that 
gapdh constitutes a good housekeeping gene (Figure 37B). Furthermore, the same 
results of Ikkα expression were obtained when qPCR data were normalized to a 
combination of the housekeeping genes gapdh, 18srna, hprt as described in 
Vandesompele et al156 and as shown in Figure 37C.  
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Figure 37: qPCR reveals site-specific differential Ikkα expression in aortic root compared to 
arch/thoracic aorta in Apoe-/- mice under normal diet and 7 weeks of high-fat diet. (A) Ikkα 
mRNA levels measured with help of Taqman qPCR. Ikkα mRNA levels were normalized to gapdh. n= 
3-9 (B) gapdh expression was measured with help of Taqman qPCR and stability was compared in 
different tissue and upon diet conditions. mRNA expression shown relative to input RNA used for 
cDNA synthesis. n= 3-4 (C) Ikkα mRNA levels measured with help of Taqman qPCR. Ikkα mRNA 
levels were normalized to gapdh, hprt and 18srna. n= 5-6. All data shown as percentage of root no 
diet. ND = normal diet; HFD = high fat diet. Graphs represent mean ± SEM, Kruskal-Wallis test with 
Dunn´s post-test, *p<0.05, **p<0.01, ***p<0.001. 
 
In conclusion, Ikkα mRNA expression was significantly different in aortic root vs 
arch and aorta, although opposite effects were seen compared to Ikkα protein 
analysis. This suggests that Ikkα protein levels are additionally regulated on post-
transcriptional level. 
 
4.2.6 Potential role for miRs in regulating Ikkα mRNA levels 
Whereas the thoracic aorta shows a laminar flow pattern, the regions of aortic root 
and arch are characterized by a disturbed laminar flow. Given the highest expression 
of Ikkα mRNA in aorta (Figure 37), I hypothesized that disturbed laminar flow, which 
is associated with lower shear stress, might reduce Ikkα mRNA levels. Therefore, I 
generated a region of low shear stress by partial ligation of the carotid artery. Ikkα 
mRNA expression levels were quantified in the carotid artery by qPCR 1 day after 
ligation, 7 days after ligation and 6 weeks after ligation. As control, non-ligated 
carotids were used and mRNA levels were normalized to the housekeeping gene 
gapdh. The data exposed a marked upregulation of Ikkα expression after partial 
ligation, which was maximal after 1 day. Ikkα expression in the carotid artery was still 
significantly increased 1 week after ligation and after 6 weeks of ligation, Ikkα 
expression was again partially decreased (Figure 38). Thus, in contrast to my data in 
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Figure 37, these data would rather suggest that, if flow conditions are indeed 
regulating Ikkα mRNA levels in the partial ligation model, disturbed flow increases 
instead of reduces Ikkα mRNA levels. However, it is also likely that Ikkα mRNA levels 
in the partial ligation model are regulated by acute inflammatory rather than flow 
conditions, e.g. by adhesion of platelets or leukocytes as already visible 1 day after 
ligation157. 
 
 
 
Figure 38: Ikkα mRNA expression levels is 
markedly upregulated under turbulent flow 
conditions in ligated carotid arteries. Ikkα 
mRNA levels measured with help of Taqman 
qPCR. RNA isolated from ligated left carotid 
arteries and non-ligated right carotid arteries 
(control). Ikkα mRNA levels was normalized to 
gapdh. Data shown as percentage of control. 
(1 day-6 weeks ligation n= 3-4; control n= 20) 
Graphs represent mean ± SEM, Kruskal Wallis 
Test with Dunn´s post-test, *p<0.05. 
 
 
MiRs are important regulators of protein expression, able to induce degradation 
of target mRNA or repress translation of the mRNA into protein. As expression of 
miRs has been shown to be altered by haemodynamic forces such as shear stress 
and thus flow in the vascular system58, I hypothesized that miR-dependent post-
transcriptional repression of Ikkα mRNA might contribute to the observed site-specific 
differences of Ikkα mRNA or alternatively, protein expression. Using microRNA.org, 6 
miRs (mir-301a/b, mir-16, mir-425, mir-23a and let7b) were chosen that were 
reported to have Ikkα mRNA as target, and their expression profile was analysed in 
ligated carotid arteries 1 day after ligation, 7 days after ligation and 6 weeks after 
ligation. Similar as for the housekeeping genes used to normalize Ikkα expression, 
stable expression of the reference miR was analysed (Figure 39). Opposite to the 
effects observed for Ikkα mRNA levels, miR-301a, miR-301b, miR-23a and let7b 
expression levels were all significantly decreased 1 day after partial ligation (Figure 
40). Seven days after ligation also miR-425 showed significantly reduced levels. 
Expression of these miRs increased again 6 weeks after ligation. Only levels of miR-
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16 were not significantly altered by partial ligation of the carotid artery.  Compared to 
the expression profile of Ikkα mRNA, these data suggest a potential role for Ikkα-
targeting miRs in regulating the stability of Ikkα mRNA in the partial ligation model. 
 
 
 
Figure 39: Expression of reference miR 
sno-135 in ligated carotid arteries. sno-135 
miR levels measured with help of Taqman miR 
assay qPCR. RNA isolated from ligated left 
carotid arteries and non-ligated right carotid 
arteries (control). sno-135 miR levels were 
normalized to input RNA. Data shown as 
percentage of control. (1 day-6 weeks ligation 
n= 4; control n= 14). Graphs represent mean ± 
SEM, Kruskal Wallis Test with Dunn´s post-
test.
 
Figure 40: Expression profiles of Ikkα targeting miRs in ligated carotid arteries are influenced 
by turbulent flow conditions. miR were isolated from carotid arteries after partial ligation  as 
indicated and quantified by Taqman miR expression profilin Taqman miR assay qPCR. MiR levels 
were normalized to a combination of housekeeping miRs sno-135 and miR-429, as described by 
Vandesompele et al156. Data are shown as percentage of non-ligated arteries (control). (1 day-6 weeks 
ligation n= 4; control n= 14). Graphs represent mean ± SEM, 1-way Anova with Newman-Keuls test, 
Indicated significance refers to comparison to unligated controls. *p<0.05, **p<0.01. 
 
Similarly, I examined expression profiles of miR-301a/b, miR-23a, let7b, miR-
425 and miR-16 in aortic root vs thoracic aorta after normal diet and high-fat diet 
conditions. Both reference miRs sno-135 (Figure 41A) and miR-429 (Figure 41B) 
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were analysed for stable expression between aortic root and aorta and upon dietary 
conditions, to ensure that both constitute good reference miRs.  
 
 
 
Figure 41: Expression of reference miR sno-135 and miR-429 in aortic root and thoracic aorta. 
sno-135 (A) and miR-429 (B) levels were measured with help of Taqman miR assay qPCR. RNA 
isolated from aortic root and thoracic aorta after no diet and 7w high-fat diet. miR expression levels 
were normalized to input RNA. Data shown as percentage of root no diet/ root high-fat diet. n=5-8 
Graphs represent mean ± SEM. 
 
The expression was quantified in aortic root and aorta, given that the major 
atherosclerotic effect was observed in these tissues. Except for miR-425 and miR-16, 
all miRs showed a reduced expression in aorta compared to root (Figure 42). 
Similarly as in the partial ligation model, this suggests that a lower expression of 
Ikkα-targeting miRs in aorta could contribute to the increased Ikkα mRNA level in 
aorta compared to root by reducing miR-mediated degradation of Ikkα mRNA. 
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Figure 42: Expression profiles of Ikkα-targeting miRs are not significantly altered in aortic root 
vs thoracic aorta, except for miR-301b. miR was isolated from aortic root and thoracic aorta after 7 
weeks of normal diet (ND) (left side) or high-fat diet (HFD) (right side) and the expression quantified by 
Taqman miR assay qPCR. MiR levels were normalized to a combination of reference miRs sno-135 
and miR-429. Data are shown either as percentage of ”Root ND” or as percentage of “Root HFD”. 
(n=4-8) Graphs represent mean ± SEM, 2-tailed t-test, *p<0.05. 
 
Results 
 
85 
 
In summary, these data suggest that Ikkα mRNA levels could be controlled by 
Ikkα-targeting miRs, whereas a potential effect of flow conditions on Ikkα mRNA 
levels in aorta vs root remains to be further investigated. 
 
4.2.7 Defective Ikkα kinase activation influences gene expression 
differently in root vs aorta and arch 
To assess whether defective Ikkα kinase activation would differentially affect gene 
expression in aortic root vs arch or thoracic aorta and could thus contribute to 
differential effects on atherosclerosis at these regions, I tested the expression profile 
of various genes, previously linked to atherosclerosis, in aortic root vs arch and 
thoracic aorta in IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- mice after 6 weeks of normal and 
high-fat diet conditions. Among chemokine Ccl19 and chemokine receptor Ccr7, 
genes encoding the interleukin Il-6, inflammatory marker gene coding for Tnf-α, 
adhesion molecule Vcam-1 and additionally matrix metalloproteinases Mmp-3, Mmp-
9 and Mmp-13 were analysed. 
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Figure 43: Loss of Ikkα activation impacts expression of Ccl19 and Ccr7 in aortic arch and 
thoracic aorta, but not in aortic root. Expression of genes with important roles in atherosclerosis 
was analysed by qPCR. Study was performed with mRNA isolated from aortic root, arch and thoracic 
aorta from IkkαAA/AAApoe-/- and Ikkα+/+Apoe-/- mice after 6 weeks of normal (ND) or high-fat dietary 
(HFD) conditions. Expression of genes was normalized to a combination of the housekeeping genes 
gapdh, hprt and 18Srna as described by Vandesompele et al156. Data shown relative to “Root ND 
Ikkα+/+ Apoe-/-“; n=4-6. Graphs represent mean ± SEM, , 2-way Anova with Bonferroni post-test for 
comparison of IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/-; 1-way Anova test Kruskal Wallis Test with Dunn´s 
post-test for comparing organs in between 1 genotype, *p<0.05; **p<0.01, ***p<0.001. 
 
Under normal dietary conditions, the aortic root from IkkαAA/AAApoe-/- revealed a 
significantly increased expression of Ccl19 compared to controls (Figure 43). 
Expression profiles of Vcam-1, Ccr7, Mmp-3, Mmp-9 and Mmp-13 displayed a similar 
trend, though without reaching statistical significance. In contrast, expression of all 
these genes was not affected at aortic arch or aorta, with the exception of Vcam-1, 
which also showed a trend for increased expression in aortic arch from 
IkkαAA/AAApoe-/- in comparison to controls. Expression of Il-6 mRNA in aortic root was 
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not significantly affected by IkkαAA/AA knock-in after normal diet, and was also not 
significantly altered at aortic arch or aorta. 
Upon high-fat diet, Ikkα+/+Apoe-/- mice showed an enhanced expression of all 
targets, which was observed both in aortic root as well as in arch and thoracic aorta. 
In case of the thoracic aorta from Ikkα+/+Apoe-/- mice the expression of Ccl19, Ccr7, 
Vcam-1 and Mmp-3 increased significantly upon high-fat diet conditions. 
Remarkably, mRNA levels of Ccl19 and Ccr7 were now significantly lower in the 
aorta of IkkαAA/AAApoe-/- mice compared to Apoe-/- controls. Similarly in the arch, a 
significant decrease in Ccr7 expression was observed in IkkαAA/AAApoe-/- mice, and 
also Ccl19 showed a trend for decreased expression in the arch of IkkαAA/AAApoe-/- 
mice. In contrast, mRNA levels of Ccr7 in the root did not vary between Ikkα+/+Apoe-/- 
and IkkαAA/AAApoe-/- mice after high-fat diet and the effect of increased Ccl19 
expression in IkkαAA/AAApoe-/- aortic roots under no diet, disappeared under high-fat 
diet conditions. 
Also, expression of Mmp-3, Mmp-9 and Mmp-13 was significantly lower in 
IkkαAA/AAApoe-/- mice compared to controls after high-fat diet in aorta. In the arch 
similar trends was observed under high-fat diet conditions and significantly 
decreased expression in IkkαAA/AAApoe-/- mice was observed for Mmp-13. 
Surprisingly, Tnf-α expression did not significantly differ between Ikkα+/+Apoe-/- and 
IkkαAA/AAApoe-/- mice or between vascular regions under any dietary condition (data 
not shown).  
Taken together, these data support the hypothesis that effects of IkkαAA/AA 
knock-in can be site-specific. Under normal diet, the expression of different pro-
inflammatory genes was increased by IkkαAA/AA knock-in only in aortic root. However, 
this was not observed anymore in atherosclerotic conditions. In contrast, under high-
fat diet, expression profiles of Ccr7 and Ccl19 were significantly reduced by IkkαAA/AA 
knock-in in arch and thoracic aorta, but not in aortic root. The chemokine Ccl19 is a 
target gene of alternative NF-κB activation158,159, while theCcr7 gene expression has 
been described to be dependent on canonical NF-κB and AP1 activation pathways 
160
. With Ikkα performing diverse roles in regulating gene expression, both in NF-κB-
dependent as well as -independent manners115, combined with the differential 
expression and activation profile of Ikkα in root vs aorta and arch (Figure 36), the 
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data point to increased kinase-dependent functions of Ikkα in arch and aorta 
compared to aortic root.  
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5. Discussion 
Atherosclerosis is characterized by a chronic inflammation of the vessel wall and 
many leukocyte subsets play crucial roles in disease initiation and progression, 
including B- and T-lymphocytes, monocytes and monocyte-derived macrophages, 
neutrophils and DCs14,15. To investigate the function of Ikkα activation in 
atherosclerosis in detail, its function in haematopoietic cells as well as its overall role 
during atherosclerosis was studied. 
The results showed a versatile function for Ikkα in haematopoietic cells as well 
as a site-specific role in vascular cells in atherogenesis. Discussed are the results 
sections separately. 
 
5.1 The haematopoietic role of Ikkα activation in context of 
atherosclerosis 
5.1.1 Bone marrow-specific loss of Ikkα activation affects T-and B-
lymphocyte populations 
After 13 weeks of high-fat diet the effect of a BM-specific non-activatable IkkαAA/AA 
knock-in on haematopoiesis in atherosclerosis was studied. A remarkable reduction 
of the B-cell population in blood and lymph nodes of atherosclerotic-prone 
IkkαAA/AAApoe-/- BM chimeras in comparison with Ikkα+/+Apoe-/- BM-transplanted 
Apoe-/- controls was observed. Similar results were obtained in a collaboration with 
Dr. Toby Lawrence lab, in which a non-atherosclerotic study after transplantation of 
IkkαAA/AA vs Ikkα+/+ BM into C57BL/6 recipient mice and IkkαAA/AA also displayed 
reduced B-lymphocyte levels in lymph nodes.  Already in 2001, Senftleben et al. 
showed that Ikkα was required for B-cell maturation and Kaisho and colleagues 
observed also a critical importance of Ikkα in the development of mature B-cells74,155.  
Similarly, reduced B-lymphocyte populations were seen in Baff-/- mice, which together 
with the results of Ikkα studies indicate a crucial role for the non-canonical Baff-Baffr-
Nik-Ikkα pathway in B-cell maturation and survival161. In this study, the Cd19+B-cell 
population was not only reduced in secondary lymphoid organs and blood, but B-
cells were also significantly decreased in BM of IkkαAA/AAApoe-/- -transplanted Apoe-/- 
mice after 13 weeks of high-fat diet, suggesting an involvement of Ikkα activity in BM 
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B-cell development. This observation corresponds to recent findings of Balkhi and 
colleagues, who identified that Ikkα-mediated signalling regulates early B 
lymphopoiesis during haematopoiesis162. They observed a decreased Cd19+, B220+ 
and Cd19+B220+ B-cell population in the BM of kinase-dead Ikkα (IkkαKA/KA) knock-in 
mice and IkkαKA/KA BM chimeras, and also revealed less B220+Cd19+ B-cells in the 
BM of irradiated Rag-/- mice reconstituted with Ikkα-/- fetal liver cells. Thus, the data 
obtained in my study support this recently identified role for Ikkα kinase activity in 
early B-cell development in the BM, which was revealed to involve both the canonical 
as well as the non-canonical NF-kB pathway162.  
Furthermore, IkkαAA/AAApoe-/- BM transplanted mice displayed an increase in 
the Cd62LhighCd44low naive T-cell population in secondary lymphoid organs, whereas 
Cd62LlowCd44high effector memory T-cells were decreased. Naïve T-cells can 
differentiate into different subtypes of Th1, Th2, Th17 and Treg cells, which have been 
involved in both pro- as well as anti-atherogenic processes163, whereas effector 
memory T-cells have been associated with increased atherosclerosis both in human 
as well as in animal models164. My findings correspond with a previous observation of 
Mancino and colleagues, who revealed that Ikkα kinase activity is required in DCs for 
priming antigen-specific T cells165. Mice deficient for Nik (kinase activating Ikkα in the 
non-canonical NF-κB signalling pathway) and Nik-/- BM chimeras also demonstrate 
similar effects on the ratio of naive vs effector memory T-cells, which was linked to a 
cell-intrinsic role of Nik in the generation or maintenance of effector memory T-
cells166,167. Nikaly/aly mice, which carry a point mutation in the Nik gene causing Nik to 
be unable to bind Ikkα and showing decreased NF-κB activation168,169, showed Nik to 
play a pivotal role in DCs and suggested that thymic DCs require Nik to shape the 
formation of Cd4+ T effector lineages during early development125. Also, splenic 
Nikaly/aly DCs expressed a considerably lower level of MhcII compared to Nikaly/+ 
DCs170, suggesting an inability of Nikaly/aly DCs to deliver T-cell co-stimulatory signals 
and contribute to the development of effector T-cells171. In agreement with this, also 
my IkkαAA/AAApoe-/- BM transplanted mice displayed a significantly reduced MhcII 
expression on splenic pDCs. The combination of observations by Mancino et al. and 
my new findings, suggest that the impact of Ikkα activity on cell-intrinsic vs DC-
mediated effects on the increased ratio of naive vs effector memory T-cells remains 
to be studied in further detail. 
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Additionally to the reduced effector memory T-cell levels, IkkαAA/AAApoe-/- BM 
chimeras displayed remarkably reduced Treg populations. Tregs develop in the thymus 
and in peripheral sites from naive Cd4+ T-cells, and have been indicated to exert 
atheroprotective functions34. When Kaijura et al examined Nik-mutant mice for factors 
controlling the physical contact between thymocytes and the thymic stroma essential 
for T-cell maturation, they observed a disorganized thymic structure with abnormal 
expression of Rel proteins in the stroma. This was associated with a defective 
establishment of self-tolerance and reduced Treg numbers172. Recently, a study of 
single Nik-/- vs mixed Nik-/-/ Nik+/+ BM chimeras indicated an additional cell-intrinsic 
role for Nik in the maintenance of peripheral Treg T-cells167. Furthermore, Nik and Ikkα 
were previously shown to be required in human DCs to trigger the development of 
Treg cells from naive Cd4+ T-cells in vitro173. One study revealed, that pDC-triggered 
Treg development from naive T-cells was associated with the induction of indoleamine 
2,3-dioxygenase (IDO) in pDCs and required NIK-mediated non-canonical NF-kB 
activation174,175 . With Ikkα being a crucial player in non-canonical NF-kB activation, 
this study directly demonstrates a role for haematopoietic Ikkα kinase activation in 
the generation of Treg cells in vivo. Yet, the relative importance of Treg-intrinsic vs DC-
mediated mechanisms remains to be investigated, both in the periphery as thymus, 
given that peripheral DCs can migrate into the thymus to actively contribute to thymic 
Treg generation176. 
Taken together, flow cytometric analysis of IkkαAA/AA knock-in mice after 13 
weeks of high-fat diet shows a critical role for Ikkα in B-cell development, in naive 
and effector memory T-cell ratios and in generation of Tregs. 
 
5.1.2 Atherosclerotic lesions are unaltered in IkkαAA/AAApoe-/- bone 
marrow chimeras 
Surprisingly, although Ikkα showed a great impact on haematopoietic lymphocytes 
and VLDL levels were altered in IkkαAA/AAApoe-/- BM transplanted mice, IkkαAA/AA 
knock-in showed no effect on the size, phenotype or cell composition of 
atherosclerotic lesions in the aortic root or aorta. The increased levels of VLDL in 
IkkαAA/AAApoe-/- BM chimeras can be associated with the reduced Treg population, as 
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depletion of Treg T-cells was recently discovered to enhance VLDL levels through 
reduced VLDL clearance177. 
Given the reduced B-cell population in IkkαAA/AAApoe-/- BM-transplanted mice, 
an atheroprogressive effect was expected due to the findings of Major and 
colleagues, who showed increased atherosclerosis in B-lymphocyte deficient mice178. 
Also several other studies have suggested an atheroprotective function for                
B-cells43,41. However, B-cells have been involved in various stages of 
atherosclerosis40 and different B-cell subsets can have opposing pro-atherogenic and 
atheroprotective roles in atherosclerosis179. Whereas B2 B-cells exacerbate 
atherosclerosis, B1 B-cells have been indicated to be rather atheroprotective by the 
secretion of natural IgM, which increases IgM deposits and reduces necrotic cores in 
atherosclerotic lesions41,180. In this context, mice deficient in Baff161, a stimulus for the 
non-canonical NF-κB activation, or its receptor Baffr181, exhibited a lack of B2 B-cells, 
whereas the B1 B-cell population was preserved. Accordingly to these observations, 
Baffr-/-Apoe-/- or Baffr-/- BM-transplanted Ldlr-/- mice showed decreased 
atherosclerotic lesion sizes182. Depletion of only B2 B-cells in Baffr-/-Apoe-/- mice 
attenuated atherosclerosis and the administration of a blocking Baffr mAb in 
hyperlipidemic Apoe-/- mice reduced the progression of atherosclerosis by the 
depletion of mature B2 cells183,184. Although my study did not examine B-cell subsets, 
Senftleben et al. observed a reduction in the mature IgMlowIgDhigh B-cell population in 
IkkαAA/AA mice and IkkαAA/AA BM transplanted mice, with IgD being a surface marker of 
follicular B2 B-cells74,41,185. Accordingly, one could assume that the reduced B-cell 
population in my IkkαAA/AAApoe-/- BM chimeras may provide atheroprotective effects 
through a potential decrease in B2 B-cells.  
Although blood and lymph nodes of IkkαAA/AAApoe−/− transplanted mice 
displayed increased Cd3+ T-cell levels in blood, the Cd3+ T-cell content in 
atherosclerotic lesions of aortic root did not differ between the two mouse groups. 
This could be caused by different ratios of naive T-cells vs effector memory T-cells 
and Treg cells, creating an equalizing effect on the lesion content. Previously, effector 
memory T-cells have been shown to be present in atherosclerotic lesions and to 
positively influence the extent of atherosclerosis in hyperlipidemic mice164.  Naive T-
cells on the contrary were associated with an atheroprotective function in 
atherosclerotic lesions in the aortic sinus164. Also, regulatory T-cells have been 
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attributed  with atheroprotective properties34 and many studies have shown that 
decreased Treg numbers are associated with increased disease activity186. The pro-
atherogenic effects of decreased Treg numbers in IkkαAA/AAApoe-/- BM chimeras may 
be compensated by atheroprotective effects of increased naive vs effector memory 
T-cells. Similar observations were made by Lutgens and colleagues upon deficiency 
of Cd40-Traf2/3/5 signalling in Apoe-/- mice, which did not affect atherosclerosis 
despite an increase in both atheroprogressive effector memory T-cells and 
atheroprotective Treg cells187. 
To summarize, the missing effect on atherosclerotic plaque development, 
phenotype and composition in IkkαAA/AAApoe−/− vs Ikkα+/+ Apoe−/− BM chimeras could 
be based on simultaneous changes in lymphocyte subsets with both 
atheroprogressive and -protective effects, which cancel each other out leading to no 
visible effect on atherosclerosis. 
 
5.1.3 Haematopoietic knock-in of the IkkαAA/AA mutant does not 
affect systemic inflammatory gene expression in Apoe-deficient 
mice 
Macrophages play a crucial role in the progression of atherosclerosis56, and Ikkα has 
been attributed an anti-inflammatory function in macrophages by the resolution of 
canonical NF-κB activation and thereby termination of pro-inflammatory gene 
expression137. Also other subsequent studies have reported, that Ikkα negatively 
regulates canonical NF-κB activation in both Ikkα-/- mouse macrophages188 and 
zebrafish with a targeted mutation in the mammalian IKKα orthologue189. 
Therefore, I examined the influence of IkkαAA/AAApoe-/- knock-in on macrophage 
lipid uptake, on lesional apoptosis and necrotic core size, NF-kB p65 activity and 
cytokine/ chemokine expression. As macrophages play an important role in the 
uptake of modified lipids in atherosclerotic lesions15,190, the intracellular lipid 
accumulation in macrophages was studied both in vitro and in vivo. However, no 
significant differences were observed in vitro after stimulation with Dil-labeled oxLDL 
or in atherosclerotic lesions of IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- BM chimeras. A 
similar effect was reported for Ldlr-/- mice with a myeloid-specific deletion of Ikkβ127. 
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Despite the expected important impact of Ikkα on macrophages, the macrophage 
content in atherosclerotic lesions of BM chimeras was also comparable. 
Furthermore, Lawrence et al showed that macrophages carrying the IkkαAA/AA 
knock-in mutation were more resistant to pathogen-induced apoptosis137. Apoptosis 
is an important process in atherogenesis, and its effect is dual. At early stages it can 
exert atheroprotective properties, as apoptotic death of SMCs and inflammatory cells 
may delay the atherosclerotic process. However, in later disease phases it is 
associated with plaque necrosis and atheroprogression, and at the end can lead to 
plaque rupture and thrombosis191,192. Given the reported resistance of IkkαAA/AA 
macrophages to apoptosis, cellular and macrophage apoptosis in IkkαAA/AAApoe-/- 
and Ikkα+/+Apoe-/- BM chimeras was analysed in atherosclerotic lesions. In addition, 
also necrotic core sizes were examined. However, no significant differences were 
observed in cellular or macrophage apoptosis, and also necrotic core sizes were 
comparable. 
Next, the activity of p65 in IkkαAA/AAApoe-/- vs Ikka+/+Apoe-/- BM-derived 
macrophages upon LPS stimulation was assessed. In previous studies IkkαAA/AA 
macrophages displayed prolonged NF-κB activation upon stimulation with LPS. Yet, 
this study did not show any differential NF-kB activity between knock-in mutant and 
wildtype macrophages after LPS stimulation, and upon atherogenic (i.e. Tnf-α, 
oxLDL) exposure, even decreased p65 activation was observed in IkkαAA/AAApoe-/- 
macrophages. These differential observations between my study and the effects of 
IkkαAA/AA on NF-kB activation described by Lawrence and colleagues137 are 
surprising. Potentially these differential effects can be attributed to the Apoe-deficient 
background used in this study. ApoE combines with lipid in the body to form 
molecules called lipoproteins. Lipoproteins are responsible for packaging cholesterol 
and other fats and carrying them through the bloodstream. Apoe-/- mice are 
commonly used atherosclerosis-prone mice, which upon high-fat diet develop 
atherosclerotic lesions morphologically similar to those found in humans193. Despite 
the widespread use of the Apoe-/- transgenic mouse model, it also carries several 
disadvantages. ApoE has been recognized to affect macrophage biology, immune 
function and adipose tissue biology194. In macrophages ApoE was revealed to be an 
important immunomodulator promoting the anti-inflammatory M2 phenotype195. Also, 
it is know that NF-κB signalling is very complex and diverse, which is thought to be 
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important for facilitating the differential and highly selective regulation of NF-κB target 
genes. The regulation of NF-κB activation behaves in a cell type-specific manner, 
also in the context of Ikkα-mediated NF-κB regulation196. Whereas LPS stimulation of 
IkkαAA/AA BM-derived macrophages showed enhanced NF-κB activity in the study of 
Lawrence and colleagues137, canonical NF-κB signalling was not affected in BM-
derived IkkαAA/AA DCs165 and IkkαAA/AA B-cells even displayed a small reduction in 
basal and LPS-induced NF-kB activation74. Furthermore, NF-kB regulatory 
mechanisms are not only cell type-specific but also stimulus-dependent and various 
intrinsic and extrinsic mechanisms allow NF-κB to regulate genes in a different way 
different cell types and in response to different stimuli196, as demonstrated in a study 
in which IkkαAA/AA knock-in did not affect Tnf-α-mediated NF-κB activation in 
fibroblasts or mammary epithelial cells144. Hence, the dissimilar effects of impaired 
Ikkα activity on LPS-/Tnf-α-/oxLDL-induced NF-kB p65 activity in macrophages in my 
study compared to previous reports137 could be due to differential macrophage 
phenotypes induced by Apoe-deficiency or could be based even on different culturing 
conditions. 
Despite the known diverse roles of Ikkα kinase in modulating gene expression 
in an NF-κB-dependent or -independent manner, my investigation did not discover 
any differences between the levels of inflammatory cytokines and chemokines. The 
supernatants of Tnf-α- or oxLDL-stimulated IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- BM-
derived macrophages did not show any differences in cytokine levels, with the 
exception of Il-12 which showed a significant increase in oxLDL-stimulated 
macrophages upon IkkαAA/AA knock-in. Also in serum of atherosclerotic 
IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- mice no significant differences in cytokine and 
chemokine levels were measured. Thus, the reported functions of Ikkα in regulation 
of gene expression do not seem strong enough in the context of atherogenesis to 
produce a major effect on systemic protein expression upon IkkαAA/AA knock-in. 
 
5.1.4 Conclusions and perspectives of BM-specific inactivation of 
Ikkα kinase during atherogenesis 
This study demonstrated a significant effect of knocking-in an activation-resistant 
Ikkα mutant on many leukocyte subsets, yet an overall zero effect on atherosclerosis 
and canonical NF-κB activation in macrophages. Taken together the data suggest 
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that the zero effect on atherosclerosis is at least partially the result of 
counterbalanced effects on different B- and T-leukocyte subsets. Also, the effects of 
Apoe-/- background on different biological processes in macrophages could overrule 
a potential impact of IkkαAA/AA knock-in on macrophage biology in the context of 
atherosclerosis.  
Future studies are needed to investigate the role of the Ikkα kinase in 
atherosclerosis in different leukocyte subsets individually, for example it would be 
interesting to perform a detailed characterization on the effect of a DC- or Treg-
specific IkkαAA/AA mutation on atherogenesis. A recent report identified both IKKα and 
IKKβ to be important in neutrophil chemotaxis to HMGB1, a nuclear protein released 
by necrotic cells, but the functions of the IKKα kinase activity in neutrophil responses 
and molecular signalling in the context of inflammation and atherosclerosis have not 
yet been investigated197. 
In human atherosclerotic lesions the NF-κB isoforms p65, c-Rel and p50 have 
been observed85, but the effect of the IKKα kinase on NF-kB stability in macrophages 
has so far only been studied for the isoforms p65 and c-Rel. It has been suggested 
that p50-p50 homodimers represent the main NF-κB activity during inflammation 
resolution, which could correspond to the findings of Kanters et al, who observed 
haematopoietic p50 deficiency to result in a higher inflammatory phenotype of 
atherosclerotic lesions in Ldlr-/- mice104. A study focusing on the canonical and non-
canonical NF-κB isoform activity in different stages of atherosclerosis and the 
potential effect of IkkαA/A mutation on activity of all isoforms is required. 
 
5.2 The global role of Ikkα activation in atherosclerosis 
5.2.1 Global Ikkα inactivity causes oppositional atherosclerotic 
effects at different vascular locations 
Atherosclerosis is a chronic inflammatory disease in which lipids and inflammatory 
cells accumulate inside the inner wall of arteries, causing the build-up of plaques. 
Over time, the plaque progresses and narrows the artery18. Atherosclerotic lesions 
develop predominantly at sites that are exposed to disturbed blood flow e.g. 
bifurcations or bends6. These areas are characterized by low/oscillatory shear stress 
on the vessel wall and these haemodynamic forces alter endothelial cell physiology 
Discussion 
 
97 
 
by enhancing inflammatory activation198. On the other hand, regions of the arterial 
tree that are exposed to uniform, unidirectional blood flow and experience high shear 
stress are protected from inflammation and lesion development. It has been shown 
that vascular ECs sense shear stress with help of mechanoreceptors, which 
transduce shear stress signals into biochemical signals resulting in the modulation of 
pro-inflammatory signalling pathways47. Several signalling pathways, especially NF-
κB-mediated signalling93,84, play crucial roles in these shear stress-induced 
pathophysiological processes and recently, miRNAs have emerged as important 
regulators of EC function by fine-tuning gene expression57. 
My study of BM-restricted IkkαAA/AA knock-in showed that only haematopoietic 
inactivation of Ikkα was not strong enough to influence atherogenesis. However, the 
study of global Ikkα inactivity demonstrated a striking effect of Ikkα inactivity on 
atherosclerotic lesion area in the aortic root, yet with an opposite effect at the aortic 
arch and thoracic aorta. IkkαAA/AA mutation decreased lesion area in aortic root by 
22%, whereas in IkkαAA/AAApoe-/- mice the lesions were increased by 65% in the total 
aorta and by 70% in the aortic arch. This dissimilar effect on lesion size was not 
associated with a differential effect on lesion composition, as IkkαAA/AA knock-in did 
not alter the cellular composition of atherosclerotic lesions in the aortic root or in the 
BCA. Previous studies similarly observed intriguing, site-specific atherosclerotic 
effects when inspecting distinctive vascular regions such as the aortic sinus vs 
thoraco-abdominal aorta. In one study, Teupser et al discovered a major reduction of 
atherosclerosis in fractalkine-deficient mice in the BCA, but not in the aortic root146. 
Another study showed Pecam-1 to be pro-atherosclerotic in the inner curvature of the 
aortic arch, whereas it exerted atheroprotective effects in the aortic root, branching 
arteries and descending aorta145. Witting et al observed an increase in lesion area in 
aortic root of male Apoe-/- mice after Western-type diet with 1% probucol for 24 
weeks, but a decrease at the aortic arch, descending aorta, and proximal abdominal 
aorta199. Ebselen, a glutathione peroxidase-1 (GPx1) mimic, reduced atherosclerotic 
lesions in the aorta of diabetic Apoe-/- mice, but not within the aortic sinus200. The 
concept that local haemodynamic factors account for differences in atherosclerotic 
lesion formation at different vascular sites has become almost universally accepted 
by researchers in the field201. There is evidence that disturbed flow patterns influence 
the expression of a large number of genes in ECs, which in turn would mean that 
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depending on the flow conditions and particular vascular location, the gene 
expression profile of vascular ECs could either promote or attenuate the 
development of atherosclerosis at these sites202. 
My study is the first one to demonstrate a site-specific effect of IkkαAA/AA 
mutation on atherosclerosis, which could be triggered by a differential extent of Ikkα 
activation at different vascular locations under atherosclerotic conditions (as 
explained in more detail in the next chapter).  However, the underlying processes 
triggering the observed effects on atherosclerosis remain currently unclear. I could 
not observe effects of IkkαAA/AA knock-in on the plaque phenotype or its cellular 
composition.  
In conclusion, my data suggested strongly a site-specific role for Ikkα kinase 
activation in atherogenesis in aortic root vs aortic arch and thoracic aorta, 
independent from effects on lesional cellular composition. As the first part of my 
study did not reveal an effect of haemotopoeietic knock-in of IkkαAA/AA on 
atherosclerosis, the observed effects are expected to be associated with effects on 
vascular cells, being ECs or SMCs. 
 
5.2.2 Site-specific effect of Ikkα on atherosclerosis based upon 
differential Ikkα expression and activation profiles 
Changes in gene expression at sites of oscillatory/turbulent flow with low shear stress 
are at least partly mediated by NF-κB and have been associated with reduced levels 
of IκBα in a flow-dependent fashion, which in turn is related to enhanced IKK 
activation203. These in vitro findings have also been mirrored in in vivo models 
demonstrating high activation of NF-κB in the lesser curvature of mouse aorta, which 
has a disrupted flow pattern and is susceptible to atherosclerosis84. Both IKKα and 
IKKβ have been presented to be up-regulated under low shear stress conditions, but 
a significant proportion of low shear-induced-kinase activity activating NF-κB is 
contributed by IKKβ130. Also, histone H3 phosphorylation has been associated to be 
induced by high shear stress204 and given the importance of IKKα in histone H3 
phosphorylation139, a gene-modulating role for IKKα regulated by shear stress could 
be assumed.  
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Therefore, I examined whether the opposite regional effects of IkkαAA/AA knock-
in on atherosclerosis could be caused either by differential, site-specific effects on 
canonical NF-κB p65 activity or oppositional effects on histone H3 phosphorylation. 
However, NF-κB p65 DNA binding-activity did not show any variation between the 
IkkαAA/AAApoe-/- mice and the control group in any of the vascular sites examined. 
Despite the reported findings of shear stress and flow condition-induced NF-κB 
activation205, the NF- κB p65 activity profile was similar between root, arch and 
thoracic aorta. A possible cause for a missing effect of defective Ikkα activation could 
be compensating effects of Ikkβ in NF-κB activation136.  Furthermore, examination of 
histone H3 phosphorylation within the aortic root, arch and thoracic aorta revealed 
that wildtype mice exhibited increased histone H3 phosphorylation levels within the 
aortic arch compared to aorta and aortic root. This was not observed in IkkαAA/AA 
knock-in mice, in which histone H3 phosphorylation levels in aortic arch were 
decreased compared to wildtype controls. In contrast to aortic arch, histone H3 
phosphorylation levels in aortic root and aorta of IkkαAA/AA knock-in mice were 
unaltered compared to wildtype controls. These data indicated that histone H3 
phosphorylation is site-specifically regulated by Ikkα, with a role for Ikkα in histone H3 
phosphorylation only in aortic arch. These findings could partially contribute to the 
differential effect of IkkαAA/AA knock-in on atherosclerosis in aortic root vs arch. 
However, they do not explain why a similar effect was observed on atherosclerosis in 
thoracic aorta and arch, as histone H3 phosphorylation was differentially affected by 
IkkαAA/AA knock-in at these vascular sites. 
Additionally, Ikkα protein expression and activation were analysed in the aortic 
root vs arch and thoracic aorta, to examine whether a differential, site-specific 
expression or activation profile of Ikkα could underlie site-specific effects of IkkαAA/AA 
knock-in on atherosclerosis.  Comparing aortic root vs arch and thoracic aorta, site-
specific differences in total Ikkα protein levels were revealed as well as site-specific 
differences in the activation of Ikkα. Whereas the aortic root showed increased 
amounts of total endogenous Ikkα, significantly higher Ikkα phosphorylation levels 
were detected in the arch and thoracic aorta. Together, these data suggest that 
differential expression and/or activation of Ikkα could exert regional-dependent 
functions. To examine whether differential protein expression was a result from 
differential mRNA production, the expression profiles of Ikkα mRNA were evaluated 
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with help of real-time qPCR after high-fat diet and normal diet in aortic root as well as 
arch and thoracic aorta. Surprisingly, qPCR data revealed opposite results compared 
to the protein data, showing significantly enhanced Ikkα mRNA expression in arch 
and thoracic aorta compared to aortic root. This suggests that Ikkα protein levels are 
further regulated on post-transcriptional level. Although the qPCR method is one of 
the most commonly used techniques for detection of gene expression due to its 
sensitivity, specificity and ease of use, many regulatory processes occur only after 
mRNA expression such as post-transcriptional and post-translational regulation, as 
well as regulation of protein stability206. These processes need to be considered 
when looking into protein concentrations and might explain the different effects 
observed in Ikkα levels when comparing mRNA vs protein data. 
 
5.2.3 Potential role for miRs in regulating Ikkα mRNA levels 
My study examining whether Ikkα mRNA expression could be triggered by flow 
conditions did not reveal a conclusive result. The highest expression of Ikkα mRNA in 
aorta would suggest that laminar flow (and thus higher shear stress) would increase 
Ikkα mRNA levels compared to aortic arch and root, which would be more subjective 
to turbulent and oscillatory, pulsatile flow conditions and thus lower shear stress207. In 
contrast, data from the partial ligation model would rather suggest that, if flow 
conditions are indeed regulating Ikkα mRNA levels in this model, disturbed laminar 
flow increases instead of reduces Ikkα mRNA levels.  However, it is also likely that 
Ikkα mRNA levels in the partial ligation model are regulated by acute inflammatory 
rather than flow conditions, e.g. by adhesion of platelets or leukocytes as already 
visible 1 day after ligation157. On the other hand, it is also possible that Ikkα mRNA 
expression in aortic root, arch and aorta is regulated differently due to phenotypic 
diversity in vascular ECs and SMCs208. Thus, more studies are required whether and 
how differential flow would affect Ikkα mRNA levels. 
MiRs have been reported to be important regulators of post-transcriptional 
repression. They are able to induce degradation of their target mRNA or repress 
translation of the mRNA into protein, and could thus be a reason for the regional 
differences in Ikkα expression profiles, either on mRNA or protein level58. As flow 
conditions, shear stress and the susceptibility of atherosclerosis have been 
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associated with the expression of miRs, expression profiles were studied for 6 Ikkα-
targeting miRs. Corresponding with the upregulation of Ikkα mRNA under turbulent 
flow conditions in the partial ligation model, miR-301a, miR-301b, miR-23a and let7b 
expression levels were all greatly decreased 1 day after partial ligation of the carotid 
artery. Similarly, when comparing miR expression profiles in aortic root, arch and 
thoracic aorta, all miRs except for miR-425 and miR-16 showed a reduced 
expression in aorta compared to root, corresponding with the highest Ikkα expression 
in aorta. Thus, both in the partial ligation model as well as in the atherosclerosis 
model, my data indicate that a lower expression of Ikkα-targeting miRs is associated 
with an increased Ikkα mRNA level, suggesting a role for these miRs in miR-
mediated degradation of Ikkα mRNA. However, a more detailed study would be 
necessary to confirm a direct role of these miRs in regulating Ikkα in these mouse 
models and whether this is controlled in a flow-specific manner. 
Although most of these miRs have not been previously reported to be regulated 
by turbulent flow conditions, most of them have been priorly implicated in 
cardiovascular diseases and shown to be expressed in endothelial cells. miR-301a/b 
and let7b were shown to be suppressed in endothelial cell-specific Dicer knock-out 
mice and let-7b has been reported to be expressed in different EC types and thereby 
to be involved in EC phenotypic differences209. The cluster miR-23-27-24 was 
demonstrated to be increased by shear stress, yet only miR-23b was described to 
have an atheroprotective role59. miR-301a was shown to elevate NF-κB activation210 
and miR-16 was reported to modulate non-canonical NF-κB activation by regulating 
Ikkα expression during macrophage differentiation211. Thus, these findings support 
the in vivo relevance of studying effects of miRs on gene expression in the context of 
pathological processes, such as atherosclerosis. 
In conclusion, these data show that the aortic root exhibits different Ikkα protein 
levels as well as a different extent of Ikkα phosphorylation/activation compared to 
aortic arch and thoracic aorta. This differential activation pattern could imply different 
functions of Ikkα in aortic root compared to aortic arch/thoracic aorta. As the aortic 
root showed higher levels of total Ikkα, increased kinase-independent functions could 
be suspected to be more relevant at this vasculature site. In contrast, the high levels 
of active Ikkα at aortic arch and thoracic aorta rather point to increased kinase-
dependent functions, such as histone H3 phosphorylation or non-canonical NF-κB 
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activation. However as IkkαAA/AA knock-in has also a significant effect on 
atherosclerotic lesion development within the aortic root, Ikkα clearly also exerts 
important kinase-dependent functions within the aortic root. These Ikkα kinase-
dependent functions however seem to be site-specific, given that the atherosclerotic 
outcome of IkkαAA/AA knock-in in aortic root compared to arch and thoracic aorta is 
oppositional. The different Ikkα expression profiles could trigger differential 
interactions of Ikkα with other proteins, causing differential atherosclerotic effects. Or 
Ikkα target proteins, which become modulated by Ikkα, could be differentially 
expressed in aortic root vs arch and aorta and could thus lead to opposing effects of 
IkkαAA/AA knock-in on atherosclerosis. To summarize, the site-specific differences in 
Ikkα expression and activation profiles may underlie the differential effects of 
IkkαAA/AA knock-in on atherosclerosis in aortic root vs aortic arch and aorta. 
 
 
Figure 44: Schematic drawing of suggested regional site-specific Ikkα functions. The aortic arch 
and thoracic aorta displayed higher levels of phosphorylated (active) Ikkα, whereas within the aortic 
root elevated total Ikkα levels were found. This leads to the suggestion that even under regular 
conditions Ikkα may exert different functions depending on the vascular region, e.g. in the arch and 
aorta Ikkα could regulate gene expression through kinase-dependent functions, whereas in the aortic 
root Ikkα could exert more kinase-independent functions or different kinase-dependent functions than 
in arch and aorta. 
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5.2.4 Site-specific roles of Ikkα regulate gene expression differently 
and may thereby cause regional differences in athero-susceptibility  
Studies in endothelial cells have shown remarkable expression differences of a 
variety of genes upon different flow patterns6,212. Ikkα has been reported to have 
diverse roles in regulating gene expression, both in NF-κB-dependent as well as -
independent manners115. Ikkα has been found to shuttle between the cytoplasm and 
the nucleus and the nuclear-specific roles of Ikkα have brought increasing complexity 
to its biological function, including to its kinase activity138. However, so far no study 
has associated Ikkα with flow-dependent or site-specific gene regulation. Thus, a 
gene expression study was performed with the hypothesis that differences in 
atherosclerosis susceptibility were based on differences in Ikkα functions at the 
different vascular regions. Various different genes, previously linked to 
atherosclerosis, were tested for their expression profile in aortic root vs arch and 
thoracic aorta in IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- mice after 6 weeks of normal or 
high-fat diet conditions, among them chemokine Ccl19 and chemokine receptor Ccr7, 
interleukin Il-6, adhesion protein Vcam-1 and additionally matrix metalloproteinases 
Mmp-3, Mmp-9 and Mmp-13.  Especially the differential expression profile of Ccr7 
and Ccl19 in aortic root compared to arch and aorta in Ikkα+/+Apoe-/- mice vs 
IkkαAA/AAApoe-/- mice reflected the hypothesis that due to site-specific Ikkα kinase 
functions, specific genes are differentially regulated leading to different 
atherosclerosis susceptibility. The chemokine receptor Ccr7 and its ligands Ccl19 
and Ccl21 play a crucial role in the homing of lymphocytes and dendritic cells to 
secondary lymphoid tissues. The Ccr7 ligand Ccl19 has been shown to be regulated 
by alternative NF-κB activation213,159 , whereas Ccr7 gene expression has been 
suggested to be dependent on NF-κB and AP1 activation pathways160. Both Ccr7 as 
well as its ligands Ccl19 and Ccl21 play a role in atherosclerosis, yet, their impact on 
atherogenesis has been controversially discussed214. Some studies have suggested 
a rather pro-atherogenic effect for Ccl19 and Ccr7. For example Damas et al found 
increased levels of Ccl19 and Ccl21 within atherosclerotic lesions of Apoe-/- mice and 
in human atherosclerotic carotid plaques compared to healthy vessels, and in plasma 
of patients with coronary artery disease compared to healthy controls215. Halvorsen 
et al observed that Ccl19 is able to induce proliferation and MMP-1 expression in 
vascular SMCs, which could contribute to a pro-atherogenic potential216. Also, a 
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recent study described  a pro-atherosclerotic function for the Ccl19/Ccr7 axis by 
promoting human monocyte adhesion and migration217. On the other hand, some 
studies suggested a protective effect. In a mouse study of atherosclerosis regression, 
Ccr7 expression levels increased in regressing lesions, potentially suggesting an 
anti-atherogenic effect of Ccr7218. A study from Wan et al also showed protective 
functions, as they found that genetic Ccr7-deficiency exacerbated atherogenesis in 
Apoe-/- mice by increased T-lymphocyte accumulation in the vessel wall219. 
Combining my plaque data with the gene expression profile of Ccr7 and Ccl19 in 
aortic arch and thoracic aorta, my study suggests that Ccr7 and Ccl19 may exert an 
anti-atherogenic function and that differential expression of Ccr7 and Ccl19 at 
different vascular sites could contribute to the observed differential effects of IkkαAA/AA 
knock-in on atherosclerosis. 
Matrix metalloproteinases contribute to the destruction of extracellular matrix at 
shoulder regions of plaques and have been shown to be linked to plaque 
destabilization97,98. Given that the Mmp-3, Mmp-9 and Mmp-13 expression in the 
aorta of Ikkα+/+Apoe-/- mice was remarkably higher compared to Ikkα mutant mice 
after high-fat diet, my data would implicate a plaque de-stabilizing function for Ikkα 
through regulation of Mmp expression. However, this did not reflect on the 
atherosclerotic lesions in aorta, where increased atherosclerosis was observed upon 
IkkαAA/AA knock-in. 
Taken together, the data support the hypothesis of a region-specific function for 
Ikkα kinase activity. Given the assumption drawn from the Ikkα ELISA that within arch 
and thoracic aorta more activated Ikkα-P is present than in aortic root, in combination 
with the significantly decreased Ccr7 and Ccl19 expression only in arch and aorta 
upon IkkαAA/AA knock-in, these observations point to increased kinase-dependent 
Ikkα functions in arch and aorta compared to aortic root and a differential Ikkα-
mediated regulation of Ccr7 and Ccl19 expression at these vascular regions. A future 
study examining the atheroprotective effect of IkkαAA/AA knock-in mutation in aortic 
root needs to performed, as both phenotypic lesion characterization as well as gene 
expression studies in roots of IkkαAA/AA knock-in mice did not reveal an indication of 
underlying mechanisms protecting against atherosclerosis. 
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5.2.5 Conclusions and perspectives on site-specific roles of Ikkα in 
atherosclerosis 
In conclusion, this study illustrates for the first time the functional diversity of Ikkα in 
atherosclerosis. Whereas within the aortic root Ikkα seems to have a pro-atherogenic 
function, in the aortic arch and thoracic aorta Ikkα has a protective function instead. 
The opposite atherosclerotic susceptibility is caused by differential kinase-dependent 
Ikkα functions. Whether these site-specific differences in Ikkα functions are caused in 
response to flow conditions should be studied further. Site-specific differences in 
atherosclerosis can be influenced by multiple factors202. Genetic background has 
been implicated to lead to variations in arterial atherosclerosis by regulating genes 
that are of variable importance at different anatomic sites, thereby causing site-
specific atherosclerotic effects220. Also, in the mouse model atherosclerosis develops 
at first at the aortic root221, and although Ikkα could have similar functions during the 
initiation of atherosclerosis, the progressed plaques in the aortic root after 13 weeks 
of high-fat diet might cause a shift in the kinase function at later stages of disease. 
Furthermore, a detailed characterization of the differences in EC phenotypic in aortic 
root compared to arch and thoracic aorta and its effect on the regulation and function 
of the Ikkα kinase could be highly interesting. The  vascular origin of ECs strongly 
affects their cell-cell junctions, orientation to flow, vesicle formation as well as 
microvilli count and studies have revealed macrovascular ECs from the aorta to 
behave differently than microvascular ECs isolated from liver sinusoids222,223. Finally, 
an extensive study on the detailed involvement of Ikkα in resident vascular cells and 
its functions related to atherosclerosis would be helpful to explain the observed 
effects on atherosclerosis.  
Taken together, my study showed that Ikkα has diverse functions, which can 
exert both pro- as well as anti-atherogenic effects depending on the vascular region.  
This suggests that Ikkα would not be an ideal target for systemic drug application. 
Still, understanding the role of Ikkα kinase activity in atherosclerosis is important, as 
drugs targeting specifically Ikkα have been suggested to be useful in preventing B-
cell-mediated autoimmune diseases108, however so far only drugs targeting Ikkβ are 
available. Furthermore, this study clearly underlines the importance to study effects 
of gene manipulations or drug treatments on atherosclerosis at different anatomic 
sites, which is currently not always standardly performed in atherosclerosis studies. 
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6. Summary 
Most fatal cardio- and cerebrovascular incidents are caused by atherosclerosis, a 
chronic inflammatory disease of the vessel wall in which the transcription factor NF-
κB has been shown to be involved. Two main pathways activate NF-κB: whereas 
inflammatory signals induce “canonical” NF-κB activation through the IKKβ/IKKγ 
kinase complex, “alternative” NF-κB activation, triggered by e.g. RANKL, CD40L and 
LT-β depends on the IKKα kinase. In addition, IKKα was reported to terminate the 
canonical NF-κB activation in macrophages, thereby contributing to the resolution of 
inflammation. Furthermore, IKKα exerts multiple NF-κB-independent functions, e.g. 
modulating gene expression by phosphorylating histone H3. Despite these known 
functions of IKKα, the contribution of IKKα to atherogenesis remained unexplored. 
Thus, the aim of this study was to identify the role of haematopoietic IKKα activation 
versus the global function of IKKα activation in atherosclerosis. For both approaches 
an activation-resistant Ikkα (IkkαAA/AA) mouse model was used, with a hyperlipidemic 
Apolipoprotein E-deficient (Apoe-/-) background. 
To study the bone marrow-specific function of Ikkα kinase activity, 
IkkαAA/AAApoe-/- or Apoe-/- bone marrow was transplanted in lethally-irradiated Apoe-/- 
mice, followed by high-fat diet for 8 or 13 weeks. Haematopoietic profiling revealed a 
significant decrease in B-cells, regulatory T-cells and effector memory T-cells in 
IkkαAA/AAApoe-/- bone marrow chimeras, whereas the naive T-cell population was 
increased. However, an overall zero effect on atherosclerosis, canonical NF-κB 
activation in macrophages and gene expression was observed. Taken together, the 
data indicate that diverse functions of Ikkα in haematopoietic cells may 
counterbalance each other or may not be strong enough to influence atherogenesis, 
and reveal that targeting haematopoietic Ikkα kinase activity alone does not 
represent a suitable therapeutic approach.  
Furthermore, the global role of Ikkα in atherosclerosis was studied in 
IkkαAA/AAApoe-/- mice after 13 weeks of high-fat diet. IkkαAA/AAApoe-/- mice showed 
significantly increased plaque formation in the aorta compared to wildtype controls, 
but surprisingly the lesions in aortic root were significantly reduced compared to the 
control group. These site-specific effects could not be attributed to differences in 
leukocyte infiltration as lesion phenotypes were comparable between the groups. 
Also, NF-κB p65 activation showed similar levels between IkkαAA/AAApoe-/- and 
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Ikkα+/+Apoe-/- mice. However, IkkαAA/AA knock-in reduced histone H3 phosphorylation 
in aortic arch. Furthermore, the aortic root showed increased amounts of total 
endogenous Ikkα compared to aortic arch and aorta, whereas levels of activated, 
phosphorylated Ikkα were significantly higher in arch and thoracic aorta. Also, gene 
expression studies in IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- mice revealed site-specific 
gene expression variations when comparing aortic root to arch and aorta, with Ccr7 
and Ccl19 to be significantly reduced in IkkαAA/AAApoe-/- mice only in arch and aorta 
but not in aortic root. The combination of the Ikkα activation profile and the gene 
studies point to regional differences of Ikkα kinase function, which might cause the 
site-specific atherosclerotic effects, although the exact mechanisms remain to be 
further examined. 
Thus, my data illustrate the functional diversity of the Ikkα kinase and indicate 
that an exploration of site-specific effects of Ikkα-targeting drugs and of drugs in 
general on atherosclerosis is required before potential therapeutic application can be 
considered. 
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7. Zusammenfassung 
Die meisten kardio- und zerebrovaskulären Ereignisse werden durch Atherosklerose 
verursacht, einer chronisch-entzündlichen Erkrankung der Gefäßwand, in dem der 
Transkriptionsfaktor NF-κB involviert ist. NF-κB kann über zwei 
Signaltransduktionswege aktiviert werden: Während pro-inflammatorische Signale 
die "kanonischen" NF-κB-Aktivierung induzieren, in welcher die Aktivierung abhängig 
ist vom IKKβ/IKKγ Kinase-Komplex, ist die "alternative" NF-κB-Aktivierung, induziert 
durch z.B. RANKL , CD40L und LT-β, abhängig von der IKKα Kinase. Darüber 
hinaus wurde gezeigt, dass IKKα in der Lage ist die kanonische NF-κB-Aktivierung in 
Makrophagen zu beenden und somit zur Auflösung der Entzündungsreaktion 
beiträgt. Zudem übt IKKα auch mehrere NF-κB-unabhängige Funktionen aus, wie 
z.B. die Modulation der Genexpression durch Histon H3 Phosphorylierung. Trotz 
dieser bereits bekannten Funktionen von IKKα, war der Beitrag von IKKα in der 
Atherogenese bisher noch unbekannt. Daher war das Ziel dieser Studie, die Rolle 
der hämatopoetischen IKKα Aktivierung gegenüber der globalen Funktion der IKKα 
Aktivierung in Atherosklerose zu identifizieren. Für beide Studien wurde ein 
aktivierungsresistentes Ikkα (IkkαAA/AA) Mausmodell verwendet, mit einem 
hyperlididämischen Apolipoprotein E-defizienten (Apoe-/-) Hintergrund.  
Um die knochenmark-spezifische Funktion der Ikkα Kinase-Aktivität zu untersuchen, 
wurden Apoe-/- Mäuse zunächst lethal bestrahlt und dann entweder mit Knochenmark 
von IkkαAA/AAApoe-/- oder Apoe-/- Mäusen transplantiert, gefolgt von einer fettreichen 
Diät für 8 oder 13 Wochen. Das hämatopoetische Profil zeigte eine signifikante 
Abnahme der B-Zellen, der regulatorischen T-Zellen und der Effektor-Memory-T-
Zellen in den IkkαAA/AAApoe-/- Knochenmark-Chimären, während die naive T-
Zellpopulation erhöht war. Allerdings konnte keine Auswirkung von IkkαAA/AA auf die 
Atherosklerose, auf die kanonische NF-κB-Aktivierung in Makrophagen oder auf 
Genexpression festgestellt werden. Zusammengefasst zeigten die Daten, dass die 
vielfältigen Funktionen von Ikkα in hämatopoetischen Zellen sich entweder 
gegenseitig ausgleichen oder nicht stark genug sind um die Atherogenese 
beeinzuflussen, und zeigen weiterhin, dass die Hemmung der hämatopoetische IKKα 
Kinase-Aktivität als Drugtarget kein geeigneter Therapieansatz darstellt.  
Darüber hinaus wurde die globale Rolle von Ikkα in der Atherosklerose untersucht in 
IkkαAA/AAApoe-/- und Ikkα+/+Apoe-/- Mäusen nach 13 Wochen fettreicher Diät. 
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IkkαAA/AAApoe-/- Mäuse zeigten eine signifikant erhöhte Plaquebildung in der Aorta im 
Vergleich zu den Wildtyp-Kontrollen, aber überraschenderweise waren die Läsionen 
in der Aortenwurzel signifikant reduziert im Vergleich zur Kontrollgruppe, obwohl die 
Läsionen weiter fortgeschritten waren als in der Aorta. Diese orts-spezifischen 
Effekte konnten nicht auf Unterschiede in der Leukozyteninfiltration beruhen, da die 
Läsionsphänotypen zwischen den Gruppen vergleichbar waren. Weiterhin zeigte NF-
κB p65 Aktivierung ähnliche Niveaus zwischen IkkαAA/AAApoe-/- und Ikkα+/+Apoe-/- 
Mäusen. Allerdings bewirkte der IkkαAA/AA Knock-in eine Reduzierung der Histon H3-
Phosphorylierung im Aortenbogen. Außerdem zeigte die Aortenwurzel eine erhöhte 
Mengen an gesamt endogenen Ikkα im Vergleich zum Aortenbogen und der Aorta, 
während die Mengen an aktivierten, phosphorylierten Ikkα deutlich höher waren im 
Aortenbogen und in der thorakalen Aorta. Auch Genexpressionsstudien in 
IkkαAA/AAApoe-/- vs Ikkα+/+Apoe-/- Mäusen zeigten orts-spezifische Schwankungen in 
der Genexpression im Vergleich von der Aortenwurzel zur Aorta, wobei die 
Expression von Ccr7 und Ccl19 in IkkαAA/AAApoe-/- im Aortenbogen und Aorta 
deutlich reduziert waren, jedoch nicht in der Aortenwurzel. Die Kombination des Ikkα 
Aktivierungsprofils und die Ergebnisse der Genstudien weisen auf regionale 
Unterschiede der Ikkα Kinase-Funktion hin, die wiederum standortspezifische 
atherosklerotische Auswirkungen haben könnten, obwohl die genauen Mechanismen 
weiterhin untersucht werden müssen. 
Meine Daten veranschaulichen die Funktionsvielfalt der Ikkα Kinase und 
zeigen, dass eine Studie der standortspezifischen Auswirkungen von Medikamenten 
zur Hemmung von Ikkα und standortsspezifische Auswirkungen allgemeiner 
Medikamente zur Behandlung der Atherosklerose erforderlich sind, bevor mögliche 
therapeutische Anwendungen in Betracht gezogen werden können. 
 
  References   
110 
 
8.  References 
1. WHO. Global status report on noncommunicable diseases 2010: World Health 
Organization; 2011. 
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease 
from 2002 to 2030. PLoS Med. 2006;3:e442. 
3. Gaziano T, Reddy KS, Paccaud F, Horton S, Chaturvedi V. Cardiovascular 
Disease. 2006. 
4. Greenberg H. Global cardiovascular disease and the academic public health 
curriculum. Prog Cardiovasc Dis;56:322-325. 
5. Go AS. Heart Disease and Stroke Statistics-2013 Update: A Report From the 
American Heart Association (vol 127, pg e6, 2013). Circulation. 2013;127:E841-
E841. 
6. Chiu JJ, Chien S. Effects of disturbed flow on vascular endothelium: 
pathophysiological basis and clinical perspectives. Physiol Rev. 2011;91:327-387. 
7. George S.J. JJ ed Atherosclerosis: Wiley-Blackwell; 2010. 
8. Lusis AJ. Atherosclerosis. Nature. 2000;407:233-241. 
9. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. 
Circulation. 2004;109:III27-32. 
10. Hopkins PN. Molecular biology of atherosclerosis. Physiol Rev. 2013;93:1317-
1542. 
11. Chatzizisis YS, Jonas M, Coskun AU, Beigel R, Stone BV, Maynard C, Gerrity 
RG, Daley W, Rogers C, Edelman ER, Feldman CL, Stone PH. Prediction of the 
localization of high-risk coronary atherosclerotic plaques on the basis of low 
endothelial shear stress: an intravascular ultrasound and histopathology natural 
history study. Circulation. 2008;117:993-1002. 
12. Chatzizisis YS, Coskun AU, Jonas M, Edelman ER, Feldman CL, Stone PH. 
Role of endothelial shear stress in the natural history of coronary atherosclerosis and 
vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol. 
2007;49:2379-2393. 
13. Tousoulis D, Kampoli AM, Tentolouris C, Papageorgiou N, Stefanadis C. The 
role of nitric oxide on endothelial function. Curr Vasc Pharmacol. 2012;10:4-18. 
14. Weber C, Noels H. Atherosclerosis: current pathogenesis and therapeutic 
options. Nat Med. 2011;17:1410-1422. 
15. Packard RR, Lichtman AH, Libby P. Innate and adaptive immunity in 
atherosclerosis. Semin Immunopathol. 2009;31:5-22. 
16. Chatzizisis YS, Baker AB, Sukhova GK, Koskinas KC, Papafaklis MI, Beigel R, 
Jonas M, Coskun AU, Stone BV, Maynard C, Shi GP, Libby P, Feldman CL, Edelman 
ER, Stone PH. Augmented expression and activity of extracellular matrix-degrading 
enzymes in regions of low endothelial shear stress colocalize with coronary 
atheromata with thin fibrous caps in pigs. Circulation;123:621-630. 
17. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874. 
18. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the 
biology of atherosclerosis. Nature. 2011;473:317-325. 
19. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte 
subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol. 
2008;8:802-815. 
References 
 
111 
 
20. Stoger JL, Gijbels MJ, van der Velden S, Manca M, van der Loos CM, Biessen 
EA, Daemen MJ, Lutgens E, de Winther MP. Distribution of macrophage polarization 
markers in human atherosclerosis. Atherosclerosis. 2012;225:461-468. 
21. Butcher MJ, Galkina EV. Phenotypic and functional heterogeneity of 
macrophages and dendritic cell subsets in the healthy and atherosclerosis-prone 
aorta. Front Physiol. 2012;3:44. 
22. Savage ND, de Boer T, Walburg KV, Joosten SA, van Meijgaarden K, Geluk 
A, Ottenhoff TH. Human anti-inflammatory macrophages induce Foxp3+ GITR+ 
CD25+ regulatory T cells, which suppress via membrane-bound TGFbeta-1. J 
Immunol. 2008;181:2220-2226. 
23. De Paoli F, Staels B, Chinetti-Gbaguidi G. Macrophage phenotypes and their 
modulation in atherosclerosis. Circ J. 2013;78:1775-1781. 
24. Mantovani A, Biswas SK, Galdiero MR, Sica A, Locati M. Macrophage 
plasticity and polarization in tissue repair and remodelling. J Pathol. 2013;229:176-
185. 
25. Drechsler M, Megens RT, van Zandvoort M, Weber C, Soehnlein O. 
Hyperlipidemia-triggered neutrophilia promotes early atherosclerosis. Circulation. 
2010;122:1837-1845. 
26. Soehnlein O. Multiple roles for neutrophils in atherosclerosis. Circ Res. 
2012;110:875-888. 
27. Megens RT, Vijayan S, Lievens D, Doring Y, van Zandvoort MA, Grommes J, 
Weber C, Soehnlein O. Presence of luminal neutrophil extracellular traps in 
atherosclerosis. Thromb Haemost. 2012;107:597-598. 
28. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD, Jr., 
Wrobleski SK, Wakefield TW, Hartwig JH, Wagner DD. Extracellular DNA traps 
promote thrombosis. Proc Natl Acad Sci U S A. 2010;107:15880-15885. 
29. Noels H, Weber C. Catching up with important players in atherosclerosis: type 
I interferons and neutrophils. Curr Opin Lipidol. 2011;22:144-145. 
30. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory 
pathways. Physiol Rev. 2006;86:515-581. 
31. Gao Q, Jiang Y, Ma T, Zhu F, Gao F, Zhang P, Guo C, Wang Q, Wang X, Ma 
C, Zhang Y, Chen W, Zhang L. A critical function of Th17 proinflammatory cells in the 
development of atherosclerotic plaque in mice. J Immunol. 2010;185:5820-5827. 
32. King VL, Szilvassy SJ, Daugherty A. Interleukin-4 deficiency decreases 
atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- 
mice. Arterioscler Thromb Vasc Biol. 2002;22:456-461. 
33. Huber SA, Sakkinen P, David C, Newell MK, Tracy RP. T helper-cell 
phenotype regulates atherosclerosis in mice under conditions of mild 
hypercholesterolemia. Circulation. 2001;103:2610-2616. 
34. Ait-Oufella H, Salomon BL, Potteaux S, Robertson AK, Gourdy P, Zoll J, 
Merval R, Esposito B, Cohen JL, Fisson S, Flavell RA, Hansson GK, Klatzmann D, 
Tedgui A, Mallat Z. Natural regulatory T cells control the development of 
atherosclerosis in mice. Nat Med. 2006;12:178-180. 
35. Jongstra-Bilen J, Haidari M, Zhu SN, Chen M, Guha D, Cybulsky MI. Low-
grade chronic inflammation in regions of the normal mouse arterial intima 
predisposed to atherosclerosis. J Exp Med. 2006;203:2073-2083. 
36. Liu P, Yu YR, Spencer JA, Johnson AE, Vallanat CT, Fong AM, Patterson C, 
Patel DD. CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima 
and reduces atherosclerotic burden. Arterioscler Thromb Vasc Biol. 2008;28:243-
250. 
  References   
112 
 
37. Doring Y, Manthey HD, Drechsler M, Lievens D, Megens RT, Soehnlein O, 
Busch M, Manca M, Koenen RR, Pelisek J, Daemen MJ, Lutgens E, Zenke M, Binder 
CJ, Weber C, Zernecke A. Auto-antigenic protein-DNA complexes stimulate 
plasmacytoid dendritic cells to promote atherosclerosis. Circulation. 2012;125:1673-
1683. 
38. Niessner A, Weyand CM. Dendritic cells in atherosclerotic disease. Clin 
Immunol. 2010;134:25-32. 
39. Daissormont IT, Christ A, Temmerman L, Sampedro Millares S, Seijkens T, 
Manca M, Rousch M, Poggi M, Boon L, van der Loos C, Daemen M, Lutgens E, 
Halvorsen B, Aukrust P, Janssen E, Biessen EA. Plasmacytoid dendritic cells protect 
against atherosclerosis by tuning T-cell proliferation and activity. Circ Res. 
2011;109:1387-1395. 
40. Zhou X, Hansson GK. Detection of B cells and proinflammatory cytokines in 
atherosclerotic plaques of hypercholesterolaemic apolipoprotein E knockout mice. 
Scand J Immunol. 1999;50:25-30. 
41. Perry HM, Bender TP, McNamara CA. B cell subsets in atherosclerosis. Front 
Immunol. 2012;3:373. 
42. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis 
(*). Annu Rev Immunol. 2009;27:165-197. 
43. Hansson GK, Hermansson A. The immune system in atherosclerosis. Nat 
Immunol. 2011;12:204-212. 
44. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: 
testing and clinical relevance. Circulation. 2007;115:1285-1295. 
45. Koskinas KC, Chatzizisis YS, Baker AB, Edelman ER, Stone PH, Feldman CL. 
The role of low endothelial shear stress in the conversion of atherosclerotic lesions 
from stable to unstable plaque. Curr Opin Cardiol. 2009;24:580-590. 
46. Wentzel JJ, Chatzizisis YS, Gijsen FJ, Giannoglou GD, Feldman CL, Stone 
PH. Endothelial shear stress in the evolution of coronary atherosclerotic plaque and 
vascular remodelling: current understanding and remaining questions. Cardiovasc 
Res. 2012;96:234-243. 
47. White CR, Frangos JA. The shear stress of it all: the cell membrane and 
mechanochemical transduction. Philos Trans R Soc Lond B Biol Sci. 2007;362:1459-
1467. 
48. Johnson BD, Mather KJ, Wallace JP. Mechanotransduction of shear in the 
endothelium: basic studies and clinical implications. Vasc Med. 2011;16:365-377. 
49. Hsieh HJ, Liu CA, Huang B, Tseng AH, Wang DL. Shear-induced endothelial 
mechanotransduction: the interplay between reactive oxygen species (ROS) and 
nitric oxide (NO) and the pathophysiological implications. J Biomed Sci. 2014;21:3. 
50. Davies PF, Civelek M, Fang Y, Fleming I. The atherosusceptible endothelium: 
endothelial phenotypes in complex haemodynamic shear stress regions in vivo. 
Cardiovasc Res. 2013;99:315-327. 
51. Marin T, Gongol B, Chen Z, Woo B, Subramaniam S, Chien S, Shyy JY. 
Mechanosensitive microRNAs-role in endothelial responses to shear stress and 
redox state. Free Radic Biol Med. 2013;64:61-68. 
52. Gargalionis AN, Basdra EK. Insights in microRNAs biology. Curr Top Med 
Chem. 2013;13:1493-1502. 
53. Pager CT, Wehner KA, Fuchs G, Sarnow P. MicroRNA-mediated gene 
silencing. Prog Mol Biol Transl Sci. 2009;90:187-210. 
54. Yamakuchi M. MicroRNAs in Vascular Biology. Int J Vasc Med. 
2012;2012:794898. 
References 
 
113 
 
55. Bronze-da-Rocha E. MicroRNAs expression profiles in cardiovascular 
diseases. Biomed Res Int. 2014;2014:985408. 
56. Weber C, Schober A, Zernecke A. MicroRNAs in arterial remodelling, 
inflammation and atherosclerosis. Curr Drug Targets. 2010;11:950-956. 
57. Sun X, Belkin N, Feinberg MW. Endothelial microRNAs and atherosclerosis. 
Curr Atheroscler Rep. 2013;15:372. 
58. Neth P, Nazari-Jahantigh M, Schober A, Weber C. MicroRNAs in flow-
dependent vascular remodelling. Cardiovasc Res. 2013;99:294-303. 
59. Boon RA, Hergenreider E, Dimmeler S. Atheroprotective mechanisms of shear 
stress-regulated microRNAs. Thromb Haemost. 2012;108:616-620. 
60. Staszel T, Zapala B, Polus A, Sadakierska-Chudy A, Kiec-Wilk B, Stepien E, 
Wybranska I, Chojnacka M, Dembinska-Kiec A. Role of microRNAs in endothelial cell 
pathophysiology. Pol Arch Med Wewn. 2011;121:361-366. 
61. Hergenreider E, Heydt S, Treguer K, Boettger T, Horrevoets AJ, Zeiher AM, 
Scheffer MP, Frangakis AS, Yin X, Mayr M, Braun T, Urbich C, Boon RA, Dimmeler 
S. Atheroprotective communication between endothelial cells and smooth muscle 
cells through miRNAs. Nat Cell Biol. 2012;14:249-256. 
62. Wei Y, Schober A, Weber C. Pathogenic arterial remodeling: the good and 
bad of microRNAs. Am J Physiol Heart Circ Physiol. 2013;304:H1050-1059. 
63. Nazari-Jahantigh M, Wei Y, Schober A. The role of microRNAs in arterial 
remodelling. Thromb Haemost. 2012;107:611-618. 
64. Sen R, Baltimore D. Multiple nuclear factors interact with the immunoglobulin 
enhancer sequences. Cell. 1986;46:705-716. 
65. de Winther MP, Kanters E, Kraal G, Hofker MH. Nuclear factor kappaB 
signaling in atherogenesis. Arterioscler Thromb Vasc Biol. 2005;25:904-914. 
66. Oeckinghaus A, Hayden MS, Ghosh S. Crosstalk in NF-kappaB signaling 
pathways. Nat Immunol. 2011;12:695-708. 
67. Pahl HL. Activators and target genes of Rel/NF-kappaB transcription factors. 
Oncogene. 1999;18:6853-6866. 
68. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in 
innate and adaptive immunity. Trends Immunol. 2004;25:280-288. 
69. Ofengeim D, Yuan J. Regulation of RIP1 kinase signalling at the crossroads of 
inflammation and cell death. Nat Rev Mol Cell Biol. 2013;14:727-736. 
70. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of 
NF-[kappa]B activity. Annu Rev Immunol. 2000;18:621-663. 
71. Hayden MS, Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004;18:2195-
2224. 
72. Oeckinghaus A, Ghosh S. The NF-kappaB family of transcription factors and 
its regulation. Cold Spring Harb Perspect Biol. 2009;1:a000034. 
73. Xiao G, Rabson AB, Young W, Qing G, Qu Z. Alternative pathways of NF-
kappaB activation: a double-edged sword in health and disease. Cytokine Growth 
Factor Rev. 2006;17:281-293. 
74. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, Chen Y, Hu Y, 
Fong A, Sun SC, Karin M. Activation by IKKalpha of a second, evolutionary 
conserved, NF-kappa B signaling pathway. Science. 2001;293:1495-1499. 
75. Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing 
kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J 
Biol Chem. 2004;279:26243-26250. 
  References   
114 
 
76. He JQ, Saha SK, Kang JR, Zarnegar B, Cheng G. Specificity of TRAF3 in its 
negative regulation of the noncanonical NF-kappa B pathway. J Biol Chem. 
2007;282:3688-3694. 
77. Razani B, Reichardt AD, Cheng G. Non-canonical NF-kappaB signaling 
activation and regulation: principles and perspectives. Immunol Rev. 2011;244:44-54. 
78. Sun SC. The noncanonical NF-kappaB pathway. Immunol Rev. 2012;246:125-
140. 
79. Hu H, Brittain GC, Chang JH, Puebla-Osorio N, Jin J, Zal A, Xiao Y, Cheng X, 
Chang M, Fu YX, Zal T, Zhu C, Sun SC. OTUD7B controls non-canonical NF-kappaB 
activation through deubiquitination of TRAF3. Nature. 2013;494:371-374. 
80. Van der Heiden K, Cuhlmann S, Luong le A, Zakkar M, Evans PC. Role of 
nuclear factor kappaB in cardiovascular health and disease. Clin Sci (Lond). 
2010;118:593-605. 
81. Dabek J, Kulach A, Gasior Z. Nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-kappaB): a new potential therapeutic target in atherosclerosis? 
Pharmacol Rep. 2010;62:778-783. 
82. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, 
Kaltschmidt C, Baeuerle PA, Neumeier D. Activated transcription factor nuclear 
factor-kappa B is present in the atherosclerotic lesion. J Clin Invest. 1996;97:1715-
1722. 
83. Zhang W, Xing SS, Sun XL, Xing QC. Overexpression of activated nuclear 
factor-kappa B in aorta of patients with coronary atherosclerosis. Clin Cardiol. 
2009;32:E42-47. 
84. Hajra L, Evans AI, Chen M, Hyduk SJ, Collins T, Cybulsky MI. The NF-kappa 
B signal transduction pathway in aortic endothelial cells is primed for activation in 
regions predisposed to atherosclerotic lesion formation. Proc Natl Acad Sci U S A. 
2000;97:9052-9057. 
85. Monaco C, Andreakos E, Kiriakidis S, Mauri C, Bicknell C, Foxwell B, 
Cheshire N, Paleolog E, Feldmann M. Canonical pathway of nuclear factor kappa B 
activation selectively regulates proinflammatory and prothrombotic responses in 
human atherosclerosis. Proc Natl Acad Sci U S A. 2004;101:5634-5639. 
86. Spiecker M, Peng HB, Liao JK. Inhibition of endothelial vascular cell adhesion 
molecule-1 expression by nitric oxide involves the induction and nuclear translocation 
of IkappaBalpha. J Biol Chem. 1997;272:30969-30974. 
87. Davel AP, Wenceslau CF, Akamine EH, Xavier FE, Couto GK, Oliveira HT, 
Rossoni LV. Endothelial dysfunction in cardiovascular and endocrine-metabolic 
diseases: an update. Braz J Med Biol Res. 2011;44:920-932. 
88. Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of 
atherosclerosis. Lab Invest. 2005;85:9-23. 
89. Nakashima Y, Raines EW, Plump AS, Breslow JL, Ross R. Upregulation of 
VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-
deficient mouse. Arterioscler Thromb Vasc Biol. 1998;18:842-851. 
90. Mohan S, Mohan N, Sprague EA. Differential activation of NF-kappa B in 
human aortic endothelial cells conditioned to specific flow environments. Am J 
Physiol. 1997;273:C572-578. 
91. Atkins GB, Simon DI. Interplay between NF-kappaB and Kruppel-like factors in 
vascular inflammation and atherosclerosis: location, location, location. J Am Heart 
Assoc. 2013;2:e000290. 
92. Chiu JJ, Usami S, Chien S. Vascular endothelial responses to altered shear 
stress: pathologic implications for atherosclerosis. Ann Med. 2009;41:19-28. 
References 
 
115 
 
93. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in 
atherogenesis? J Clin Invest. 2001;107:255-264. 
94. Bourcier T, Sukhova G, Libby P. The nuclear factor kappa-B signaling 
pathway participates in dysregulation of vascular smooth muscle cells in vitro and in 
human atherosclerosis. J Biol Chem. 1997;272:15817-15824. 
95. Ritchie ME. Nuclear factor-kappaB is selectively and markedly activated in 
humans with unstable angina pectoris. Circulation. 1998;98:1707-1713. 
96. Ren S, Fan X, Peng L, Pan L, Yu C, Tong J, Zhang W, Liu P. Expression of 
NF-kappaB, CD68 and CD105 in carotid atherosclerotic plaque. J Thorac Dis. 
2013;5:771-776. 
97. Newby AC. Metalloproteinase expression in monocytes and macrophages and 
its relationship to atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol. 
2008;28:2108-2114. 
98. Bond M, Chase AJ, Baker AH, Newby AC. Inhibition of transcription factor NF-
kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth 
muscle cells. Cardiovasc Res. 2001;50:556-565. 
99. Madonna R, De Caterina R. Relevance of new drug discovery to reduce NF-
kappaB activation in cardiovascular disease. Vascul Pharmacol. 2012;57:41-47. 
100. Chiba T, Kondo Y, Shinozaki S, Kaneko E, Ishigami A, Maruyama N, 
Umezawa K, Shimokado K. A selective NFkappaB inhibitor, DHMEQ, reduced 
atherosclerosis in ApoE-deficient mice. J Atheroscler Thromb. 2006;13:308-313. 
101. Yoshida T, Yamashita M, Horimai C, Hayashi M. Smooth muscle-selective 
inhibition of nuclear factor-kappaB attenuates smooth muscle phenotypic switching 
and neointima formation following vascular injury. J Am Heart Assoc. 
2013;2:e000230. 
102. Djuric Z, Kashif M, Fleming T, Muhammad S, Piel D, von Bauer R, Bea F, 
Herzig S, Zeier M, Pizzi M, Isermann B, Hecker M, Schwaninger M, Bierhaus A, 
Nawroth PP. Targeting activation of specific NF-kappaB subunits prevents stress-
dependent atherothrombotic gene expression. Mol Med. 2012;18:1375-1386. 
103. Goossens P, Vergouwe MN, Gijbels MJ, Curfs DM, van Woezik JH, 
Hoeksema MA, Xanthoulea S, Leenen PJ, Rupec RA, Hofker MH, de Winther MP. 
Myeloid IkappaBalpha deficiency promotes atherogenesis by enhancing leukocyte 
recruitment to the plaques. PLoS One. 2011;6:e22327. 
104. Kanters E, Gijbels MJ, van der Made I, Vergouwe MN, Heeringa P, Kraal G, 
Hofker MH, de Winther MP. Hematopoietic NF-kappaB1 deficiency results in small 
atherosclerotic lesions with an inflammatory phenotype. Blood. 2004;103:934-940. 
105. Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role 
for NF-kappaB in the resolution of inflammation. Nat Med. 2001;7:1291-1297. 
106. Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C, Goktuna SI, 
Neuenhahn M, Fierer J, Paxian S, Van Rooijen N, Xu Y, O'Cain T, Jaffee BB, Busch 
DH, Duyster J, Schmid RM, Eckmann L, Karin M. NF-kappaB is a negative regulator 
of IL-1beta secretion as revealed by genetic and pharmacological inhibition of 
IKKbeta. Cell. 2007;130:918-931. 
107. Pamukcu B, Lip GY, Shantsila E. The nuclear factor--kappa B pathway in 
atherosclerosis: a potential therapeutic target for atherothrombotic vascular disease. 
Thromb Res. 2012;128:117-123. 
108. Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system: a treasure 
trove for drug development. Nat Rev Drug Discov. 2004;3:17-26. 
109. Hacker H, Karin M. Regulation and function of IKK and IKK-related kinases. 
Sci STKE. 2006;2006:re13. 
  References   
116 
 
110. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IkappaBalpha 
by a novel ubiquitination-dependent protein kinase activity. Cell. 1996;84:853-862. 
111. DiDonato JA, Hayakawa M, Rothwarf DM, Zandi E, Karin M. A cytokine-
responsive IkappaB kinase that activates the transcription factor NF-kappaB. Nature. 
1997;388:548-554. 
112. Yamaoka S, Courtois G, Bessia C, Whiteside ST, Weil R, Agou F, Kirk HE, 
Kay RJ, Israel A. Complementation cloning of NEMO, a component of the IkappaB 
kinase complex essential for NF-kappaB activation. Cell. 1998;93:1231-1240. 
113. Israel A. The IKK complex, a central regulator of NF-kappaB activation. Cold 
Spring Harb Perspect Biol. 2010;2:a000158. 
114. Mercurio F, Zhu H, Murray BW, Shevchenko A, Bennett BL, Li J, Young DB, 
Barbosa M, Mann M, Manning A, Rao A. IKK-1 and IKK-2: cytokine-activated 
IkappaB kinases essential for NF-kappaB activation. Science. 1997;278:860-866. 
115. Hinz M, Scheidereit C. The IkappaB kinase complex in NF-kappaB regulation 
and beyond. EMBO Rep. 2014;15:46-61. 
116. Sil AK, Maeda S, Sano Y, Roop DR, Karin M. IkappaB kinase-alpha acts in the 
epidermis to control skeletal and craniofacial morphogenesis. Nature. 2004;428:660-
664. 
117. Ling L, Cao Z, Goeddel DV. NF-kappaB-inducing kinase activates IKK-alpha 
by phosphorylation of Ser-176. Proc Natl Acad Sci U S A. 1998;95:3792-3797. 
118. Zhang J, Clark K, Lawrence T, Peggie MW, Cohen P. An unexpected twist to 
the activation of IKKbeta: TAK1 primes IKKbeta for activation by 
autophosphorylation. Biochem J. 2014;461:531-537. 
119. Tang ED, Inohara N, Wang CY, Nunez G, Guan KL. Roles for homotypic 
interactions and transautophosphorylation in IkappaB kinase beta IKKbeta) activation 
[corrected]. J Biol Chem. 2003;278:38566-38570. 
120. Solt LA, May MJ. The IkappaB kinase complex: master regulator of NF-
kappaB signaling. Immunol Res. 2008;42:3-18. 
121. Liu S, Misquitta YR, Olland A, Johnson MA, Kelleher KS, Kriz R, Lin LL, Stahl 
M, Mosyak L. Crystal structure of a human IkappaB kinase beta asymmetric dimer. J 
Biol Chem. 2013;288:22758-22767. 
122. Liu F, Xia Y, Parker AS, Verma IM. IKK biology. Immunol Rev. 2012;246:239-
253. 
123. Huang TT, Feinberg SL, Suryanarayanan S, Miyamoto S. The zinc finger 
domain of NEMO is selectively required for NF-kappa B activation by UV radiation 
and topoisomerase inhibitors. Mol Cell Biol. 2002;22:5813-5825. 
124. Shifera AS. The zinc finger domain of IKKgamma (NEMO) protein in health 
and disease. J Cell Mol Med. 2010;14:2404-2414. 
125. Schrofelbauer B, Polley S, Behar M, Ghosh G, Hoffmann A. NEMO ensures 
signaling specificity of the pleiotropic IKKbeta by directing its kinase activity toward 
IkappaBalpha. Mol Cell. 2012;47:111-121. 
126. Schmid JA, Birbach A. IkappaB kinase beta (IKKbeta/IKK2/IKBKB)--a key 
molecule in signaling to the transcription factor NF-kappaB. Cytokine Growth Factor 
Rev. 2008;19:157-165. 
127. Kanters E, Pasparakis M, Gijbels MJ, Vergouwe MN, Partouns-Hendriks I, 
Fijneman RJ, Clausen BE, Forster I, Kockx MM, Rajewsky K, Kraal G, Hofker MH, de 
Winther MP. Inhibition of NF-kappaB activation in macrophages increases 
atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2003;112:1176-1185. 
References 
 
117 
 
128. Fong CH, Bebien M, Didierlaurent A, Nebauer R, Hussell T, Broide D, Karin M, 
Lawrence T. An antiinflammatory role for IKKbeta through the inhibition of "classical" 
macrophage activation. J Exp Med. 2008;205:1269-1276. 
129. Park SH, Sui Y, Gizard F, Xu J, Rios-Pilier J, Helsley RN, Han SS, Zhou C. 
Myeloid-specific IkappaB kinase beta deficiency decreases atherosclerosis in low-
density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 
2012;32:2869-2876. 
130. Mohan S, Koyoma K, Thangasamy A, Nakano H, Glickman RD, Mohan N. 
Low shear stress preferentially enhances IKK activity through selective sources of 
ROS for persistent activation of NF-kappaB in endothelial cells. Am J Physiol Cell 
Physiol. 2007;292:C362-371. 
131. Pathak R, Shao L, Chafekar SM, Feng W, Ponnappan U, Fink LM, Zhou D, 
Hauer-Jensen M. IKKbeta regulates endothelial thrombomodulin in a Klf2-dependent 
manner. J Thromb Haemost. 2014;12:1533-1544. 
132. Ashida N, Senbanerjee S, Kodama S, Foo SY, Coggins M, Spencer JA, Zamiri 
P, Shen D, Li L, Sciuto T, Dvorak A, Gerszten RE, Lin CP, Karin M, Rosenzweig A. 
IKKbeta regulates essential functions of the vascular endothelium through kinase-
dependent and -independent pathways. Nat Commun. 2011;2:318. 
133. Sui Y, Park SH, Xu J, Monette S, Helsley RN, Han SS, Zhou C. IKKbeta links 
vascular inflammation to obesity and atherosclerosis. J Exp Med. 2014;211:869-886. 
134. Gareus R, Kotsaki E, Xanthoulea S, van der Made I, Gijbels MJ, Kardakaris R, 
Polykratis A, Kollias G, de Winther MP, Pasparakis M. Endothelial cell-specific NF-
kappaB inhibition protects mice from atherosclerosis. Cell Metab. 2008;8:372-383. 
135. Lam LT, Davis RE, Ngo VN, Lenz G, Wright G, Xu W, Zhao H, Yu X, Dang L, 
Staudt LM. Compensatory IKKalpha activation of classical NF-kappaB signaling 
during IKKbeta inhibition identified by an RNA interference sensitization screen. Proc 
Natl Acad Sci U S A. 2008;105:20798-20803. 
136. Adli M, Merkhofer E, Cogswell P, Baldwin AS. IKKalpha and IKKbeta each 
function to regulate NF-kappaB activation in the TNF-induced/canonical pathway. 
PLoS One. 2010;5:e9428. 
137. Lawrence T, Bebien M, Liu GY, Nizet V, Karin M. IKKalpha limits macrophage 
NF-kappaB activation and contributes to the resolution of inflammation. Nature. 
2005;434:1138-1143. 
138. Huang WC, Hung MC. Beyond NF-kappaB activation: nuclear functions of 
IkappaB kinase alpha. J Biomed Sci. 2013;20:3. 
139. Yamamoto Y, Verma UN, Prajapati S, Kwak YT, Gaynor RB. Histone H3 
phosphorylation by IKK-alpha is critical for cytokine-induced gene expression. 
Nature. 2003;423:655-659. 
140. Anest V, Hanson JL, Cogswell PC, Steinbrecher KA, Strahl BD, Baldwin AS. A 
nucleosomal function for IkappaB kinase-alpha in NF-kappaB-dependent gene 
expression. Nature. 2003;423:659-663. 
141. Liu B, Yang Y, Chernishof V, Loo RR, Jang H, Tahk S, Yang R, Mink S, Shultz 
D, Bellone CJ, Loo JA, Shuai K. Proinflammatory stimuli induce IKKalpha-mediated 
phosphorylation of PIAS1 to restrict inflammation and immunity. Cell. 2007;129:903-
914. 
142. Shembade N, Pujari R, Harhaj NS, Abbott DW, Harhaj EW. The kinase 
IKKalpha inhibits activation of the transcription factor NF-kappaB by phosphorylating 
the regulatory molecule TAX1BP1. Nat Immunol. 2011. 
143. Olivotto EO, M.; Astolfi, A.; Platano, D.; Facchini, A.; Pagani, S.; Flamigni, F.; 
Facchini, A.; Goldring, M.B.; Borzı`, R.M.; Marcu, K.B. IKKα/CHUK regulates 
  References   
118 
 
extracellular matrix remodeling independent of its kinase activity to facilitate articular 
chondrocyte differentiation. PLoS One. 2013;8. 
144. Cao Y, Bonizzi G, Seagroves TN, Greten FR, Johnson R, Schmidt EV, Karin 
M. IKKalpha provides an essential link between RANK signaling and cyclin D1 
expression during mammary gland development. Cell. 2001;107:763-775. 
145. Goel R, Schrank BR, Arora S, Boylan B, Fleming B, Miura H, Newman PJ, 
Molthen RC, Newman DK. Site-specific effects of PECAM-1 on atherosclerosis in 
LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2008;28:1996-2002. 
146. Teupser D, Pavlides S, Tan M, Gutierrez-Ramos JC, Kolbeck R, Breslow JL. 
Major reduction of atherosclerosis in fractalkine (CX3CL1)-deficient mice is at the 
brachiocephalic artery, not the aortic root. Proc Natl Acad Sci U S A. 
2004;101:17795-17800. 
147. Fuster JJ, Castillo AI, Zaragoza C, Ibanez B, Andres V. Animal models of 
atherosclerosis. Prog Mol Biol Transl Sci. 2012;105:1-23. 
148. Nam D, Ni CW, Rezvan A, Suo J, Budzyn K, Llanos A, Harrison D, Giddens D, 
Jo H. Partial carotid ligation is a model of acutely induced disturbed flow, leading to 
rapid endothelial dysfunction and atherosclerosis. Am J Physiol Heart Circ Physiol. 
2009;297:H1535-1543. 
149. Marim FM, Silveira TN, Lima DS, Jr., Zamboni DS. A method for generation of 
bone marrow-derived macrophages from cryopreserved mouse bone marrow cells. 
PLoS One. 2010;5:e15263. 
150. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. 
Genome Res. 1996;6:986-994. 
151. Wei Y, Nazari-Jahantigh M, Chan L, Zhu M, Heyll K, Corbalan-Campos J, 
Hartmann P, Thiemann A, Weber C, Schober A. The microRNA-342-5p fosters 
inflammatory macrophage activation through an Akt1- and microRNA-155-dependent 
pathway during atherosclerosis. Circulation. 2013;127:1609-1619. 
152. Arya M, Shergill IS, Williamson M, Gommersall L, Arya N, Patel HR. Basic 
principles of real-time quantitative PCR. Expert Rev Mol Diagn. 2005;5:209-219. 
153. Matos LL, Trufelli DC, de Matos MG, da Silva Pinhal MA. 
Immunohistochemistry as an important tool in biomarkers detection and clinical 
practice. Biomark Insights. 2010;5:9-20. 
154. Xu S, Huang Y, Xie Y, Lan T, Le K, Chen J, Chen S, Gao S, Xu X, Shen X, 
Huang H, Liu P. Evaluation of foam cell formation in cultured macrophages: an 
improved method with Oil Red O staining and DiI-oxLDL uptake. Cytotechnology. 
2010;62:473-481. 
155. Kaisho T, Takeda K, Tsujimura T, Kawai T, Nomura F, Terada N, Akira S. 
IkappaB kinase alpha is essential for mature B cell development and function. J Exp 
Med. 2001;193:417-426. 
156. Vandesompele J. dPK, Pattyn F., Poppe B., Van Roy N., de Paepe A., 
Speleman F. Accurate normalization of real-time quantitative RT-PCR data by 
geometric averaging of multiple internal control genes. Genome Biology. 2002;3. 
157. Kawasaki T, Dewerchin M, Lijnen HR, Vreys I, Vermylen J, Hoylaerts MF. 
Mouse carotid artery ligation induces platelet-leukocyte-dependent luminal fibrin, 
required for neointima development. Circ Res. 2001;88:159-166. 
158. Lawrence T, Bebien M. IKKalpha in the regulation of inflammation and 
adaptive immunity. Biochem Soc Trans. 2007;35:270-272. 
159. Bonizzi G, Bebien M, Otero DC, Johnson-Vroom KE, Cao Y, Vu D, Jegga AG, 
Aronow BJ, Ghosh G, Rickert RC, Karin M. Activation of IKKalpha target genes 
References 
 
119 
 
depends on recognition of specific kappaB binding sites by RelB:p52 dimers. Embo 
J. 2004;23:4202-4210. 
160. Mburu YK, Egloff AM, Walker WH, Wang L, Seethala RR, van Waes C, Ferris 
RL. Chemokine receptor 7 (CCR7) gene expression is regulated by NF-kappaB and 
activator protein 1 (AP1) in metastatic squamous cell carcinoma of head and neck 
(SCCHN). J Biol Chem. 2012;287:3581-3590. 
161. Schiemann B, Gommerman JL, Vora K, Cachero TG, Shulga-Morskaya S, 
Dobles M, Frew E, Scott ML. An essential role for BAFF in the normal development 
of B cells through a BCMA-independent pathway. Science. 2001;293:2111-2114. 
162. Balkhi MY, Willette-Brown J, Zhu F, Chen Z, Liu S, Guttridge DC, Karin M, Hu 
Y. IKKalpha-mediated signaling circuitry regulates early B lymphopoiesis during 
hematopoiesis. Blood. 2012;119:5467-5477. 
163. Tse K, Tse H, Sidney J, Sette A, Ley K. T cells in atherosclerosis. Int Immunol. 
2013;25:615-622. 
164. Ammirati E, Cianflone D, Vecchio V, Banfi M, Vermi AC, De Metrio M, Grigore 
L, Pellegatta F, Pirillo A, Garlaschelli K, Manfredi AA, Catapano AL, Maseri A, Palini 
AG, Norata GD. Effector Memory T cells Are Associated With Atherosclerosis in 
Humans and Animal Models. J Am Heart Assoc. 2013;1:27-41. 
165. Mancino A, Habbeddine M, Johnson E, Luron L, Bebien M, Memet S, Fong C, 
Bajenoff M, Wu X, Karin M, Caamano J, Chi H, Seed M, Lawrence T. I kappa B 
kinase alpha (IKKalpha) activity is required for functional maturation of dendritic cells 
and acquired immunity to infection. EMBO J. 2013;32:816-828. 
166. Hacker H, Chi L, Rehg JE, Redecke V. NIK prevents the development of 
hypereosinophilic syndrome-like disease in mice independent of IKKalpha activation. 
J Immunol. 2012;188:4602-4610. 
167. Murray SE. Cell-intrinsic role for NF-kappa B-inducing kinase in peripheral 
maintenance but not thymic development of Foxp3+ regulatory T cells in mice. PLoS 
One. 2013;8:e76216. 
168. Fagarasan S, Shinkura R, Kamata T, Nogaki F, Ikuta K, Tashiro K, Honjo T. 
Alymphoplasia (aly)-type nuclear factor kappaB-inducing kinase (NIK) causes defects 
in secondary lymphoid tissue chemokine receptor signaling and homing of peritoneal 
cells to the gut-associated lymphatic tissue system. J Exp Med. 2000;191:1477-1486. 
169. Xiao G, Harhaj EW, Sun SC. NF-kappaB-inducing kinase regulates the 
processing of NF-kappaB2 p100. Mol Cell. 2001;7:401-409. 
170. Tamura C, Nakazawa M, Kasahara M, Hotta C, Yoshinari M, Sato F, Minami 
M. Impaired function of dendritic cells in alymphoplasia (aly/aly) mice for expansion 
of CD25+CD4+ regulatory T cells. Autoimmunity. 2006;39:445-453. 
171. Hofmann J, Mair F, Greter M, Schmidt-Supprian M, Becher B. NIK signaling in 
dendritic cells but not in T cells is required for the development of effector T cells and 
cell-mediated immune responses. J Exp Med. 2011;208:1917-1929. 
172. Kajiura F, Sun S, Nomura T, Izumi K, Ueno T, Bando Y, Kuroda N, Han H, Li 
Y, Matsushima A, Takahama Y, Sakaguchi S, Mitani T, Matsumoto M. NF-kappa B-
inducing kinase establishes self-tolerance in a thymic stroma-dependent manner. J 
Immunol. 2004;172:2067-2075. 
173. Tas SW, Vervoordeldonk MJ, Hajji N, Schuitemaker JH, van der Sluijs KF, 
May MJ, Ghosh S, Kapsenberg ML, Tak PP, de Jong EC. Noncanonical NF-kappaB 
signaling in dendritic cells is required for indoleamine 2,3-dioxygenase (IDO) 
induction and immune regulation. Blood. 2007;110:1540-1549. 
  References   
120 
 
174. Puccetti P, Grohmann U. IDO and regulatory T cells: a role for reverse 
signalling and non-canonical NF-kappaB activation. Nat Rev Immunol. 2007;7:817-
823. 
175. Chen W, Liang X, Peterson AJ, Munn DH, Blazar BR. The indoleamine 2,3-
dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced 
adaptive T regulatory cell generation. J Immunol. 2008;181:5396-5404. 
176. Proietto AI, van Dommelen S, Zhou P, Rizzitelli A, D'Amico A, Steptoe RJ, 
Naik SH, Lahoud MH, Liu Y, Zheng P, Shortman K, Wu L. Dendritic cells in the 
thymus contribute to T-regulatory cell induction. Proc Natl Acad Sci U S A. 
2008;105:19869-19874. 
177. Klingenberg R, Gerdes N, Badeau RM, Gistera A, Strodthoff D, Ketelhuth DF, 
Lundberg AM, Rudling M, Nilsson SK, Olivecrona G, Zoller S, Lohmann C, Luscher 
TF, Jauhiainen M, Sparwasser T, Hansson GK. Depletion of FOXP3+ regulatory T 
cells promotes hypercholesterolemia and atherosclerosis. J Clin Invest. 
2013;123:1323-1334. 
178. Major AS, Fazio S, Linton MF. B-lymphocyte deficiency increases 
atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol. 
2002;22:1892-1898. 
179. Kyaw T, Tipping P, Toh BH, Bobik A. Current understanding of the role of B 
cell subsets and intimal and adventitial B cells in atherosclerosis. Curr Opin Lipidol. 
2011;22:373-379. 
180. Kyaw T, Tay C, Krishnamurthi S, Kanellakis P, Agrotis A, Tipping P, Bobik A, 
Toh BH. B1a B lymphocytes are atheroprotective by secreting natural IgM that 
increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ 
Res. 2011;109:830-840. 
181. Sasaki Y, Casola S, Kutok JL, Rajewsky K, Schmidt-Supprian M. TNF family 
member B cell-activating factor (BAFF) receptor-dependent and -independent roles 
for BAFF in B cell physiology. J Immunol. 2004;173:2245-2252. 
182. Sage AP, Tsiantoulas D, Baker L, Harrison J, Masters L, Murphy D, Loinard C, 
Binder CJ, Mallat Z. BAFF receptor deficiency reduces the development of 
atherosclerosis in mice--brief report. Arterioscler Thromb Vasc Biol. 2012;32:1573-
1576. 
183. Kyaw T, Tay C, Hosseini H, Kanellakis P, Gadowski T, MacKay F, Tipping P, 
Bobik A, Toh BH. Depletion of B2 but not B1a B cells in BAFF receptor-deficient 
ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation. 
PLoS One. 2012;7:e29371. 
184. Kyaw T, Cui P, Tay C, Kanellakis P, Hosseini H, Liu E, Rolink AG, Tipping P, 
Bobik A, Toh BH. BAFF receptor mAb treatment ameliorates development and 
progression of atherosclerosis in hyperlipidemic ApoE(-/-) mice. PLoS One. 
2013;8:e60430. 
185. Sage AP, Mallat Z. Multiple potential roles for B cells in atherosclerosis. Ann 
Med. 2014;46:297-303. 
186. Pastrana JL, Sha X, Virtue A, Mai J, Cueto R, Lee IA, Wang H, Yang XF. 
Regulatory T cells and Atherosclerosis. J Clin Exp Cardiolog. 2012;2012:2. 
187. Lutgens E, Lievens D, Beckers L, Wijnands E, Soehnlein O, Zernecke A, 
Seijkens T, Engel D, Cleutjens J, Keller AM, Naik SH, Boon L, Oufella HA, Mallat Z, 
Ahonen CL, Noelle RJ, de Winther MP, Daemen MJ, Biessen EA, Weber C. Deficient 
CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the 
immune response toward an antiinflammatory profile. J Exp Med. 2010;207:391-404. 
References 
 
121 
 
188. Li Q, Lu Q, Bottero V, Estepa G, Morrison L, Mercurio F, Verma IM. Enhanced 
NF-kappaB activation and cellular function in macrophages lacking IkappaB kinase 1 
(IKK1). Proc Natl Acad Sci U S A. 2005;102:12425-12430. 
189. Correa RG, Matsui T, Tergaonkar V, Rodriguez-Esteban C, Izpisua-Belmonte 
JC, Verma IM. Zebrafish IkappaB kinase 1 negatively regulates NF-kappaB activity. 
Curr Biol. 2005;15:1291-1295. 
190. Miller YI, Choi SH, Fang L, Tsimikas S. Lipoprotein modification and 
macrophage uptake: role of pathologic cholesterol transport in atherogenesis. 
Subcell Biochem. 2010;51:229-251. 
191. Karaflou M, Lambrinoudaki I, Christodoulakos G. Apoptosis in atherosclerosis: 
a mini-review. Mini Rev Med Chem. 2008;8:912-918. 
192. Tabas I. Macrophage apoptosis in atherosclerosis: consequences on plaque 
progression and the role of endoplasmic reticulum stress. Antioxid Redox Signal. 
2009;11:2333-2339. 
193. Whitman SC. A practical approach to using mice in atherosclerosis research. 
Clin Biochem Rev. 2004;25:81-93. 
194. Getz GS, Reardon CA. Animal models of atherosclerosis. Arterioscler Thromb 
Vasc Biol. 2012;32:1104-1115. 
195. Baitsch D, Bock HH, Engel T, Telgmann R, Muller-Tidow C, Varga G, Bot M, 
Herz J, Robenek H, von Eckardstein A, Nofer JR. Apolipoprotein E induces 
antiinflammatory phenotype in macrophages. Arterioscler Thromb Vasc Biol. 
2011;31:1160-1168. 
196. Sen R, Smale ST. Selectivity of the NF-{kappa}B response. Cold Spring Harb 
Perspect Biol. 2010;2:a000257. 
197. Penzo M, Molteni R, Suda T, Samaniego S, Raucci A, Habiel DM, Miller F, 
Jiang HP, Li J, Pardi R, Palumbo R, Olivotto E, Kew RR, Bianchi ME, Marcu KB. 
Inhibitor of NF-kappa B kinases alpha and beta are both essential for high mobility 
group box 1-mediated chemotaxis [corrected]. J Immunol. 2010;184:4497-4509. 
198. Warboys CM, Amini N, de Luca A, Evans PC. The role of blood flow in 
determining the sites of atherosclerotic plaques. F1000 Med Rep. 2011;3:5. 
199. Witting PK, Pettersson K, Letters J, Stocker R. Site-specific antiatherogenic 
effect of probucol in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 
2000;20:E26-33. 
200. Chew P, Yuen DY, Koh P, Stefanovic N, Febbraio MA, Kola I, Cooper ME, de 
Haan JB. Site-specific antiatherogenic effect of the antioxidant ebselen in the diabetic 
apolipoprotein E-deficient mouse. Arterioscler Thromb Vasc Biol. 2009;29:823-830. 
201. Steinman DA. Image-based computational fluid dynamics: a new paradigm for 
monitoring hemodynamics and atherosclerosis. Curr Drug Targets Cardiovasc 
Haematol Disord. 2004;4:183-197. 
202. VanderLaan PA, Reardon CA, Getz GS. Site specificity of atherosclerosis: 
site-selective responses to atherosclerotic modulators. Arterioscler Thromb Vasc 
Biol. 2004;24:12-22. 
203. Bhullar IS, Li YS, Miao H, Zandi E, Kim M, Shyy JY, Chien S. Fluid shear 
stress activation of IkappaB kinase is integrin-dependent. J Biol Chem. 
1998;273:30544-30549. 
204. Illi B, Nanni S, Scopece A, Farsetti A, Biglioli P, Capogrossi MC, Gaetano C. 
Shear stress-mediated chromatin remodeling provides molecular basis for flow-
dependent regulation of gene expression. Circ Res. 2003;93:155-161. 
  References   
122 
 
205. Li M, Tan Y, Stenmark KR, Tan W. High Pulsatility Flow Induces Acute 
Endothelial Inflammation through Overpolarizing Cells to Activate NF-kappaB. 
Cardiovasc Eng Technol. 2013;4:26-38. 
206. Vogel C, Marcotte EM. Insights into the regulation of protein abundance from 
proteomic and transcriptomic analyses. Nat Rev Genet. 2012;13:227-232. 
207. Back M, Gasser TC, Michel JB, Caligiuri G. Biomechanical factors in the 
biology of aortic wall and aortic valve diseases. Cardiovasc Res. 2013;99:232-241. 
208. Hoffman GS, Calabrese LH. Vasculitis: determinants of disease patterns. Nat 
Rev Rheumatol. 2014;10:454-462. 
209. McCall MN, Kent OA, Yu J, Fox-Talbot K, Zaiman AL, Halushka MK. 
MicroRNA profiling of diverse endothelial cell types. BMC Med Genomics. 2011;4:78. 
210. Ma X, Becker Buscaglia LE, Barker JR, Li Y. MicroRNAs in NF-kappaB 
signaling. J Mol Cell Biol. 2011;3:159-166. 
211. Li T, Morgan MJ, Choksi S, Zhang Y, Kim YS, Liu ZG. MicroRNAs modulate 
the noncanonical transcription factor NF-kappaB pathway by regulating expression of 
the kinase IKKalpha during macrophage differentiation. Nat Immunol. 2010;11:799-
805. 
212. Brooks AR, Lelkes PI, Rubanyi GM. Gene expression profiling of human aortic 
endothelial cells exposed to disturbed flow and steady laminar flow. Physiol 
Genomics. 2002;9:27-41. 
213. Lawrence T. The nuclear factor NF-kappaB pathway in inflammation. Cold 
Spring Harb Perspect Biol. 2009;1:a001651. 
214. Zernecke A, Shagdarsuren E, Weber C. Chemokines in atherosclerosis: an 
update. Arterioscler Thromb Vasc Biol. 2008;28:1897-1908. 
215. Damas JK, Smith C, Oie E, Fevang B, Halvorsen B, Waehre T, Boullier A, 
Breland U, Yndestad A, Ovchinnikova O, Robertson AK, Sandberg WJ, Kjekshus J, 
Tasken K, Froland SS, Gullestad L, Hansson GK, Quehenberger O, Aukrust P. 
Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical 
and experimental atherosclerosis: possible pathogenic role in plaque destabilization. 
Arterioscler Thromb Vasc Biol. 2007;27:614-620. 
216. Halvorsen B, Dahl TB, Smedbakken LM, Singh A, Michelsen AE, Skjelland M, 
Krohg-Sorensen K, Russell D, Hopken UE, Lipp M, Damas JK, Holm S, Yndestad A, 
Biessen EA, Aukrust P. Increased levels of CCR7 ligands in carotid atherosclerosis: 
different effects in macrophages and smooth muscle cells. Cardiovasc Res. 
2013;102:148-156. 
217. Cai W, Tao J, Zhang X, Tian X, Liu T, Feng X, Bai J, Yan C, Han Y. 
Contribution of homeostatic chemokines CCL19 and CCL21 and their receptor CCR7 
to coronary artery disease. Arterioscler Thromb Vasc Biol. 2014;34:1933-1941. 
218. Trogan E, Feig JE, Dogan S, Rothblat GH, Angeli V, Tacke F, Randolph GJ, 
Fisher EA. Gene expression changes in foam cells and the role of chemokine 
receptor CCR7 during atherosclerosis regression in ApoE-deficient mice. Proc Natl 
Acad Sci U S A. 2006;103:3781-3786. 
219. Wan W, Lionakis MS, Liu Q, Roffe E, Murphy PM. Genetic deletion of 
chemokine receptor Ccr7 exacerbates atherogenesis in ApoE-deficient mice. 
Cardiovasc Res. 2013;97:580-588. 
220. Reardon CA, Blachowicz L, Lukens J, Nissenbaum M, Getz GS. Genetic 
background selectively influences innominate artery atherosclerosis: immune system 
deficiency as a probe. Arterioscler Thromb Vasc Biol. 2003;23:1449-1454. 
221. Paigen B, Morrow A, Holmes PA, Mitchell D, Williams RA. Quantitative 
assessment of atherosclerotic lesions in mice. Atherosclerosis. 1987;68:231-240. 
References 
 
123 
 
222. Aird WC. Phenotypic heterogeneity of the endothelium: II. Representative 
vascular beds. Circ Res. 2007;100:174-190. 
223. Bhasin M, Yuan L, Keskin DB, Otu HH, Libermann TA, Oettgen P. 
Bioinformatic identification and characterization of human endothelial cell-restricted 
genes. BMC Genomics. 2010;11:342. 
 
  Appendix- List of Figures   
124 
 
9.  Appendix 
FIGURE 1: STRUCTURE OF AN ARTERY .................................................................................................................... 2 
FIGURE 2: INITIATION AND PROGRESSION OF ATHEROSCLEROSIS ......................................................................... 5 
FIGURE 3: ATHEROSCLEROSIS MAINLY DEVELOPS AT REGIONS WITH DISTURBED BLOOD FLOW. ........................ 8 
FIGURE 4: BIOGENESIS OF MICRORNA (MIR) ........................................................................................................ 10 
FIGURE 5: SIGNALLING PATHWAYS TO NF-ΚB ACTIVATION .................................................................................. 14 
FIGURE 6: NF-ΚB AND HAEMODYNAMIC FORCES ................................................................................................. 16 
FIGURE 7: DOMAIN STRUCTURES OF IKK COMPLEX FAMILY MEMBERS............................................................... 19 
FIGURE 8: SCHEMATIC REPRESENTATION OF THE PARTIAL LIGATION MODEL .................................................... 34 
FIGURE 9: HAEMATOPOIESIS. ............................................................................................................................... 53 
FIGURE 10: REDUCED B-CELL AND INCREASED T-CELL POPULATION IN IKKΑ
AA/AA
APOE
-/-
 TRANSPLANTED MICE..
 ..................................................................................................................................................................... 55 
FIGURE 11: DECREASE OF TREGS IN IKKΑ
AA/AA
APOE
−/−
 BM CHIMERAS .................................................................... 56 
FIGURE 12: IKKΑ
AA/AA
APOE
-/-
 BM CHIMERAS HAVE LESS EFFECTOR MEMORY T-CELLS, BUT MORE NAIVE T-CELLS 
IN SPLEEN AND LYMPH NODES. ........................................................................................................ 57 
FIGURE 13: LEVELS OF CDCS AND PDCS ARE UNALTERED IN IKKΑ
AA/AA
APOE
-/-
 BM CHIMERAS ............................. 58 
FIGURE 14: IKKΑ
AA/AA
APOE
−/− 
BONE
 
MARROW CHIMERAS HAVE THE SAME WEIGHT AS IKKΑ
+/+
APOE
−/−
, BUT 
EXHIBIT INCREASED VLDL VALUES AND THEREBY INCREASED CHOLESTEROL LEVELS ...................... 59 
FIGURE 15: ATHEROSCLEROTIC LESION ANALYSIS IN AORTA, AORTIC ROOT AND BCA ARE UNALTERED IN 
IKKΑ
AA/AA
APOE
−/− 
BM CHIMERAS. ....................................................................................................... 60 
FIGURE 16: ATHEROSCLEROTIC PLAQUE CLASSIFICATION SHOW SAME PLAQUE SEVERITY BETWEEN 
IKKΑ
AA/AA
APOE
−/− 
AND IKKΑ
+/+
APOE
−/−  
BM-TRANSPLANTED MICE IN BCA AND AORTIC ROOT ......... 61 
FIGURE 17: IKKΑ
AA/AA
 KNOCK-IN IN HAEMATOPOIETIC CELLS DOES NOT INFLUENCE ATHEROSCLEROTIC LESION 
COMPOSITION. .................................................................................................................................. 62 
FIGURE 18: INACTIVATABLE IKKΑ KINASE KNOCK-IN IN BM CELLS DOES NOT ALTER NEUTROPHIL INFILTRATION 
IN ATHEROSCLEROTIC LESIONS ......................................................................................................... 63 
FIGURE 19: KNOCK-IN OF IKKΑ
AA/AA
 IN HAEMATOPOIETIC CELLS DOES NOT INFLUENCE APOPTOSIS OR NECROSIS 
IN ATHEROSCLEROTIC LESIONS ......................................................................................................... 63 
FIGURE 20: INTRACELLULAR LIPID DEPOSITIONS AND LIPID-LADEN MACROPHAGES WERE NOT INFLUENCED BY 
THE ACTIVATION-RESISTANT IKKΑ MUTATION IN HAEMATOPOIETIC CELLS .................................... 64 
FIGURE 21: IKKΑ
AA/AA
APOE
-/-
 BONE MARROW TRANSPLANTATION INTO APOE
-/-
 MICE DOES NOT INFLUENCE 
WEIGHT OR CHOLESTEROL LEVELS AFTER 8 WEEKS OF HIGH-FAT DIET ........................................... 65 
FIGURE 22: TRANSPLANTATION OF BM CARRYING AN ACTIVATION-RESISTANT IKKΑ MUTANT DOES NOT AFFECT 
EARLY STAGE ATHEROSCLEROSIS ...................................................................................................... 66 
FIGURE 23: IKKΑ
AA/AA
 KNOCK-IN IN BM CELLS DOES NOT INFLUENCE LESION CLASSIFICATION AT EARLY STAGES 
OF ATHEROGENESIS .......................................................................................................................... 67 
FIGURE 24: IKKΑ
AA/AA
 KNOCK-IN DOES NOT ENHANCE OR PROLONG NF-KB P65 ACTIVITY IN VITRO .................. 68 
Appendix- List of Figures 
 
125 
 
FIGURE 25: EFFECT OF IKKΑ
AA/AA
 KNOCK-IN ON CYTOKINE SECRETION FROM BM-DERIVED MACROPHAGES ..... 69 
FIGURE 26: ACTIVATION-RESISTANT IKKΑ
AA/AA
 MUTATION IN HAEMATOPOIETIC CELLS DOES NOT ALTER 
CYTOKINE OR CHEMOKINE CONCENTRATION IN VIVO ..................................................................... 69 
FIGURE 27: BM-DERIVED MACROPHAGES FROM IKKΑ
AA/AA
APOE
-/-
 MICE DOES NOT REVEAL ALTERED LIPID 
UPTAKE .............................................................................................................................................. 70 
FIGURE 28: GLOBAL KNOCK-IN OF IKKΑ
AA/AA
 DOES NOT INFLUENCE BODY WEIGHT, SERUM LIPID LEVELS OR 
CYTOKINE CONCENTRATIONS ........................................................................................................... 72 
FIGURE 29: ATHEROSCLEROTIC PLAQUE SIZES ARE INCREASED IN AORTA OF IKKΑ
AA/AA
APOE
-/-
 COMPARED TO 
IKKΑ
+/+
APOE
-/-
 MICE AFTER 13 WEEKS OF HIGH-FAT DIET................................................................. 73 
FIGURE 30: ATHEROSCLEROTIC PLAQUE SIZES SHOW AN INCREASED TREND IN BCA OF IKKΑ
AA/AA
APOE
-/-
 
COMPARED TO IKKΑ
+/+
APOE
-/-
 MICE AFTER 13 WEEKS OF HIGH-FAT DIET ....................................... 74 
FIGURE 31: LOSS OF IKKΑ ACTIVITY DECREASES ATHEROSCLEROTIC LESION DEVELOPMENT IN AORTIC ROOTS 74 
FIGURE 32: GLOBAL IKKΑ
AA/AA
 KNOCK-IN DOES NOT INFLUENCE ATHEROSCLEROTIC LESION COMPOSITION... ..75 
FIGURE 33: IKKΑ
AA/AA
 KNOCK-IN DOES NOT ALTER APOPTOSIS OR THE COLLAGEN CONTENT IN 
ATHEROSCLEROTIC LESIONS OF AORTIC ROOTS ............................................................................... 76 
FIGURE 34: GLOBAL IKKΑ
AA/AA
 KNOCK-IN DOES NOT INFLUENCE ATHEROSCLEROTIC LESION COMPOSITION IN 
BCA .................................................................................................................................................... 76 
FIGURE 35: ACTIVATION-RESISTANT IKKΑ MUTATION DOES NOT ALTER NF-ΚB P65 ACTIVITY, BUT REDUCES 
ENHANCED HISTONE H3 PHOSPHORYLATION IN AORTIC ARCH COMPARED TO AORTA AND AORTIC 
ROOT ................................................................................................................................................. 78 
FIGURE 36: IKKΑ IS DIFFERENTIALLY EXPRESSED AND ACTIVATED IN AORTIC ROOT COMPARED TO 
ARCH/THORACIC AORTA IN APOE
-/- 
MICE. ........................................................................................ 79 
FIGURE 37: QPCR REVEALS SITE-SPECIFIC DIFFERENTIAL IKKΑ EXPRESSION IN AORTIC ROOT COMPARED TO 
ARCH/THORACIC AORTA IN APOE
-/-
 MICE UNDER NORMAL DIET AND 7 WEEKS OF HIGH-FAT DIET 80 
FIGURE 38: IKKΑ MRNA EXPRESSION LEVELS IS MARKEDLY UPREGULATED UNDER TURBULENT FLOW 
CONDITIONS IN LIGATED CAROTID ARTERIES ................................................................................... 81 
FIGURE 39: EXPRESSION OF REFERENCE MIR SNO-135 IN LIGATED CAROTID ARTERIES ..................................... 82 
FIGURE 40: EXPRESSION PROFILES OF IKKΑ TARGETING MIRS IN LIGATED CAROTID ARTERIES ARE INFLUENCED 
BY TURBULENT FLOW CONDITIONS .................................................................................................. 82 
FIGURE 41: EXPRESSION OF REFERENCE MIR SNO-135 AND MIR-429 IN AORTIC ROOT AND THORACIC AORTA.83 
FIGURE 42: EXPRESSION PROFILES OF IKKΑ-TARGETING MIRS ARE NOT SIGNIFICANTLY ALTERED IN AORTIC 
ROOT VS THORACIC AORTA, EXCEPT FOR MIR-301B. ....................................................................... 84 
FIGURE 43: LOSS OF IKKΑ ACTIVATION IMPACTS EXPRESSION OF CCL19 AND CCR7 IN AORTIC ARCH AND 
THORACIC AORTA, BUT NOT IN AORTIC ROOT. ................................................................................ 86 
FIGURE 44: SCHEMATIC DRAWING OF SUGGESTED REGIONAL SITE-SPECIFIC IKKΑ FUNCTIONS. ...................... 102 
 
  Appendix- List of Tables 
126 
 
TABLE 1: LIST OF GENERAL EQUIPMENT ............................................................................................................... 25 
TABLE 2: LIST OF CONSUMABLES .......................................................................................................................... 26 
TABLE 3: LIST OF MISCELLANEOUS REAGENTS AND SUPPLIERS ........................................................................... 26 
TABLE 4: PREPARATION OF BUFFERS, SOLUTIONS AND MEDIA ........................................................................... 27 
TABLE 5: LIST OF CYTOKINES, ENDOTOXINS AND INHIBITORS .............................................................................. 29 
TABLE 6: LIST OF ANTIBODIES ............................................................................................................................... 29 
TABLE 7: LIST OF ASSAY KITS ................................................................................................................................. 30 
TABLE 8: LIST OF PRIMERS .................................................................................................................................... 31 
TABLE 9: LIST OF SOFTWARE ................................................................................................................................. 32 
TABLE 10: PCR MASTERMIX FOR GENOTYPING IKKΑ MUTANT (IKKΑ
AA/AA
) AND WILDTYPE ALLELE ..................... 37 
TABLE 11: PCR RUN FOR IKKΑ GENOTYPING ......................................................................................................... 37 
TABLE 12: STEPS FOR DEPARAFFINIZATION .......................................................................................................... 44 
TABLE 13: STEPS FOR DEHYDRATATION ............................................................................................................... 44 
TABLE 14: PROTOCOL FOR OIL-RED-O STAINING OF AORTIC ROOT AND AORTA ................................................. 45 
TABLE 15: PROTOCOL OF IMMUNOSTAINING ...................................................................................................... 46 
TABLE 16: PROTOCOL FOR IN SITU TUNEL STAINING ........................................................................................... 47 
TABLE 17: PROTOCOL FOR CHLOROESTERASE STAINING ..................................................................................... 47 
TABLE 18: PROTOCOL OF EVG STAINING .............................................................................................................. 48 
TABLE 19: PROTOCOL OF SIRIUS RED STAINING ................................................................................................... 48 
TABLE 20: MONOCYTE, MONOCYTE SUBSETS AND NEUTROPHIL POPULATION IN PERIPHERAL BLOOD. ............ 58 
TABLE 21: WHOLE BLOOD CELL COUNT FROM IKKΑ
AA/AA
APOE
-/-
 OR IKKΑ
+/+
APOE
-/- 
MICE AFTER 6 WEEKS OF 
HIGH-FAT DIET...................................................................................................................................... 72 
Acknowledgements 
 
127 
 
Acknowledgements 
Herrn Univ.-Prof. Dr. med. Christian Weber danke ich für die Möglichkeit an seinem 
Institut meine Promotion beginnen zu können und für seine sowohl finanzielle als 
auch wissenschaftliche Unterstützung meiner Doktorarbeit. Herrn Univ.-Prof. Dr. rer. 
nat. Joachim Jankowski danke ich für die Möglichkeit an seinem Institut meine 
Promotion beenden zu können. 
Ganz besonders möchte ich mich bei Univ.-Prof. Dr. rer. nat. Jürgen Bernhagen für 
die Betreuung meiner Promotion und für die immer währende Unterstützung meiner 
Arbeit und Person bedanken. 
Frau Univ.-Prof. Dr. phil. nat. Gabriele Pradel danke ich an dieser Stelle für die 
Übernahme der Zweitkorrektur dieser Arbeit und für die wertvollen Kommentare und 
Anregungen zu meiner Arbeit.  
Weiterhin möchte ich mich besonders bei meiner Arbeitsgruppenleiterin und 
Betreuerin Dr. Heidi Noels bedanken, ohne deren Hilfe diese Arbeit nicht möglich 
gewesen wäre. Danke für den wissenschaftlichen Diskurs, die Hilfe bei der Planung 
aller Experimente, die unermüdliche Unterstützung und Korrektur meiner Arbeit, und 
dafür, dass du mir die Chance ermöglicht hast, meine Promotion im Bereich der 
medizinischen Forschung zu machen trotz fehlender Vorkenntnisse. Ich habe viel 
von Dir gelernt und du warst mir eine wundervolle Mentorin. 
Dr. Toby Lawrence und seinen Mitarbeitern Dr. Mohamed Habbeddine und Dr. 
Celine Cudejko danke ich für die inspirierende Kollaboration und für die 
Durchführung der nicht atherosklerotischen, hämatopoetischen Studien. 
Zudem danke ich Priv.-Doz. Dr. rer. nat. Rory R. Koenen für die Durchführung der 
Lipid Fraktionierung und für die vielen freundlichen, hilfreichen Gespräche. 
Prof. Dr. Menno de Winther danke ich für die zahlreichen Diskussionen, die zum 
Gelingen dieser Arbeit beigetragen haben und ich danke Marion Gijbels für die 
experimentelle Hilfestellung bei der morphologischen Klassifizierung der 
atherosklerotischen Plaques. 
 
  Acknowledgements 
128 
 
Ein besonderer Dank gilt den medizinisch technischen Assistenten/innen des 
IMCAR, von denen ich so viele Techniken erlernt habe und stets Expertenmeinungen 
einholen konnte. Insbesondere möchte ich an dieser Stelle Leon, Melanie, Sabine, 
Steffie, Yuan, Sandra und meiner „Ersatzmutti“ Roya danken, für ihre Unterstützung 
und Mithilfe beim Genotypisieren, RTQ-PCR, Organisolationen, Einbetten, 
Schneiden und Färben meiner Proben aber vor allem bedanke ich mich für die vielen 
netten, lustigen Gespräche. Ihr habt den Laboralltag stets schöner gemacht. Vielen 
Dank auch an Frau Mayer, die gute Seele des IMCAR, für ihre verlässliche Hilfe und 
Unterstützung bei den kleinen Alltags- und administrativen Problemen.  
Ein großes Dankeschön geht an Priv.-Doz. Dr. nat. med. Dr. med. Elisa Liehn für das 
Beibringen verschiedener vielfältiger Methoden, die eine große Bereicherung für 
mich waren und dafür dass ihre Tür stets offen stand. 
Ein weiteres Dankeschön geht an Dr. Wendy Theelen für wissenschaftliche 
Unterstützung bei den microRNA und RTQ Studien und aufmunternden Gespräche. 
Natürlich möchte ich gerne allen meinen Arbeitskollegen und Freunden aus dem 
IMCAR und aus der Prof. Dr. med. N. Marx Gruppe für ihre fachliche Unterstützung 
und die schöne Zeit in Aachen danken. Ihr habt mir die Zeit sowohl innerhalb als 
auch außerhalb des Labors zu etwas Besonderem gemacht, an dessen 
Erinnerungen ich mich immer gerne zurückdenken werde. Ich danke euch Lukas, 
Jaco, Janine, Mareike, Adelina, Wu, Xiaofeng, Santosh, Baixue, Martin, Maryam, 
Yaw, Julia, Ana, Sebastian und Florian. Es war mir eine Freude mit euch zu arbeiten 
und ich hoffe, dass sich unsere Wege weiterhin in Zukunft kreuzen und wir uns 
sehen werden. 
Vielen Dank auch an die „ehemaligen“ IMCAR Studenten. Danke an Shamima und 
Maliheh für die technische Unterstützung der RNA Studien und für eure unendliche 
Geduld mit all meinen Fragen. Weiterhin auch ein Dankeschön an Yvonne und Maik 
für die vielen wissenschaftlichen Ratschläge, Tipps und Tricks. Und obwohl sie mich 
nicht bis zum Ende meiner Promotion begleiten konnten, danke ich Isabella und 
Sakine, die mich zu Beginn meiner Promotion ins IMCAR eingeführt haben und mir 
immer eine Schulter zum Anlehnen geboten haben. 
 
Acknowledgements 
 
129 
 
Danke auch an meine Freunde außerhalb des Labors für Eure Unterstützung und 
Geduld. Danke an Helene für den Zuspruch, Motivation und unsere großartige, 
brillante Freundschaft. Ich bin sehr froh, dass es dich gibt. Robert- ein riesiges 
Dankeschön für Deine Unterstützung dieser Arbeit, für Deine Geduld mit mir und für 
die vielen freudigen und schönen Momente der letzten Jahre. 
Last, but not least möchte ich einen herzlichen Dank an meine Eltern und meine 
Familie aussprechen. Ich danke meinen Eltern für den fortwährenden Rückhalt, das 
Vertrauen in mir und meinen Fähigkeiten, den Zuspruch und die Geduld mit mir. Ich 
danke meinen Bruder, dafür dass er mich stets in meinen Zielen bestärkt und immer 
an mich glaubt. Anita und Per danke ich ebenfalls für den unendlichen Beistand und 
für den Glauben an mich und meine Arbeit. Ich bin sehr dankbar, eine so 
wundervolle, unterstützende Familie zu haben. 
